

# Increased Vascular Endothelial Growth Factor Levels in Proliferative Diabetic Retinopathy

American Journal of Ophthalmology

118, 445-450

DOI: [10.1016/s0002-9394\(14\)75794-0](https://doi.org/10.1016/s0002-9394(14)75794-0)

Citation Report

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Glaucoma After Surgery on the Retina and Vitreous. <i>Seminars in Ophthalmology</i> , 1994, 9, 258-265.  | 0.8  | 12        |
| 2  | Vascular Endothelial Growth Factor – Its Role in Retinal Vascular Proliferation. <i>New England Journal of Medicine</i> , 1994, 331, 1519-1520.  | 13.9 | 62        |
| 3  | Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995, 92, 10457-10461. | 3.3  | 1,168     |
| 4  | Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. <i>Journal of Neuroscience</i> , 1995, 15, 4738-4747.   | 1.7  | 911       |
| 5  | The role of vascular endothelial growth factor in pathological angiogenesis. <i>Breast Cancer Research and Treatment</i> , 1995, 36, 127-137.  | 1.1  | 387       |
| 6  | Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. <i>Journal of Molecular Medicine</i> , 1995, 73, 333-46.  | 1.7  | 472       |
| 7  | Angiogenesis in cancer, vascular, rheumatoid and other disease. <i>Nature Medicine</i> , 1995, 1, 27-30.   | 15.2 | 7,257     |
| 8  | Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. <i>Nature Medicine</i> , 1995, 1, 1024-1028.  | 15.2 | 1,462     |
| 9  | Hypoxic Induction of Endothelial Cell Growth Factors in Retinal Cells: Identification and Characterization of Vascular Endothelial Growth Factor (VEGF) as the Mitogen. <i>Molecular Medicine</i> , 1995, 1, 182-193.  | 1.9  | 326       |
| 10 | Hypoxia Induces Vascular Endothelial Growth Factor in Cultured Human Endothelial Cells. <i>Journal of Biological Chemistry</i> , 1995, 270, 31189-31195.   | 1.6  | 413       |
| 11 | Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. <i>Current Eye Research</i> , 1995, 14, 1045-1053.  | 0.7  | 205       |
| 12 | Hypoxic induction of vascular endothelial growth factor (VEGF) in human epithelial cells is mediated by increases in mRNA stability. <i>FEBS Letters</i> , 1995, 370, 203-208.   | 1.3  | 263       |
| 13 | MMP-9 (gelatinase B) mRNA is expressed during mouse neurogenesis and may be associated with vascularization. <i>Developmental Brain Research</i> , 1995, 88, 37-52.  | 2.1  | 61        |
| 14 | Hypoxic Regulation of Vascular Endothelial Growth Factor in Retinal Cells. <i>JAMA Ophthalmology</i> , 1995, 113, 1538.  | 2.6  | 509       |
| 15 | Shedding Light on Diabetic Retinopathy. <i>Ophthalmology</i> , 1995, 102, 1127-1128.   | 2.5  | 6         |
| 16 | DIABETIC EYE DISEASE. <i>Endocrinology and Metabolism Clinics of North America</i> , 1996, 25, 271-291.  | 1.2  | 19        |
| 17 | Basic Fibroblast Growth Factor and Vascular Endothelial Growth Factor Are Present in Epiretinal and Choroidal Neovascular Membranes. <i>American Journal of Ophthalmology</i> , 1996, 122, 393-403.  | 1.7  | 328       |
| 18 | Progesterone induces vascular endothelial growth factor on retinal pigment epithelial cells in culture. <i>Life Sciences</i> , 1996, 59, 21-25.  | 2.0  | 32        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 19 | Vascular Endothelial Growth Factor Is Induced by Long-Term High Glucose Concentration and Up-Regulated by Acute Glucose Deprivation in Cultured Bovine Retinal Pigmented Epithelial Cells. <i>Biochemical and Biophysical Research Communications</i> , 1996, 221, 193-198. | 1.0  | 104       |
| 20 | Normal and pathological mechanisms in retinalvascular development. <i>Survey of Ophthalmology</i> , 1996, 40, 481-490.  | 1.7  | 27        |
| 21 | Vascular endothelial growth factor. <i>European Journal of Cancer</i> , 1996, 32, 2413-2422.  | 1.3  | 327       |
| 22 | Vascular endothelial growth factor and its receptors. <i>Cytokine and Growth Factor Reviews</i> , 1996, 7, 259-270.   | 3.2  | 547       |
| 23 | Intravitreal Injections of Vascular Endothelial Growth Factor Produce Retinal Ischemia and Microangiopathy in an Adult Primate. <i>Ophthalmology</i> , 1996, 103, 1820-1828.  | 2.5  | 493       |
| 24 | Vascular Endothelial Growth Factor and the Eye. <i>JAMA Ophthalmology</i> , 1996, 114, 1252.  | 2.6  | 35        |
| 25 | Vascular Endothelial Growth Factor Level in Aqueous Humor of Diabetic Patients With Rubeotic Glaucoma Is Markedly Elevated. <i>Diabetes Care</i> , 1996, 19, 1306-1307.   | 4.3  | 45        |
| 26 | Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996, 93, 4851-4856.   | 3.3  | 328       |
| 27 | Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996, 93, 9764-9769.   | 3.3  | 444       |
| 28 | Growth factors in the retina and retinal pigmented epithelium. <i>Progress in Retinal and Eye Research</i> , 1996, 15, 547-567.   | 7.3  | 29        |
| 29 | Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. <i>Nature</i> , 1996, 380, 439-442.   | 13.7 | 3,312     |
| 30 | Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation.. <i>British Journal of Ophthalmology</i> , 1996, 80, 363-366.   | 2.1  | 141       |
| 31 | Upregulated expression of vascular endothelial growth factor in proliferative diabetic retinopathy.. <i>British Journal of Ophthalmology</i> , 1996, 80, 241-245.   | 2.1  | 142       |
| 32 | Correlation of Vascular Permeability Factor/Vascular Endothelial Growth Factor With Extraretinal Neovascularization in the Rat. <i>JAMA Ophthalmology</i> , 1996, 114, 1210.  | 2.6  | 114       |
| 33 | Vascular Endothelial Growth Factor Is Sufficient to Produce Iris Neovascularization and Neovascular Glaucoma in a Nonhuman Primate. <i>JAMA Ophthalmology</i> , 1996, 114, 964.   | 2.6  | 309       |
| 34 | Localization of Vascular Endothelial Growth Factor in Human Retina and Choroid. <i>JAMA Ophthalmology</i> , 1996, 114, 971.   | 2.6  | 247       |
| 35 | Identification and Characterization of Vascular Endothelial Growth Factor Receptor (Flt) in Bovine Retinal Pericytes. <i>Diabetes</i> , 1996, 45, 1016-1023.  | 0.3  | 100       |
| 36 | Inhibition of Vascular Endothelial Growth Factor Prevents Retinal Ischemia-Associated Iris Neovascularization in a Nonhuman Primate. <i>JAMA Ophthalmology</i> , 1996, 114, 66.   | 2.6  | 586       |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Regulation of Vascular Endothelial Growth Factor Expression by Insulin-Like Growth Factor I. <i>Diabetes</i> , 1997, 46, 1619-1626.  | 0.3 | 165       |
| 38 | Intravitreal growth factors in proliferative diabetic retinopathy: correlation with neovascular activity and glycaemic management. <i>British Journal of Ophthalmology</i> , 1997, 81, 228-233.  | 2.1 | 109       |
| 39 | An Aldose Reductase Inhibitor and Aminoguanidine Prevent Vascular Endothelial Growth Factor Expression in Rats With Long-term Galactosemia. <i>JAMA Ophthalmology</i> , 1997, 115, 1036.   | 2.6 | 65        |
| 40 | Vascular Endothelial Growth Factor-Induced Retinal Permeability Is Mediated by Protein Kinase C In Vivo and Suppressed by an Orally Effective $\text{I}^2$ -Isoform-Selective Inhibitor. <i>Diabetes</i> , 1997, 46, 1473-1480.  | 0.3 | 642       |
| 41 | Localisation of vascular endothelial growth factor and its receptors to cells of vascular and avascular epiretinal membranes. <i>British Journal of Ophthalmology</i> , 1997, 81, 919-926.   | 2.1 | 88        |
| 42 | Advanced Glycation End Products-driven Angiogenesis in Vitro. <i>Journal of Biological Chemistry</i> , 1997, 272, 8723-8730.   | 1.6 | 253       |
| 43 | Systemic Hyperoxia Decreases Vascular Endothelial Growth Factor Gene Expression in Ischemic Primate Retina. <i>JAMA Ophthalmology</i> , 1997, 115, 1553.   | 2.6 | 46        |
| 44 | Elevated $\text{I}^3$ -Aminobutyric Acid, Glutamate, and Vascular Endothelial Growth Factor Levels in the Vitreous of Patients With Proliferative Diabetic Retinopathy. <i>JAMA Ophthalmology</i> , 1997, 115, 1161.   | 2.6 | 275       |
| 45 | Role of vascular permeability factor/vascular endothelial growth factor in eye disease. <i>British Journal of Ophthalmology</i> , 1997, 81, 501-512.   | 2.1 | 78        |
| 46 | Antiangiogenic Drug Therapy for Macular Degeneration. <i>Seminars in Ophthalmology</i> , 1997, 12, 10-13.  | 0.8 | 0         |
| 47 | Elevated ocular levels of vascular endothelial growth factor in patients with von Hippel-Lindau disease. <i>Annals of Oncology</i> , 1997, 8, 1015-1022.   | 0.6 | 49        |
| 48 | Growth factor antagonists for the treatment of diabetic vascular complications. <i>Expert Opinion on Investigational Drugs</i> , 1997, 6, 1671-1684.   | 1.9 | 4         |
| 49 | The Biology of Vascular Endothelial Growth Factor. <i>Endocrine Reviews</i> , 1997, 18, 4-25.  | 8.9 | 3,822     |
| 50 | Vascular Endothelial Growth Factor and Severity of Nonproliferative Diabetic Retinopathy Mediate Retinal Hemodynamics In Vivo: A Potential Role for Vascular Endothelial Growth Factor in the Progression of Nonproliferative Diabetic Retinopathy. <i>American Journal of Ophthalmology</i> , 1997, 124, 433-446. | 1.7 | 154       |
| 51 | Vascular Endothelial Growth Factor and Fibroblast Growth Factor 5 are Colocalized in Vascular and Avascular Epiretinal Membranes. <i>American Journal of Ophthalmology</i> , 1997, 124, 447-454.   | 1.7 | 27        |
| 52 | Endothelial dysfunction and pathogenesis of diabetic angiopathy. <i>Cardiovascular Research</i> , 1997, 34, 55-68.   | 1.8 | 368       |
| 53 | A Novel Technique for Culture of Human Dermal Microvascular Endothelial Cells under either Serum-Free or Serum-Supplemented Conditions: Isolation by Panning and Stimulation with Vascular Endothelial Growth Factor. <i>Experimental Cell Research</i> , 1997, 230, 244-251.                                      | 1.2 | 77        |
| 54 | Intravitreal Sustained Release of VEGF Causes Retinal Neovascularization in Rabbits and Breakdown of the Blood-Retinal Barrier in Rabbits and Primates. <i>Experimental Eye Research</i> , 1997, 64, 505-517.  | 1.2 | 241       |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 Å... resolution: multiple copy flexibility and receptor binding. <i>Structure</i> , 1997, 5, 1325-1338.   | 1.6 | 222       |
| 56 | Ischemia-Driven Angiogenesis. <i>Trends in Cardiovascular Medicine</i> , 1997, 7, 289-294.   | 2.3 | 71        |
| 57 | Mechanisms of retinal angiogenesis. <i>Progress in Retinal and Eye Research</i> , 1997, 16, 157-181.   | 7.3 | 60        |
| 58 | Vitreous levels of vascular endothelial growth factor are not influenced by its serum concentrations in diabetic retinopathy. <i>Diabetologia</i> , 1997, 40, 1107-1109.   | 2.9 | 96        |
| 59 | An immunocytochemical study of isolated human retinal Müller cells in culture. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 1997, 235, 411-414.   | 1.0 | 5         |
| 60 | Anterior segment sparing to reduce charged particle radiotherapy complications in uveal melanoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997, 39, 997-1010.   | 0.4 | 77        |
| 61 | Lipid hydroperoxide stimulates retinal neovascularization in rabbit retina through expression of tumor necrosis factor-alpha, vascular endothelial growth factor and platelet-derived growth factor. <i>Angiogenesis</i> , 1998, 2, 93-104.                  | 3.7 | 63        |
| 62 | Aqueous Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor Decrease During Regression of Rabbit Pupillary Membrane. <i>Japanese Journal of Ophthalmology</i> , 1998, 42, 157-161.   | 0.9 | 5         |
| 63 | Functions of the VEGF Receptor-1 (FLT-1) in the Vasculature. <i>Trends in Cardiovascular Medicine</i> , 1998, 8, 241-245.  | 2.3 | 37        |
| 64 | Expression of vascular endothelial growth factor (VEGF) and its receptors is regulated in eyes with intra-ocular tumours. , 1998, 186, 306-312.  |     | 92        |
| 65 | Systemic sclerosis stimulates angiogenesis in the chick embryo chorioallantoic membrane. <i>Clinical Rheumatology</i> , 1998, 17, 115-120.   | 1.0 | 16        |
| 66 | Effect of basic fibroblast growth factor on angiogenesis in the infarcted porcine heart. <i>Basic Research in Cardiology</i> , 1998, 93, 30-37.  | 2.5 | 116       |
| 67 | Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. <i>Ophthalmology</i> , 1998, 105, 232-237.   | 2.5 | 264       |
| 68 | Vascular endothelial growth factor upregulation in human central retinal vein occlusion11The authors have no proprietary interest in any of the materials used in this study.. <i>Ophthalmology</i> , 1998, 105, 412-416.                                    | 2.5 | 249       |
| 69 | Increased vascular endothelial growth factor (VEGF) and transforming growth factor $\beta$ 2 (TGF $\beta$ 2) in experimental autoimmune uveoretinitis: upregulation of VEGF without neovascularization. <i>Journal of Neuroimmunology</i> , 1998, 89, 43-50. | 1.1 | 75        |
| 70 | An immunohistochemical study of endothelin-1 in the human eye. <i>Current Eye Research</i> , 1998, 17, 541-545.  | 0.7 | 56        |
| 71 | Vascular Endothelial Growth Factor Increases Release of Gelatinase A and Decreases Release of Tissue Inhibitor of Metalloproteinases by Microvascular Endothelial Cells in Vitro. <i>Microvascular Research</i> , 1998, 55, 29-42.                           | 1.1 | 262       |
| 72 | Increased Expression of KDR/Flk-1 (VEGFR-2) in Murine Model of Ischemia-Induced Retinal Neovascularization. <i>Microvascular Research</i> , 1998, 56, 183-191.   | 1.1 | 46        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 74 | Basic Fibroblast Growth Factor Is Neither Necessary nor Sufficient for the Development of Retinal Neovascularization. <i>American Journal of Pathology</i> , 1998, 153, 757-765.                         | 1.9 | 94        |
| 75 | Identification of a Human VPF/VEGF 3' Untranslated Region Mediating Hypoxia-induced mRNA Stability. <i>Molecular Biology of the Cell</i> , 1998, 9, 469-481.   | 0.9 | 161       |
| 76 | VEGF localisation in diabetic retinopathy. <i>British Journal of Ophthalmology</i> , 1998, 82, 561-568.  | 2.1 | 159       |
| 77 | 2'-Fluoropyrimidine RNA-based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF165). <i>Journal of Biological Chemistry</i> , 1998, 273, 20556-20567.                      | 1.6 | 648       |
| 78 | Role for heparin-binding growth factors in glucose-induced vascular dysfunction. <i>Diabetes</i> , 1998, 47, 1771-1778.  | 0.3 | 12        |
| 79 | Transcription Factors Sp1 and Sp3 Alter Vascular Endothelial Growth Factor Receptor Expression through a Novel Recognition Sequence. <i>Journal of Biological Chemistry</i> , 1998, 273, 19294-19303.    | 1.6 | 119       |
| 80 | Upregulation of Retinal Vascular Endothelial Growth Factor mRNAs in Spontaneously Diabetic Rats without Ophthalmoscopic Retinopathy. <i>Ophthalmic Research</i> , 1998, 30, 333-339.                     | 1.0 | 63        |
| 81 | Angiotensin II Potentiates Vascular Endothelial Growth Factor-Induced Angiogenic Activity in Retinal Microcapillary Endothelial Cells. <i>Circulation Research</i> , 1998, 82, 619-628.                  | 2.0 | 267       |
| 82 | Transforming Growth Factor $\beta$ 2 in the Vitreous in Proliferative Diabetic Retinopathy. <i>JAMA Ophthalmology</i> , 1998, 116, 738.  | 2.6 | 60        |
| 83 | Vascular endothelial growth factor (VEGF) and its receptors. <i>FASEB Journal</i> , 1999, 13, 9-22.  | 0.2 | 3,124     |
| 84 | Diabetic retinopathy: Some cellular, molecular and therapeutic considerations. <i>Eye</i> , 1999, 13, 497-523.   | 1.1 | 61        |
| 85 | Increased Vitreous Concentrations of Human Hepatocyte Growth Factor in Proliferative Diabetic Retinopathy1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 659-662.                 | 1.8 | 51        |
| 86 | Immunolocalisation of the VEGF receptors FLT-1, KDR, and FLT-4 in diabetic retinopathy. <i>British Journal of Ophthalmology</i> , 1999, 83, 486-494.   | 2.1 | 43        |
| 87 | Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA. <i>Nucleic Acids Research</i> , 1999, 27, 2569-2577.  | 6.5 | 81        |
| 88 | Basic fibroblast growth factor induces expression of VEGF receptor KDR through a protein kinase C and p44/p42 mitogen-activated protein kinase-dependent pathway. <i>Diabetes</i> , 1999, 48, 1145-1155. | 0.3 | 92        |
| 89 | Elevated Plasma Vascular Endothelial Cell Growth Factor and Thrombomodulin in Juvenile Diabetic Patients. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 1999, 5, 21-24.                            | 0.7 | 46        |
| 90 | Molecular Mechanisms of Vascular Permeability in Diabetic Retinopathy. <i>Seminars in Ophthalmology</i> , 1999, 14, 240-248.   | 0.8 | 202       |
| 91 | Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys. <i>Biomedical Applications</i> , 1999, 732, 203-212.             | 1.7 | 151       |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 92  | Role of vascular endothelial growth factor in the regulation of angiogenesis. <i>Kidney International</i> , 1999, 56, 794-814.   | 2.6 | 640       |
| 93  | Circulating vascular endothelial growth factor is not increased during relapses of steroid-sensitive nephrotic syndrome. <i>Kidney International</i> , 1999, 55, 1063-1071.  | 2.6 | 48        |
| 94  | Angiogenesis and ophthalmic disease. <i>Angiogenesis</i> , 1999, 3, 9-14.  | 3.7 | 97        |
| 95  | Molecular and biological properties of vascular endothelial growth factor. <i>Journal of Molecular Medicine</i> , 1999, 77, 527-543.   | 1.7 | 1,007     |
| 96  | Glucose transport in brain and retina: implications in the management and complications of diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 1999, 15, 261-273.  | 1.7 | 131       |
| 97  | Pigment Epithelium-Derived Factor: A Potent Inhibitor of Angiogenesis. <i>Science</i> , 1999, 285, 245-248.  | 6.0 | 1,417     |
| 98  | Cytotoxic and Growth Inhibitory Effect of Ascorbic Acid on Cultured Bovine Vascular Endothelial Cells. <i>Zoological Science</i> , 1999, 16, 99-104.   | 0.3 | 1         |
| 99  | Soluble cellular adhesion molecules in proliferative vitreoretinopathy and proliferative diabetic retinopathy. <i>Current Eye Research</i> , 1999, 19, 219-227.  | 0.7 | 43        |
| 100 | Vascular, glial and neuronal effects of vascular endothelial growth factor in mesencephalic explant cultures. <i>Neuroscience</i> , 1999, 90, 1529-1541.   | 1.1 | 228       |
| 101 | New surgical approach for removing massive foveal hard exudates in diabetic macular edema11The authors have no financial interest in any aspect of this study.. <i>Ophthalmology</i> , 1999, 106, 249-257.         | 2.5 | 72        |
| 102 | Discussion by Donald S. Fong, MD, MPH. <i>Ophthalmology</i> , 1999, 106, 256-257.  | 2.5 | 9         |
| 103 | Vitrectomy in the Management of Diabetic Retinopathy. <i>Survey of Ophthalmology</i> , 1999, 43, 491-507.  | 1.7 | 98        |
| 104 | ProMMP-9 (92 kDa gelatinase) in vitreous fluid of patients with proliferative diabetic retinopathy. <i>Life Sciences</i> , 1999, 64, 2307-2315.  | 2.0 | 43        |
| 105 | Effects of intraocular or systemic administration of neutralizing antibody against vascular endothelial growth factor on the murine experimental model of retinopathy. <i>Life Sciences</i> , 1999, 65, 2573-2580. | 2.0 | 40        |
| 106 | Vascular Endothelial Growth Factor Molecular and Biological Aspects. <i>Advances in Organ Biology</i> , 1999, 7, 25-57.  | 0.1 | 8         |
| 107 | Expression of Thrombospondin-1 in Ischemia-Induced Retinal Neovascularization. <i>American Journal of Pathology</i> , 1999, 154, 343-354.  | 1.9 | 66        |
| 108 | Dramatic Inhibition of Retinal and Choroidal Neovascularization by Oral Administration of a Kinase Inhibitor. <i>American Journal of Pathology</i> , 1999, 154, 1743-1753.   | 1.9 | 167       |
| 109 | Pro-Inflammatory Cytokines Induce Expression of Matrix-Metabolizing Enzymes in Human Cervical Smooth Muscle Cells. <i>American Journal of Pathology</i> , 1999, 154, 1755-1762.                                    | 1.9 | 156       |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 110 | Insulin Stimulates the Growth and Tube Formation of Human Microvascular Endothelial Cells through Autocrine Vascular Endothelial Growth Factor. <i>Microvascular Research</i> , 1999, 57, 329-339.   | 1.1  | 61        |
| 111 | Changes in vitreous concentrations of human hepatocyte growth factor (hHGF) in proliferative diabetic retinopathy: implications for intraocular hHGF production. <i>Clinical Science</i> , 2000, 98, 9-14.                                       | 1.8  | 11        |
| 112 | Changes in vitreous concentrations of human hepatocyte growth factor (hHGF) in proliferative diabetic retinopathy: implications for intraocular hHGF production. <i>Clinical Science</i> , 2000, 98, 9.  | 1.8  | 3         |
| 113 | VEGF release by retinal glia depends on both oxygen and glucose supply. <i>NeuroReport</i> , 2000, 11, 3533-3537.  | 0.6  | 75        |
| 114 | Angiotensin 2 expression in the retina: upregulation during physiologic and pathologic neovascularization. <i>Journal of Cellular Physiology</i> , 2000, 184, 275-284.   | 2.0  | 163       |
| 115 | Retinal and choroidal neovascularization. <i>Journal of Cellular Physiology</i> , 2000, 184, 301-310.  | 2.0  | 358       |
| 116 | Cell injury unmasks a latent proangiogenic phenotype in mice with increased expression of FGF2 in the retina. <i>Journal of Cellular Physiology</i> , 2000, 185, 135-142.  | 2.0  | 50        |
| 117 | Role of vascular endothelial growth factor in diabetic vascular complications. <i>Kidney International</i> , 2000, 58, S113-S119.  | 2.6  | 236       |
| 118 | Vascular endothelial growth factor (VEGF) in children, adolescents and young adults with Type 1 diabetes mellitus: relation to glycaemic control and microvascular complications. <i>Diabetic Medicine</i> , 2000, 17, 650-656.                  | 1.2  | 124       |
| 119 | Vascular-specific growth factors and blood vessel formation. <i>Nature</i> , 2000, 407, 242-248.   | 13.7 | 3,413     |
| 120 | Experimental models of growth factor-mediated angiogenesis and blood-retinal barrier breakdown. <i>General Pharmacology</i> , 2000, 35, 233-239.   | 0.7  | 14        |
| 121 | Clinical Trials in Coronary Angiogenesis: Issues, Problems, Consensus. <i>Circulation</i> , 2000, 102, E73-86.   | 1.6  | 390       |
| 123 | Regulation of connective tissue growth factor gene expression in retinal vascular endothelial cells by angiogenic growth factors. <i>Graefes' Archive for Clinical and Experimental Ophthalmology</i> , 2000, 238, 910-915.                      | 1.0  | 28        |
| 124 | Genetic heterogeneity of angiogenesis in mice. <i>FASEB Journal</i> , 2000, 14, 871-876.   | 0.2  | 216       |
| 125 | Angiography of Fluoresceinated Anti-Vascular Endothelial Growth Factor Antibody and Dextran in Experimental Choroidal Neovascularization. <i>JAMA Ophthalmology</i> , 2000, 118, 78.   | 2.6  | 45        |
| 126 | Concentration of Vascular Endothelial Growth Factor in the Subretinal Fluid of Retinal Detachment. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2000, 16, 463-469.   | 0.6  | 25        |
| 127 | The Conformation-Dependent Interaction of alpha sub2 -Macroglobulin with Vascular Endothelial Growth Factor: A Novel Mechanism of alpha sub2 -Macroglobulin/Growth Factor Binding. <i>Journal of Biological Chemistry</i> , 2000, 275, 26806-11. | 1.6  | 29        |
| 128 | Clinical factors related to the aqueous levels of vascular endothelial growth factor and hepatocyte growth factor in proliferative diabetic retinopathy. <i>Current Eye Research</i> , 2000, 21, 655-661.  | 0.7  | 45        |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 129 | Matrix metalloproteinases and their natural inhibitors in fibrovascular membranes of proliferative diabetic retinopathy. <i>British Journal of Ophthalmology</i> , 2000, 84, 1091-1096.                     | 2.1 | 87        |
| 130 | Blockade of Vascular Endothelial Cell Growth Factor Receptor Signaling Is Sufficient to Completely Prevent Retinal Neovascularization. <i>American Journal of Pathology</i> , 2000, 156, 697-707.           | 1.9 | 332       |
| 131 | Vascular Endothelial Growth Factor (VEGF)-Induced Retinal Vascular Permeability Is Mediated by Intercellular Adhesion Molecule-1 (ICAM-1). <i>American Journal of Pathology</i> , 2000, 156, 1733-1739.     | 1.9 | 314       |
| 132 | Ophthalmology update for the primary practitioner. <i>Disease-a-Month</i> , 2000, 46, 533-543.  | 0.4 | 1         |
| 133 | Therapeutic Angiogenesis. <i>BioDrugs</i> , 2000, 14, 13-20.  | 2.2 | 6         |
| 134 | New therapies for the treatment of age-related macular degeneration. <i>Expert Opinion on Therapeutic Patents</i> , 2000, 10, 333-341.  | 2.4 | 1         |
| 135 | Histopathology and pathogenesis of diabetic retinopathy. , 2000, , 32-43.   |     | 1         |
| 136 | Acute effects of insulin on aqueous humor flow in patients with type 1 diabetes. <i>American Journal of Ophthalmology</i> , 2001, 132, 321-327.   | 1.7 | 13        |
| 137 | Vitreotomy for diabetic macular edema: the role of posterior vitreous detachment and epimacular membrane. <i>American Journal of Ophthalmology</i> , 2001, 132, 369-377.                                    | 1.7 | 183       |
| 138 | Glucose, VEGF-A, and Diabetic Complications. <i>American Journal of Pathology</i> , 2001, 158, 1181-1184.   | 1.9 | 62        |
| 139 | Retinopathy of prematurity: causation. <i>Seminars in Fetal and Neonatal Medicine</i> , 2001, 6, 453-460.   | 2.8 | 49        |
| 140 | VLF: un nuevo activador no convencional de la vÃa del calcio aislado del humor vÃtreo. <i>Endocrinología Y Nutricion: Organo De La Sociedad Espanola De Endocrinología Y Nutricion</i> , 2001, 48, 120-123. | 0.8 | 0         |
| 141 | Intravitreal VEGF and bFGF produce florid retinal neovascularization and hemorrhage in the rabbit. <i>Current Eye Research</i> , 2001, 22, 140-147.   | 0.7 | 56        |
| 142 | Vitreous levels of insulin-like growth factor-I in patients with proliferative diabetic retinopathy. <i>Current Eye Research</i> , 2001, 23, 368-371.   | 0.7 | 26        |
| 143 | Monocyte Chemotactic Protein-1 in the Vitreous of Patients with Proliferative Diabetic Retinopathy. <i>Ophthalmologica</i> , 2001, 215, 415-418.  | 1.0 | 90        |
| 144 | Role of vascular endothelial growth factor in regulation of physiological angiogenesis. <i>American Journal of Physiology - Cell Physiology</i> , 2001, 280, C1358-C1366.                                   | 2.1 | 913       |
| 145 | High Glucose Dialysis Solutions Increase Synthesis of Vascular Endothelial Growth Factors by Peritoneal Vascular Endothelial Cells. <i>Peritoneal Dialysis International</i> , 2001, 21, 35-40.             | 1.1 | 24        |
| 146 | Response of Experimental Retinal Neovascularization to Thiazolidinediones. <i>JAMA Ophthalmology</i> , 2001, 119, 709.  | 2.6 | 84        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 147 | RETINAL ANGIOMATOUS PROLIFERATION IN AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2001, 21, 416-434.  | 1.0 | 690       |
| 148 | RELATIONSHIP BETWEEN VASCULAR ENDOTHELIAL GROWTH FACTOR AND INTERLEUKIN-6 IN DIABETIC RETINOPATHY. <i>Retina</i> , 2001, 21, 469-477.  | 1.0 | 89        |
| 149 | Vascular Endothelial Growth Factor and Its Receptors Expression in the Rat Eye.. <i>Acta Histochemica Et Cytochemica</i> , 2001, 34, 329-335.  | 0.8 | 5         |
| 151 | Circulating plasma vascular endothelial growth factor and microvascular complications of Type 1 diabetes mellitus: the influence of ACE inhibition. <i>Diabetic Medicine</i> , 2001, 18, 288-294.  | 1.2 | 54        |
| 152 | Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. <i>Journal of Cellular Physiology</i> , 2001, 188, 253-263.   | 2.0 | 326       |
| 153 | The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats. <i>Diabetologia</i> , 2001, 44, 883-888.   | 2.9 | 58        |
| 154 | Clinical Applications of Cardiovascular Angiogenesis. <i>Journal of Cardiac Surgery</i> , 2001, 16, 490-497.   | 0.3 | 7         |
| 155 | Stimulation and Inhibition of Angiogenesis in Diabetic Retinopathy. <i>Japanese Journal of Ophthalmology</i> , 2001, 45, 577-584.  | 0.9 | 42        |
| 156 | Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 2593-2597.                                 | 3.3 | 348       |
| 157 | Troglitazone Treatment Increases Plasma Vascular Endothelial Growth Factor in Diabetic Patients and Its mRNA in 3T3-L1 Adipocytes. <i>Diabetes</i> , 2001, 50, 1166-1170.  | 0.3 | 91        |
| 158 | Angiotensin II Induces Expression of the Tie2 Receptor Ligand, Angiopoietin-2, in Bovine Retinal Endothelial Cells. <i>Diabetes</i> , 2001, 50, 867-875.   | 0.3 | 96        |
| 159 | Evaluation of Intraocular Pharmacokinetics and Toxicity of Prinomastat (AG3340) in the Rabbit. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2001, 17, 295-304.   | 0.6 | 18        |
| 160 | Systemically Expressed Soluble Tie2 Inhibits Intraocular Neovascularization. <i>Human Gene Therapy</i> , 2001, 12, 1311-1321.  | 1.4 | 67        |
| 161 | Selective Inhibition of Vascular Endothelial Growth Factor-Mediated Angiogenesis by Cyclosporin a. <i>Journal of Experimental Medicine</i> , 2001, 193, 607-620.   | 4.2 | 412       |
| 162 | Cyclic Stretch and Hypertension Induce Retinal Expression of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2: Potential Mechanisms for Exacerbation of Diabetic Retinopathy by Hypertension. <i>Diabetes</i> , 2001, 50, 444-454. | 0.3 | 128       |
| 163 | Assessment of Risks Associated With Cardiovascular Gene Therapy in Human Subjects. <i>Circulation Research</i> , 2001, 89, 389-400.  | 2.0 | 141       |
| 164 | Inhibition of Angiogenesis by Adenovirus-Mediated sFlt-1 Expression in a Rat Model of Corneal Neovascularization. <i>Human Gene Therapy</i> , 2001, 12, 1299-1310.   | 1.4 | 97        |
| 165 | Differential retinal angiogenic response to sustained intravitreal release of VEGF and bFGF in different pigmented rabbit breeds. <i>Current Eye Research</i> , 2002, 24, 245-252.   | 0.7 | 8         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 166 | Endothelial Dysfunction in Children with Type 1 Diabetes Mellitus. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2002, 15, 343-61.  | 0.4 | 24        |
| 167 | Down-regulation of Vascular Endothelial Growth Factor and Up-regulation of Pigment Epithelium-derived Factor. <i>Journal of Biological Chemistry</i> , 2002, 277, 9492-9497.   | 1.6 | 119       |
| 168 | Blood pressure control and diabetic retinopathy. <i>British Journal of Ophthalmology</i> , 2002, 86, 365-367.  | 2.1 | 51        |
| 169 | Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF $\alpha$ suppression. <i>FASEB Journal</i> , 2002, 16, 438-440.  | 0.2 | 544       |
| 170 | Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1. <i>Gene Therapy</i> , 2002, 9, 320-326.   | 2.3 | 149       |
| 171 | Regulation of Angiogenesis in Diabetic Retinopathy. <i>JAMA Ophthalmology</i> , 2002, 120, 1075.   | 2.6 | 82        |
| 172 | Advanced Glycation End Product-induced Apoptosis and Overexpression of Vascular Endothelial Growth Factor and Monocyte Chemoattractant Protein-1 in Human-cultured Mesangial Cells. <i>Journal of Biological Chemistry</i> , 2002, 277, 20309-20315.                   | 1.6 | 275       |
| 173 | Therapies directed at vascular endothelial growth factor. <i>Expert Opinion on Investigational Drugs</i> , 2002, 11, 1715-1736.  | 1.9 | 89        |
| 174 | Difference in Ischemic Regulation of Vascular Endothelial Growth Factor and Pigment Epithelium-Derived Factor in Brown Norway and Sprague Dawley Rats Contributing to Different Susceptibilities to Retinal Neovascularization. <i>Diabetes</i> , 2002, 51, 1218-1225. | 0.3 | 91        |
| 175 | Decreased Cardiac Expression of Vascular Endothelial Growth Factor and Its Receptors in Insulin-Resistant and Diabetic States. <i>Circulation</i> , 2002, 105, 373-379.  | 1.6 | 325       |
| 176 | Review: The renin-angiotensin-aldosterone system and the eye in diabetes. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2002, 3, 243-246.   | 1.0 | 41        |
| 177 | PRECLINICAL AND PHASE 1A CLINICAL EVALUATION OF AN ANTI-VEGF PEGYLATED APTAMER (EYE001) FOR THE TREATMENT OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2002, 22, 143-152.  | 1.0 | 411       |
| 178 | Vascular endothelial growth factor gene regulation and action in diabetic retinopathy. <i>Ophthalmology Clinics of North America</i> , 2002, 15, 69-79.  | 1.8 | 33        |
| 179 | Intraventricular Infusion of Vascular Endothelial Growth Factor Promotes Cerebral Angiogenesis with Minimal Brain Edema. <i>Neurosurgery</i> , 2002, 50, 589-598.  | 0.6 | 86        |
| 180 | RETINAL ANGIOPATHY AND POLYPOIDAL CHOROIDAL VASCULOPATHY. <i>Retina</i> , 2002, 22, 455-463.   | 1.0 | 20        |
| 181 | Intraventricular Infusion of Vascular Endothelial Growth Factor Promotes Cerebral Angiogenesis with Minimal Brain Edema. <i>Neurosurgery</i> , 2002, 50, 589-598.  | 0.6 | 67        |
| 182 | [34] A survival model for the study of myocardial angiogenesis. <i>Methods in Enzymology</i> , 2002, 352, 391-407.   | 0.4 | 6         |
| 183 | Correlation of Increased Vascular Endothelial Growth Factor With Neovascularization and Permeability in Ischemic Central Vein Occlusion. <i>JAMA Ophthalmology</i> , 2002, 120, 1644.  | 2.6 | 213       |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 184 | Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. <i>American Journal of Ophthalmology</i> , 2002, 133, 373-385.  | 1.7 | 240       |
| 185 | Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors. <i>American Journal of Ophthalmology</i> , 2002, 133, 693-698.  | 1.7 | 106       |
| 186 | Inducible Expression of Vascular Endothelial Growth Factor in Adult Mice Causes Severe Proliferative Retinopathy and Retinal Detachment. <i>American Journal of Pathology</i> , 2002, 160, 711-719.  | 1.9 | 166       |
| 187 | Inhibition of Proliferative Retinopathy by the Anti-Vascular Agent Combretastatin-A4. <i>American Journal of Pathology</i> , 2002, 160, 1097-1103.   | 1.9 | 53        |
| 188 | Effects of Angiogenic Growth Factor Combinations on Retinal Endothelial Cells. <i>Experimental Eye Research</i> , 2002, 74, 523-535.   | 1.2 | 99        |
| 189 | Hypoxic Preconditioning Triggers Myocardial Angiogenesis: a Novel Approach to Enhance Contractile Functional Reserve in Rat with Myocardial Infarction. <i>Journal of Molecular and Cellular Cardiology</i> , 2002, 34, 335-348.                     | 0.9 | 80        |
| 190 | Advanced Glycation End Products-Induced Apoptosis and Overexpression of Vascular Endothelial Growth Factor in Bovine Retinal Pericytes. <i>Biochemical and Biophysical Research Communications</i> , 2002, 290, 973-978.                             | 1.0 | 204       |
| 191 | Oxidative Stress and Stress-Activated Signaling Pathways: A Unifying Hypothesis of Type 2 Diabetes. <i>Endocrine Reviews</i> , 2002, 23, 599-622.  | 8.9 | 1,818     |
| 192 | Selective induction of neuropilin-1 by vascular endothelial growth factor (VEGF): A mechanism contributing to VEGF-induced angiogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 383-388. | 3.3 | 150       |
| 193 | A Common Polymorphism in the 5'-Untranslated Region of the VEGF Gene Is Associated With Diabetic Retinopathy in Type 2 Diabetes. <i>Diabetes</i> , 2002, 51, 1635-1639.  | 0.3 | 501       |
| 194 | VEGF-Trap: A VEGF blocker with potent antitumor effects. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 11393-11398.   | 3.3 | 1,572     |
| 195 | Is diabetic retinopathy an inflammatory disease?. <i>British Journal of Ophthalmology</i> , 2002, 86, 363-365.   | 2.1 | 306       |
| 196 | Principals of neovascularization for tissue engineering. <i>Molecular Aspects of Medicine</i> , 2002, 23, 463-483.   | 2.7 | 366       |
| 197 | Sorbitol dehydrogenase overexpression potentiates glucose toxicity to cultured retinal pericytes. <i>Biochemical and Biophysical Research Communications</i> , 2002, 299, 183-188.   | 1.0 | 56        |
| 198 | Vascular endothelial growth factor gene expression in a retinal pigmented cell is up-regulated by glucose deprivation through 3' UTR. <i>Life Sciences</i> , 2002, 71, 1607-1614.  | 2.0 | 17        |
| 199 | Prediction of macular edema exacerbation after phacoemulsification in patients with nonproliferative diabetic retinopathy. <i>Journal of Cataract and Refractive Surgery</i> , 2002, 28, 1355-1363.  | 0.7 | 59        |
| 200 | Angiopoietin-2 Is Required for Postnatal Angiogenesis and Lymphatic Patterning, and Only the Latter Role Is Rescued by Angiopoietin-1. <i>Developmental Cell</i> , 2002, 3, 411-423.   | 3.1 | 903       |
| 201 | Plasma Level of Interleukin-6 Is an Indicator for Predicting Diabetic Macular Edema. <i>Japanese Journal of Ophthalmology</i> , 2002, 46, 78-83.   | 0.9 | 39        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 202 | Non-Paralleled Increase of Hepatocyte Growth Factor and Vascular Endothelial Growth Factor in the Eyes with Angiogenic and Nonangiogenic Fibroproliferation. <i>Ophthalmic Research</i> , 2002, 34, 43-47.  | 1.0  | 43        |
| 203 | Correlation of Blood-Glucose Control with Oxidative Metabolites in Plasma and Vitreous Body of Diabetic Patients. <i>European Journal of Ophthalmology</i> , 2002, 12, 94-101.  | 0.7  | 17        |
| 204 | Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2002, 124, 28-34.   | 0.4  | 145       |
| 205 | Therapeutic Efficacy of <i>Stephania tetrandra</i> S. Moore for treatment of neovascularization of retinal capillary (retinopathy) in diabetes – in vitro study. <i>Phytomedicine</i> , 2002, 9, 377-384.   | 2.3  | 30        |
| 206 | Advanced glycation end products increase, through a protein kinase C-dependent pathway, vascular endothelial growth factor expression in retinal endothelial cells. <i>Journal of Diabetes and Its Complications</i> , 2002, 16, 284-293.             | 1.2  | 62        |
| 207 | Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin. <i>Journal of Neurochemistry</i> , 2002, 80, 667-677.  | 2.1  | 257       |
| 208 | The pathogenesis of diabetic retinopathy: old concepts and new questions. <i>Eye</i> , 2002, 16, 242-260.   | 1.1  | 287       |
| 209 | VEGF and the quest for tumour angiogenesis factors. <i>Nature Reviews Cancer</i> , 2002, 2, 795-803.  | 12.8 | 1,363     |
| 210 | Use of somatostatin receptor ligands in obesity and diabetic complications. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2002, 16, 493-509.   | 1.0  | 33        |
| 211 | Novel Function of Ascorbic Acid as an Angiostatic Factor. <i>Angiogenesis</i> , 2003, 6, 259-269.   | 3.7  | 63        |
| 212 | HGF/NK4 inhibited VEGF-induced angiogenesis in in vitro cultured endothelial cells and in vivo rabbit model. <i>Diabetologia</i> , 2003, 46, 115-123.   | 2.9  | 38        |
| 213 | Low content of the natural ocular anti-angiogenic agent pigment epithelium-derived factor (PEDF) in aqueous humor predicts progression of diabetic retinopathy. <i>Diabetologia</i> , 2003, 46, 394-400.  | 2.9  | 134       |
| 214 | Vascular endothelial growth factors and angiogenesis in eye disease. <i>Progress in Retinal and Eye Research</i> , 2003, 22, 1-29.  | 7.3  | 829       |
| 215 | Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition. <i>Progress in Retinal and Eye Research</i> , 2003, 22, 721-748.   | 7.3  | 212       |
| 216 | Cerebral angiogenesis and expression of VEGF after subarachnoid hemorrhage (SAH) in rats. <i>Brain Research</i> , 2003, 981, 58-69.   | 1.1  | 52        |
| 217 | Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. <i>European Journal of Pharmacology</i> , 2003, 458, 283-289.  | 1.7  | 135       |
| 218 | Inhibition of protein kinase C decreases prostaglandin-induced breakdown of the blood-retinal barrier. <i>Journal of Cellular Physiology</i> , 2003, 195, 210-219.  | 2.0  | 51        |
| 219 | Transforming growth factor- $\beta$ induces expression of vascular endothelial growth factor in human retinal pigment epithelial cells: Involvement of mitogen-activated protein kinases. <i>Journal of Cellular Physiology</i> , 2003, 197, 453-462. | 2.0  | 158       |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 220 | Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. <i>Diabetes/Metabolism Research and Reviews</i> , 2003, 19, 442-455.   | 1.7 | 253       |
| 221 | Angiogenesis of the heart. <i>Microscopy Research and Technique</i> , 2003, 60, 138-158.  | 1.2 | 42        |
| 222 | Intrapericardial administration of basic fibroblast growth factor: Myocardial and tissue distribution and comparison with intracoronary and intravenous administration. <i>Catheterization and Cardiovascular Interventions</i> , 2003, 58, 375-381.  | 0.7 | 55        |
| 223 | The renin-angiotensin system and the long-term complications of diabetes: pathophysiological and therapeutic considerations. <i>Diabetic Medicine</i> , 2003, 20, 607-621.  | 1.2 | 75        |
| 224 | Angiopoietin/Tek Interactions Regulate MMP-9 Expression and Retinal Neovascularization. <i>Laboratory Investigation</i> , 2003, 83, 1637-1645.  | 1.7 | 73        |
| 225 | Perspectives on diabetic retinopathy. <i>American Journal of Ophthalmology</i> , 2003, 136, 122-135.  | 1.7 | 251       |
| 226 | Experimental Diabetes Causes Breakdown of the Blood-Retina Barrier by a Mechanism Involving Tyrosine Nitration and Increases in Expression of Vascular Endothelial Growth Factor and Urokinase Plasminogen Activator Receptor. <i>American Journal of Pathology</i> , 2003, 162, 1995-2004. | 1.9 | 187       |
| 227 | Expression of pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in sickle cell retina and choroid. <i>Experimental Eye Research</i> , 2003, 77, 433-445.   | 1.2 | 71        |
| 228 | A peptide encoded by exon 6 of VEGF (EG3306) inhibits VEGF-induced angiogenesis in vitro and ischaemic retinal neovascularisation in vivo. <i>Biochemical and Biophysical Research Communications</i> , 2003, 302, 793-799.   | 1.0 | 26        |
| 229 | Age-Related Macular Degeneration: Etiology, Pathogenesis, and Therapeutic Strategies. <i>Survey of Ophthalmology</i> , 2003, 48, 257-293.   | 1.7 | 863       |
| 230 | Increased concentration of pentosidine, an advanced glycation end product, and interleukin-6 in the vitreous of patients with proliferative diabetic retinopathy. <i>Diabetes Research and Clinical Practice</i> , 2003, 61, 93-101.  | 1.1 | 58        |
| 231 | Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration. <i>Ophthalmology</i> , 2003, 110, 979-986.  | 2.5 | 330       |
| 232 | Combretastatins: from natural products to drug discovery. <i>Natural Product Reports</i> , 2003, 20, 558.   | 5.2 | 203       |
| 233 | Pathogenesis of retinopathy of prematurity. <i>Seminars in Fetal and Neonatal Medicine</i> , 2003, 8, 469-473.  | 2.8 | 187       |
| 234 | Vascular endothelial growth factor. , 2003, , 1017-1034.  |     | 3         |
| 235 | Therapeutic angiogenesis: protein-based therapy for coronary artery disease. <i>Expert Opinion on Pharmacotherapy</i> , 2003, 4, 219-226.   | 0.9 | 8         |
| 236 | Angiogenesis: basic pathophysiology and implications for disease. <i>European Heart Journal</i> , 2003, 24, 586-603.  | 1.0 | 156       |
| 237 | The therapeutic potential of somatostatin receptor ligands in the treatment of obesity and diabetes. <i>Expert Opinion on Investigational Drugs</i> , 2003, 12, 1501-1509.  | 1.9 | 22        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 238 | A Selective and Oral Small Molecule Inhibitor of Vascular Epithelial Growth Factor Receptor (VEGFR)-2 and VEGFR-1 Inhibits Neovascularization and Vascular Permeability. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 306, 838-845. | 1.3 | 43        |
| 239 | Enhanced Recombinant Adeno-Associated Virus-Mediated Vascular Endothelial Growth Factor Expression in the Adult Mouse Retina: A Potential Model for Diabetic Retinopathy. <i>Diabetes</i> , 2003, 52, 857-863.  | 0.3 | 36        |
| 240 | Production and Activation of Matrix Metalloproteinase-2 in Proliferative Diabetic Retinopathy. , 2003, 44, 2163.  |     | 124       |
| 241 | Proliferative Diabetic Retinopathy is Associated with a Low Level of the Natural Ocular Anti-angiogenic Agent Pigment Epithelium-derived Factor (PEDF) in Aqueous Humor. A Pilot Study. <i>Hormone and Metabolic Research</i> , 2003, 35, 382-386.          | 0.7 | 46        |
| 242 | Rapid Insulin-Like Growth Factor (IGF)-Independent Effects of IGF Binding Protein-3 on Endothelial Cell Survival. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 900-907.  | 1.8 | 75        |
| 243 | Retinal Oxygen. <i>JAMA Ophthalmology</i> , 2003, 121, 547.   | 2.6 | 481       |
| 244 | Gene therapy for ocular angiogenesis. <i>Clinical Science</i> , 2003, 104, 561-575.   | 1.8 | 45        |
| 245 | Choroidal Neovascular Membranes Treated With Photodynamic Therapy. <i>JAMA Ophthalmology</i> , 2003, 121, 898.  | 2.6 | 14        |
| 246 | Subconjunctival Nano- and Microparticles Sustain Retinal Delivery of Budesonide, a Corticosteroid Capable of Inhibiting VEGF Expression. , 2003, 44, 1192.  |     | 227       |
| 247 | The Kinase Inhibitor PKC412 Suppresses Epiretinal Membrane Formation and Retinal Detachment in Mice with Proliferative Retinopathies. , 2003, 44, 3656.   |     | 21        |
| 248 | Corneal Transduction to Inhibit Angiogenesis and Graft Failure. , 2003, 44, 1837.   |     | 55        |
| 249 | VEGF164Is Proinflammatory in the Diabetic Retina. , 2003, 44, 2155.   |     | 360       |
| 250 | Supplemental Oxygen Improves Diabetic Macular Edema: A Pilot Study. , 2004, 45, 617.  |     | 174       |
| 251 | Cardiovascular Gene Therapy: Angiogenesis and Beyond. <i>American Journal of the Medical Sciences</i> , 2004, 327, 139-148.   | 0.4 | 18        |
| 252 | Development and pathology of the hyaloid, choroidal and retinal vasculature. <i>International Journal of Developmental Biology</i> , 2004, 48, 1045-1058.   | 0.3 | 349       |
| 253 | Effect of Glucose Degradation Products on the Peritoneal Membrane in a Chronic Inflammatory Infusion Model of Peritoneal Dialysis in the Rat. <i>Peritoneal Dialysis International</i> , 2004, 24, 115-122.   | 1.1 | 33        |
| 254 | VEGF164(165)as the Pathological Isoform: Differential Leukocyte and Endothelial Responses through VEGFR1 and VEGFR2. , 2004, 45, 368.   |     | 153       |
| 255 | Possible Role of VEGF in the Progression of Kidney Disease in Streptozotocin (STZ)-induced Diabetic Rats: Effects of an ACE Inhibitor and an Angiotensin II Receptor Antagonist. <i>Hormone and Metabolic Research</i> , 2004, 36, 458-464.                 | 0.7 | 19        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 256 | Connective Tissue Growth Factor Is Up-Regulated in the Diabetic Retina: Amelioration by Angiotensin-Converting Enzyme Inhibition. <i>Endocrinology</i> , 2004, 145, 860-866.   | 1.4 | 69        |
| 257 | Accumulation of NH <sub>2</sub> -Terminal Fragment of Connective Tissue Growth Factor in the Vitreous of Patients With Proliferative Diabetic Retinopathy. <i>Diabetes Care</i> , 2004, 27, 758-764.                                   | 4.3 | 78        |
| 258 | Discovery of a Novel Control Element within the 5'UTR of the Vascular Endothelial Growth Factor. <i>Journal of Biological Chemistry</i> , 2004, 279, 37808-37814.  | 1.6 | 3         |
| 259 | Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy. <i>FASEB Journal</i> , 2004, 18, 805-815.  | 0.2 | 73        |
| 260 | Risk evaluation of outcome of vitreous surgery for proliferative diabetic retinopathy based on vitreous level of vascular endothelial growth factor and angiotensin II. <i>British Journal of Ophthalmology</i> , 2004, 88, 1064-1068. | 2.1 | 24        |
| 261 | Association of the VEGF Gene With Proliferative Diabetic Retinopathy But Not Proteinuria in Diabetes. <i>Diabetes</i> , 2004, 53, 861-864.   | 0.3 | 170       |
| 262 | Effects of Growth-Factor Combinations on Vascular Endothelial Cell Growth In Vitro. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2004, 20, 554-562.  | 0.6 | 5         |
| 263 | Prolactin in Eyes of Patients with Retinopathy of Prematurity: Implications for Vascular Regression. , 2004, 45, 2049.   |     | 52        |
| 264 | Medical management of diabetic retinopathy. <i>Diabetic Medicine</i> , 2004, 21, 666-672.  | 1.2 | 14        |
| 265 | Growth factors and protein kinase C inhibitors as novel therapies for the medical management diabetic retinopathy. <i>Eye</i> , 2004, 18, 117-125.   | 1.1 | 19        |
| 266 | Vascular factors altered in glucose-treated mesangial cells and diabetic glomeruli. Changes in vascular factors impair endothelial cell growth and matrix. <i>Laboratory Investigation</i> , 2004, 84, 597-606.                        | 1.7 | 29        |
| 267 | Inhibition of the vascular-endothelial growth factor-induced intracellular signaling and mitogenesis of human endothelial cells by epigallocatechin-3 gallate. <i>European Journal of Pharmacology</i> , 2004, 483, 223-227.           | 1.7 | 46        |
| 268 | Retinal Delivery of Celecoxib Is Several-Fold Higher Following Subconjunctival Administration Compared to Systemic Administration. <i>Pharmaceutical Research</i> , 2004, 21, 1797-1804.   | 1.7 | 64        |
| 269 | Plasminogen kringle 5 reduces vascular leakage in the retina in rat models of oxygen-induced retinopathy and diabetes. <i>Diabetologia</i> , 2004, 47, 124-131.  | 2.9 | 58        |
| 270 | Intraocular gutless adenoviral-vectored VEGF stimulates anterior segment but not retinal neovascularization. <i>Journal of Cellular Physiology</i> , 2004, 199, 399-411.   | 2.0 | 17        |
| 271 | Marked inhibition of retinal neovascularization in rats following soluble-flt-1 gene transfer. <i>Journal of Gene Medicine</i> , 2004, 6, 992-1002.  | 1.4 | 57        |
| 272 | Matrix Metalloproteinase Release From Placental Explants of Pregnancies Complicated by Intrauterine Growth Restriction. <i>Journal of the Society for Gynecologic Investigation</i> , 2004, 11, 97-103.                                | 1.9 | 34        |
| 273 | VEGF increases paracellular transport without altering the solvent-drag reflection coefficient. <i>Microvascular Research</i> , 2004, 68, 295-302.   | 1.1 | 17        |



| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 274 | Pegaptanib for Neovascular Age-Related Macular Degeneration. <i>New England Journal of Medicine</i> , 2004, 351, 2805-2816.  | 13.9 | 2,204     |
| 275 | Pathogenesis of retinopathy of prematurity. <i>Growth Hormone and IGF Research</i> , 2004, 14, 140-144.  | 0.5  | 176       |
| 276 | Effect of COX inhibitors on VEGF-induced retinal vascular leakage and experimental corneal and choroidal neovascularization. <i>Experimental Eye Research</i> , 2004, 79, 275-285.                             | 1.2  | 61        |
| 277 | Inhibition of in vitro VEGF expression and choroidal neovascularization by synthetic dendrimer peptide mediated delivery of a sense oligonucleotide. <i>Experimental Eye Research</i> , 2004, 79, 525-535.     | 1.2  | 89        |
| 278 | Variable oxygen and retinal VEGF levels: correlation with incidence and severity of pathology in a rat model of oxygen-induced retinopathy. <i>Experimental Eye Research</i> , 2004, 79, 623-630.              | 1.2  | 62        |
| 279 | Intravitreal triamcinolone does not alter basal vascular endothelial growth factor mRNA expression in rat retina. <i>Vision Research</i> , 2004, 44, 349-356.  | 0.7  | 38        |
| 280 | PEDF derived from glial MÃ¼ller cells: a possible regulator of retinal angiogenesis. <i>Experimental Cell Research</i> , 2004, 299, 68-78.   | 1.2  | 86        |
| 281 | Persistent secretion of vascular endothelial growth factor into the vitreous cavity in proliferative diabetic retinopathy after vitrectomy. <i>Ophthalmology</i> , 2004, 111, 1880-1884.                       | 2.5  | 53        |
| 282 | Insulin-Like Growth Factor-I Plays a Pathogenetic Role in Diabetic Retinopathy. <i>American Journal of Pathology</i> , 2004, 165, 457-469.   | 1.9  | 136       |
| 283 | Simvastatin Inhibits Leukocyte Accumulation and Vascular Permeability in the Retinas of Rats with Streptozotocin-Induced Diabetes. <i>American Journal of Pathology</i> , 2004, 164, 1697-1706.                | 1.9  | 94        |
| 284 | The relationship between glycemic control and plasma vascular endothelial growth factor and endothelin-1 concentration in diabetic patients. <i>Metabolism: Clinical and Experimental</i> , 2004, 53, 550-555. | 1.5  | 91        |
| 285 | Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor: implications for ocular angiogenesis. <i>American Journal of Ophthalmology</i> , 2004, 137, 668-674.              | 1.7  | 81        |
| 286 | Expression of ephrinB2 and its receptors on fibroproliferative membranes in ocular angiogenic diseases. <i>American Journal of Ophthalmology</i> , 2004, 138, 270-279.   | 1.7  | 35        |
| 287 | The effect of angiostatin on vascular leakage and VEGF expression in rat retina. <i>FEBS Letters</i> , 2004, 564, 19-23.   | 1.3  | 44        |
| 288 | Supplemental oxygen improves diabetic macular edema: a pilot study. <i>American Journal of Ophthalmology</i> , 2004, 137, 975.   | 1.7  | 7         |
| 289 | Therapeutic angiogenesis: the next frontier for interventional radiology. <i>Techniques in Vascular and Interventional Radiology</i> , 2004, 7, 40-48.   | 0.4  | 10        |
| 290 | Pharmacotherapy for diabetic retinopathy. <i>Current Opinion in Ophthalmology</i> , 2004, 15, 508-518.   | 1.3  | 56        |
| 291 | Angiogenesis-related factors derived from retinal glial (MÃ¼ller) cells in hypoxia. <i>NeuroReport</i> , 2004, 15, 1633-1637.  | 0.6  | 94        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 294 | Proliferative Diabetic Retinopathy. International Ophthalmology Clinics, 2004, 44, 69-84.   | 0.3  | 37        |
| 295 | Anti-Vascular Endothelial Growth Factor Strategies for the Treatment of Choroidal Neovascularization From Age-Related Macular Degeneration. International Ophthalmology Clinics, 2004, 44, 23-32.                       | 0.3  | 31        |
| 296 | Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor: implications for ocular angiogenesis*1. American Journal of Ophthalmology, 2004, 137, 668-674.                             | 1.7  | 131       |
| 297 | Retinal Bioengineering. , 2005, , 421-484.  |      | 1         |
| 298 | A Novel Src Kinase Inhibitor, M475271, Inhibits VEGF-Induced Human Umbilical Vein Endothelial Cell Proliferation and Migration. Journal of Pharmacological Sciences, 2005, 98, 130-141.                                 | 1.1  | 37        |
| 299 | THE ROLE OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN OCULAR HEALTH AND DISEASE. Retina, 2005, 25, 111-118.   | 1.0  | 325       |
| 300 | ENHANCED EFFICACY ASSOCIATED WITH EARLY TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH PEGAPTANIB SODIUM. Retina, 2005, 25, 815-827.  | 1.0  | 113       |
| 301 | Micro- and nanoparticulates. Advanced Drug Delivery Reviews, 2005, 57, 2047-2052.   | 6.6  | 86        |
| 302 | Impaired vascular function during short-term poor glycaemic control in Type 1 diabetic patients. Diabetic Medicine, 2005, 22, 871-876.  | 1.2  | 35        |
| 303 | Retinal angiogenesis in development and disease. Nature, 2005, 438, 960-966.  | 13.7 | 613       |
| 304 | Treatments for choroidal and retinal neovascularization: a focus on oligonucleotide therapy and delivery for the regulation of gene function. Clinical and Experimental Ophthalmology, 2005, 33, 81-89.                 | 1.3  | 13        |
| 305 | Retinal neovascularisation without ischaemia in the spontaneously diabetic Torii rat. Diabetologia, 2005, 48, 1663-1668.  | 2.9  | 42        |
| 306 | Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor. Diabetologia, 2005, 48, 2422-2427.  | 2.9  | 200       |
| 307 | Intravitreal injection of specific receptor tyrosine kinase inhibitor PTK787/ZK222 584 improves ischemia-induced retinopathy in mice. Graefe's Archive for Clinical and Experimental Ophthalmology, 2005, 243, 593-600. | 1.0  | 31        |
| 308 | Anti-inflammatory Effect of Docosahexaenoic Acid on Cytokine-Induced Adhesion Molecule Expression in Human Retinal Vascular Endothelial Cells. , 2005, 46, 4342.  |      | 149       |
| 309 | Disorders of the Eye. , 2005, , 1539-1555.  |      | 1         |
| 310 | Intraretinal pH in Diabetic Cats. Current Eye Research, 2005, 30, 229-240.  | 0.7  | 28        |
| 311 | Regulation of Vascular Genes by Glucose. Current Pharmaceutical Design, 2005, 11, 2367-2381.  | 0.9  | 41        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 312 | Diabetic Vascular Complications: Pathophysiology, Biochemical Basis and Potential Therapeutic Strategy. <i>Current Pharmaceutical Design</i> , 2005, 11, 2279-2299.  | 0.9 | 432       |
| 313 | Down-Regulation of Angiogenic Inhibitors: A Potential Pathogenic Mechanism for Diabetic Complications. <i>Current Diabetes Reviews</i> , 2005, 1, 183-196.   | 0.6 | 17        |
| 314 | Role of Cytokines and Trophic Factors in the Pathogenesis of Diabetic Retinopathy. <i>Current Diabetes Reviews</i> , 2005, 1, 73-81.   | 0.6 | 42        |
| 315 | Advanced Glycation End Products (AGEs) and Diabetic Vascular Complications. <i>Current Diabetes Reviews</i> , 2005, 1, 93-106.   | 0.6 | 141       |
| 316 | Suppression and Regression of Choroidal Neovascularization by Polyamine Analogues. , 2005, 46, 3323.   |     | 26        |
| 317 | Vascular Targeting of Ocular Neovascularization with a Vascular Endothelial Growth Factor121/Gelonin Chimeric Protein. <i>Molecular Pharmacology</i> , 2005, 68, 1543-1550.  | 1.0 | 28        |
| 318 | Dicer Is Required for Embryonic Angiogenesis during Mouse Development. <i>Journal of Biological Chemistry</i> , 2005, 280, 9330-9335.  | 1.6 | 472       |
| 319 | Vascular Endothelial Growth Factor and Diabetic Retinopathy: Role of Oxidative Stress. <i>Current Drug Targets</i> , 2005, 6, 511-524.   | 1.0 | 212       |
| 320 | Long-term Evaluation of AAV-Mediated sFlt-1 Gene Therapy for Ocular Neovascularization in Mice and Monkeys. <i>Molecular Therapy</i> , 2005, 12, 659-668.  | 3.7 | 120       |
| 321 | Adeno-Associated Virus-Mediated Expression of Vascular Endothelial Growth Factor Peptides Inhibits Retinal Neovascularization in a Mouse Model of Oxygen-Induced Retinopathy. <i>Human Gene Therapy</i> , 2005, 16, 1247-1254.             | 1.4 | 17        |
| 322 | Nonhuman Primate Models for Diabetic Ocular Neovascularization Using AAV2-Mediated Overexpression of Vascular Endothelial Growth Factor. <i>Diabetes</i> , 2005, 54, 1141-1149.  | 0.3 | 64        |
| 323 | Retinal Vascular Regeneration. <i>Seminars in Ophthalmology</i> , 2005, 20, 43-50.   | 0.8 | 9         |
| 324 | Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. <i>Canadian Journal of Ophthalmology</i> , 2005, 40, 352-368.   | 0.4 | 241       |
| 326 | Preclinical Pharmacokinetics of Ranibizumab (rhuFabV2) after a Single Intravitreal Administration. , 2005, 46, 726.  |     | 472       |
| 327 | Systemic and Periocular Deliveries of Plasminogen Kringle 5 Reduce Vascular Leakage in Rat Models of Oxygen-Induced Retinopathy and Diabetes. <i>Current Eye Research</i> , 2005, 30, 681-689.   | 0.7 | 19        |
| 328 | Vascular endothelial growth factor expression and microvessel parameters of colonic mucosa correlate with sensitivity to steroid in patients with ulcerative colitis. <i>Scandinavian Journal of Gastroenterology</i> , 2005, 40, 188-193. | 0.6 | 7         |
| 329 | Oxygen distribution and vascular injury in the mouse eye measured by phosphorescence-lifetime imaging. <i>Applied Optics</i> , 2005, 44, 5239.   | 2.1 | 46        |
| 330 | Aptamers: An Emerging Class of Therapeutics. <i>Annual Review of Medicine</i> , 2005, 56, 555-583.   | 5.0 | 868       |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 331 | Vascular Endothelial Growth Factor Gene Delivery by Magnetic DNA Nanospheres Ameliorates Limb Ischemia in Rabbits <sup>1</sup> . <i>Journal of Surgical Research</i> , 2005, 126, 48-54.                        | 0.8 | 32        |
| 332 | Upregulation of placental growth factor by vascular endothelial growth factor via a post-transcriptional mechanism. <i>FEBS Letters</i> , 2005, 579, 1227-1234.   | 1.3 | 34        |
| 333 | Maximum Tolerated Dose of a Humanized Anti-VEGF Vascular Endothelial Growth Factor Antibody Fragment for Treating Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2005, 112, 1048-1053.e4. | 2.5 | 219       |
| 334 | A Phase II Randomized Double-Masked Trial of Pegaptanib, an Anti-VEGF Vascular Endothelial Growth Factor Aptamer, for Diabetic Macular Edema. <i>Ophthalmology</i> , 2005, 112, 1747-1757.                      | 2.5 | 581       |
| 335 | Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. <i>American Journal of Ophthalmology</i> , 2005, 139, 476-481.                    | 1.7 | 187       |
| 336 | Expression of VEGF and angiopoietins in subfoveal membranes from patients with age-related macular degeneration. <i>American Journal of Ophthalmology</i> , 2005, 139, 589-596.                                 | 1.7 | 75        |
| 337 | The role of VEGF in the regulation of physiological and pathological angiogenesis. , 2005, , 209-231.   |     | 195       |
| 338 | Neural Engineering. <i>Bioelectric Engineering</i> , 2005, , .  | 0.7 | 46        |
| 339 | Aptamers to Proteins. , 2006, , 131-166.  |     | 7         |
| 340 | Applications in the Clinic: The Anti-VEGF Aptamer. , 2006, , 443-460.   |     | 1         |
| 342 | AAV-mediated gene transfer for retinal diseases. <i>Expert Opinion on Biological Therapy</i> , 2006, 6, 1279-1294.  | 1.4 | 36        |
| 343 | Neuroprotective and Blood-Retinal Barrier-Preserving Effects of Cannabidiol in Experimental Diabetes. <i>American Journal of Pathology</i> , 2006, 168, 235-244.  | 1.9 | 235       |
| 344 | VEGF function in vascular pathogenesis. <i>Experimental Cell Research</i> , 2006, 312, 527-537.   | 1.2 | 114       |
| 345 | Anti-VEGF Therapies for Diseases of the Retina and Choroid. , 2006, , 309-339.  |     | 0         |
| 346 | Single Periocular Injection of Celecoxib-PLGA Microparticles Inhibits Diabetes-Induced Elevations in Retinal PGE <sub>2</sub> , VEGF, and Vascular Leakage. , 2006, 47, 1149.                                   |     | 148       |
| 347 | Inhibition of Ocular Angiogenesis by Diced Small Interfering RNAs (siRNAs) Specific to Vascular Endothelial Growth Factor (VEGF). <i>Current Eye Research</i> , 2006, 31, 171-180.                              | 0.7 | 48        |
| 348 | Regression of Iris Neovascularization After Intravitreal Injection of Bevacizumab in Patients With Proliferative Diabetic Retinopathy. <i>American Journal of Ophthalmology</i> , 2006, 142, 155-157.e1.        | 1.7 | 186       |
| 349 | Intracameral Bevacizumab for Iris Rubeosis. <i>American Journal of Ophthalmology</i> , 2006, 142, 158-160.  | 1.7 | 192       |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 350 | Progression of Choroidal Neovascularization Following Injection of Pegaptanib Sodium (Macugen) in Two Eyes With Neovascular Age-related Macular Degeneration. American Journal of Ophthalmology, 2006, 142, 683-685.e1.                                       | 1.7 | 6         |
| 351 | Downregulation of vascular endothelial growth factor and integrin $\alpha$ 3 by endostatin in a mouse model of retinal neovascularization. Experimental Eye Research, 2006, 82, 74-80.  | 1.2 | 18        |
| 352 | High levels of pigment epithelium-derived factor in the retina of a rat model of type 2 diabetes. Experimental Eye Research, 2006, 82, 172-178.   | 1.2 | 29        |
| 353 | Inhibition of TNF $\alpha$ reduces laser-induced choroidal neovascularization. Experimental Eye Research, 2006, 83, 1325-1334.  | 1.2 | 117       |
| 354 | Glucosamine-induced phosphorylation of the $\alpha$ -subunit of eukaryotic initiation factor 2 is mediated by the protein kinase R-like endoplasmic-reticulum associated kinase. International Journal of Biochemistry and Cell Biology, 2006, 38, 1004-1014. | 1.2 | 17        |
| 355 | Changes in Retinal Neovascularization after Pegaptanib (Macugen) Therapy in Diabetic Individuals. Ophthalmology, 2006, 113, 23-28.  | 2.5 | 243       |
| 356 | Pegaptanib Sodium for Neovascular Age-Related Macular Degeneration. Ophthalmology, 2006, 113, 992-1001.e6.  | 2.5 | 239       |
| 357 | Year 2 Efficacy Results of 2 Randomized Controlled Clinical Trials of Pegaptanib for Neovascular Age-Related Macular Degeneration. Ophthalmology, 2006, 113, 1508.e1-1508.e25.  | 2.5 | 155       |
| 358 | Ocular Oxygenation and the Treatment of Diabetic Retinopathy. Survey of Ophthalmology, 2006, 51, 364-380.   | 1.7 | 239       |
| 359 | VEGF Activation of Protein Kinase C Stimulates Occludin Phosphorylation and Contributes to Endothelial Permeability. , 2006, 47, 5106.  |     | 215       |
| 361 | Retinopathy Is Reduced during Experimental Diabetes in a Mouse Model of Outer Retinal Degeneration. , 2006, 47, 5561.   |     | 117       |
| 362 | Bovine and Porcine Transscleral Solute Transport: Influence of Lipophilicity and the Choroid $\rightarrow$ Bruch $\rightarrow$ TM's Layer. , 2006, 47, 4513.  |     | 86        |
| 364 | Vitreous Fluid Biomarkers. Advances in Clinical Chemistry, 2006, 42, 111-166.   | 1.8 | 12        |
| 365 | INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT OF PROLIFERATIVE DIABETIC RETINOPATHY COMPLICATED BY VITREOUS HEMORRHAGE. Retina, 2006, 26, 275-278.   | 1.0 | 484       |
| 366 | INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR PERSISTENT NEW VESSELS IN DIABETIC RETINOPATHY (IBEPE) Tj ETQq0 0 0 rgBT /Overloc  | 1.0 | 237       |
| 367 | SAFETY OF INTRAVITREAL INJECTION OF BEVACIZUMAB IN RABBIT EYES. Retina, 2006, 26, 882-888.  | 1.0 | 71        |
| 368 | INTRAVITREAL BEVACIZUMAB (AVASTIN) THERAPY FOR PERSISTENT DIFFUSE DIABETIC MACULAR EDEMA. Retina, 2006, 26, 999-1005.   | 1.0 | 423       |
| 369 | Preventive effects of glycaemic control on ocular complications of Spontaneously Diabetic Torii rat. Diabetes, Obesity and Metabolism, 2006, 8, 501-507.  | 2.2 | 47        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 370 | Ocular angiogenesis: the role of growth factors. <i>Acta Ophthalmologica</i> , 2006, 84, 282-288.   | 0.4  | 98        |
| 371 | Intravitreal steroids in the management of macular oedema. <i>Acta Ophthalmologica</i> , 2006, 84, 722-733.   | 0.4  | 64        |
| 372 | New therapies for neovascular age-related macular degeneration: critical appraisal of the current evidence. <i>Acta Ophthalmologica</i> , 2006, 85, 6-20.   | 0.4  | 13        |
| 373 | Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. <i>Nature Reviews Drug Discovery</i> , 2006, 5, 123-132.  | 21.5 | 1,263     |
| 374 | Proliferating endothelial cell-specific expression of IGF-I receptor ribozyme inhibits retinal neovascularization. <i>Gene Therapy</i> , 2006, 13, 752-760.   | 2.3  | 25        |
| 375 | Anti-VEGF Aptamer (Pegaptanib) Therapy for Ocular Vascular Diseases. <i>Annals of the New York Academy of Sciences</i> , 2006, 1082, 151-171.   | 1.8  | 129       |
| 376 | Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA. <i>Advanced Drug Delivery Reviews</i> , 2006, 58, 1203-1223.  | 6.6  | 126       |
| 377 | Pro-angiogenic cytokines and their role in tumor angiogenesis. <i>Cancer and Metastasis Reviews</i> , 2006, 25, 373-385.  | 2.7  | 80        |
| 378 | Expression of Pigment Epithelium-Derived Factor and Vascular Endothelial Growth Factor in Fibrovascular Membranes from Patients with Proliferative Diabetic Retinopathy. <i>Japanese Journal of Ophthalmology</i> , 2006, 50, 116-120.            | 0.9  | 34        |
| 379 | Triamcinolone acetonide suppresses interleukin-1 beta-mediated increase in vascular endothelial growth factor expression in cultured rat MÄ¼ller cells. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2006, 244, 226-231. | 1.0  | 22        |
| 380 | A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2. <i>Cellular and Molecular Life Sciences</i> , 2006, 63, 2067-2077.   | 2.4  | 168       |
| 381 | Long-term global retinal microvascular changes in a transgenic vascular endothelial growth factor mouse model. <i>Diabetologia</i> , 2006, 49, 1690-1701.   | 2.9  | 49        |
| 382 | Angiogenesisâ€”a new target for future therapy. <i>Vascular Pharmacology</i> , 2006, 44, 265-274.   | 1.0  | 277       |
| 383 | Sequential induction of angiogenic growth factors by TNF-Î± in choroidal endothelial cells. <i>Journal of Neuroimmunology</i> , 2006, 171, 45-56.   | 1.1  | 51        |
| 384 | The role of cytokines and trophic factors in epiretinal membranes: Involvement of signal transduction in glial cells. <i>Progress in Retinal and Eye Research</i> , 2006, 25, 149-164.  | 7.3  | 120       |
| 385 | Implication of the hypoxia response element of the vegf promoter in mouse models of retinal and choroidal neovascularization, but not retinal vascular development. <i>Journal of Cellular Physiology</i> , 2006, 206, 749-758.                   | 2.0  | 92        |
| 386 | Intraocular injection of an aptamer that binds PDGF-B: A potential treatment for proliferative retinopathies. <i>Journal of Cellular Physiology</i> , 2006, 207, 407-412.   | 2.0  | 60        |
| 387 | Trabeculectomy with Mitomycin C for Treatment of Neovascular Glaucoma in Diabetic Patients. <i>Ophthalmologica</i> , 2006, 220, 383-388.  | 1.0  | 55        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 388 | Different Plasma Levels of Vascular Endothelial Growth Factor and Nitric Oxide between Patients with Choroidal and Retinal Neovascularization. <i>Ophthalmologica</i> , 2006, 220, 246-251.                                    | 1.0 | 39        |
| 389 | Genetics of Diabetic Retinopathy. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2006, 114, 275-294.  | 0.6 | 73        |
| 390 | Telmisartan, its Potential Therapeutic Implications in Cardiometabolic Disorders. <i>Recent Patents on Cardiovascular Drug Discovery</i> , 2006, 1, 79-83.   | 1.5 | 2         |
| 391 | Angiogenic and Antiangiogenic Factors in Proliferative Diabetic Retinopathy. <i>Current Diabetes Reviews</i> , 2006, 2, 71-98.   | 0.6 | 324       |
| 392 | Feline Models of Type 2 Diabetes Mellitus. <i>ILAR Journal</i> , 2006, 47, 234-242.  | 1.8 | 86        |
| 393 | DNA and RNA Aptamers: From Tools for Basic Research Towards Therapeutic Applications. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2006, 9, 619-632.   | 0.6 | 82        |
| 394 | Antineovascular Agents in the Treatment of Eye Diseases. <i>Current Pharmaceutical Design</i> , 2006, 12, 2645-2660.   | 0.9 | 32        |
| 395 | Advanced Glycation End Products (AGEs) and their Receptor (RAGE) System in Diabetic Retinopathy. <i>Current Drug Discovery Technologies</i> , 2006, 3, 83-88.  | 0.6 | 38        |
| 396 | Atorvastatin and Diabetic Vascular Complications. <i>Current Pharmaceutical Design</i> , 2006, 12, 1549-1554.  | 0.9 | 32        |
| 397 | TAGE (Toxic AGEs) Theory in Diabetic Complications. <i>Current Molecular Medicine</i> , 2006, 6, 351-358.  | 0.6 | 174       |
| 398 | Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF receptor 2 binding in diabetic retinopathy. <i>Journal of Molecular Endocrinology</i> , 2006, 37, 1-12. | 1.1 | 238       |
| 399 | Vascular endothelial growth factor biology: clinical implications for ocular treatments. <i>British Journal of Ophthalmology</i> , 2006, 90, 1542-1547.  | 2.1 | 149       |
| 400 | Obesity and Diabetes. , 2006, , .  |     | 4         |
| 401 | Ocular Angiogenesis. , 2006, , .   |     | 5         |
| 402 | Ranibizumab: treatment in patients with neovascular age-related macular degeneration. <i>Expert Opinion on Biological Therapy</i> , 2006, 6, 1237-1245.  | 1.4 | 32        |
| 403 | Overexpression of FasL in retinal pigment epithelial cells reduces choroidal neovascularization. <i>FASEB Journal</i> , 2006, 20, 1689-1691.   | 0.2 | 33        |
| 404 | Effect of Topical Nipradilol on Retinal Microvascular Leukocyte Adhesion in Diabetic Rats. <i>Ophthalmic Research</i> , 2006, 38, 270-273.   | 1.0 | 8         |
| 405 | Expression of hypoxia-inducible factor-1 $\alpha$ and the protein products of its target genes in diabetic fibrovascular epiretinal membranes. <i>British Journal of Ophthalmology</i> , 2007, 91, 822-826.                    | 2.1 | 63        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 406 | Potential Utility of Telmisartan, an Angiotensin II Type 1 Receptor Blocker with Peroxisome Proliferator-Activated Receptor- $\beta$ (PPAR- $\beta$ )-Modulating Activity for the Treatment of Cardiometabolic Disorders. <i>Current Molecular Medicine</i> , 2007, 7, 463-469. | 0.6 | 72        |
| 407 | Pharmacotherapies for Diabetic Retinopathy: Present and Future. <i>Experimental Diabetes Research</i> , 2007, 2007, 1-8.  | 3.8 | 18        |
| 408 | Vascular Endothelial Growth Factor and the Potential Therapeutic Use of Pegaptanib (Macugen <sup>®</sup> ) in Diabetic Retinopathy. , 2007, 39, 122-148.  |     | 64        |
| 409 | Suppression of Diabetes-Induced Retinal Inflammation by Blocking the Angiotensin II Type 1 Receptor or Its Downstream Nuclear Factor- $\kappa$ B Pathway. , 2007, 48, 4342.   |     | 177       |
| 411 | A chronic grey matter penumbra, lateral microvascular intussusception and venous peduncular avulsion underlie diabetic vitreous haemorrhage. <i>British Journal of Ophthalmology</i> , 2007, 91, 677-689.   | 2.1 | 21        |
| 412 | Rat strain-dependent susceptibility to ischemia-induced retinopathy associated with retinal vascular endothelial growth factor regulation. <i>Journal of Molecular Endocrinology</i> , 2007, 38, 423-432.   | 1.1 | 9         |
| 413 | Grading of Diabetic Retinopathy. , 2007, , 291-391.   |     | 1         |
| 414 | Emerging pharmacotherapies for diabetic macular edema. <i>Expert Opinion on Emerging Drugs</i> , 2007, 12, 591-603.   | 1.0 | 17        |
| 415 | Preclinical Safety Evaluation of Intravitreal Injection of Full-Length Humanized Vascular Endothelial Growth Factor Antibody in Rabbit Eyes. <i>Investigative Ophthalmology and Visual Science</i> , 2007, 48, 1773-1781.   | 3.3 | 117       |
| 416 | The 100 Most Frequently Cited Articles in Ophthalmology Journals. <i>JAMA Ophthalmology</i> , 2007, 125, 952.   | 2.6 | 91        |
| 417 | Prevention of diabetic retinopathy by intraocular soluble flt-1 gene transfer in a spontaneously diabetic rat model. <i>International Journal of Molecular Medicine</i> , 0, , .  | 1.8 | 20        |
| 418 | Vascular Endothelial Growth Factor in Aqueous Humor Before and After Intravitreal Injection of Bevacizumab in Eyes With Diabetic Retinopathy. <i>JAMA Ophthalmology</i> , 2007, 125, 1363.  | 2.6 | 80        |
| 419 | PHARMACOKINETICS AND RETINAL DISTRIBUTION OF RANIBIZUMAB, A HUMANIZED ANTIBODY FRAGMENT DIRECTED AGAINST VEGF-A, FOLLOWING INTRAVITREAL ADMINISTRATION IN RABBITS. <i>Retina</i> , 2007, 27, 1260-1266.   | 1.0 | 162       |
| 420 | Kinetics, Role and Therapeutic Implications of Endogenous Soluble form of Receptor for Advanced Glycation end Products (sRAGE) in Diabetes. <i>Current Drug Targets</i> , 2007, 8, 1138-1143.   | 1.0 | 71        |
| 421 | Antiangiogenic Therapy in Neovascular Age-related Macular Degeneration. <i>International Ophthalmology Clinics</i> , 2007, 47, 117-137.   | 0.3 | 12        |
| 422 | Anti-vascular endothelial growth factor therapy for ocular neovascular disease. <i>Current Opinion in Ophthalmology</i> , 2007, 18, 502-508.  | 1.3 | 234       |
| 423 | Intravitreal Bevacizumab (Avastin) for the Treatment of Chorioretinal Vascular Diseases. <i>Techniques in Ophthalmology</i> , 2007, 5, 40-45.   | 0.1 | 0         |
| 424 | Signal Transduction Therapy of Diabetic Vascular Complication. <i>Current Signal Transduction Therapy</i> , 2007, 2, 91-100.  | 0.3 | 5         |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 425 | Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema. <i>Ophthalmology</i> , 2007, 114, 743-750.   | 2.5 | 318       |
| 426 | CXCR4 down-regulation by small interfering RNA inhibits invasion and tubule formation of human retinal microvascular endothelial cells. <i>Biochemical and Biophysical Research Communications</i> , 2007, 358, 990-996.  | 1.0 | 17        |
| 427 | Effect of curcumin on hyperglycemia-induced vascular endothelial growth factor expression in streptozotocin-induced diabetic rat retina. <i>Biochemical and Biophysical Research Communications</i> , 2007, 361, 528-532. | 1.0 | 111       |
| 428 | Regulation of VEGF mRNA expression and protein secretion by TGF- $\beta$ 2 in human retinal pigment epithelial cells. <i>Experimental Eye Research</i> , 2007, 84, 812-822.   | 1.2 | 90        |
| 429 | Angiotensin II receptor blocker inhibits abnormal accumulation of advanced glycation end products and retinal damage in a rat model of type 2 diabetes. <i>Experimental Eye Research</i> , 2007, 85, 406-412.             | 1.2 | 55        |
| 430 | Changes in growth factor expression in normal aging of the rat retina. <i>Experimental Eye Research</i> , 2007, 85, 817-824.  | 1.2 | 17        |
| 431 | Retinal and choroidal microangiopathies: Therapeutic opportunities. <i>Microvascular Research</i> , 2007, 74, 131-144.  | 1.1 | 60        |
| 432 | Comparison of Vitrectomy Alone and Combined Vitrectomy, Phacoemulsification and Intraocular Lens Implantation for Proliferative Diabetic Retinopathy. <i>Kaohsiung Journal of Medical Sciences</i> , 2007, 23, 339-343.   | 0.8 | 18        |
| 433 | Fractalkine, a CX3C Chemokine, as a Mediator of Ocular Angiogenesis. , 2007, 48, 5290.  |     | 37        |
| 434 | Emerging Therapies for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema. <i>BioDrugs</i> , 2007, 21, 245-257.   | 2.2 | 63        |
| 435 | The Therapeutic Potential of VEGF Inhibition in Diabetic Microvascular Complications. <i>American Journal of Cardiovascular Drugs</i> , 2007, 7, 393-398.   | 1.0 | 30        |
| 436 | Pegaptanib sodium for the treatment of ocular vascular disease. <i>Expert Review of Ophthalmology</i> , 2007, 2, 45-60.   | 0.3 | 1         |
| 438 | VEGF in physiological process and thyroid disease. <i>Annales D'Endocrinologie</i> , 2007, 68, 438-448.   | 0.6 | 17        |
| 439 | Therapeutic angiogenesis in cardiovascular disease. <i>Journal of Cardiothoracic Surgery</i> , 2007, 2, 49.   | 0.4 | 45        |
| 440 | Oxidative Stress, Glucose Metabolism, and the Prevention of Type 2 Diabetes: Pathophysiological Insights. <i>Antioxidants and Redox Signaling</i> , 2007, 9, 911-929.   | 2.5 | 94        |
| 442 | Pigment epithelium-derived factor acts as an opponent of growth-stimulatory factors in retinal glial endothelial cell interactions. <i>Glia</i> , 2007, 55, 642-651.  | 2.5 | 40        |
| 443 | 4-Aryl-5-cyano-2-aminopyrimidines as VEGF-R2 inhibitors: Synthesis and biological evaluation. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 3266-3270.  | 1.0 | 41        |
| 444 | Increased vitreous levels of hydroimidazolone in type 2 diabetes patients are associated with retinopathy: a case-control study. <i>Acta Ophthalmologica</i> , 2007, 85, 618-622.   | 0.4 | 21        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 445 | Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy. <i>Progress in Retinal and Eye Research</i> , 2007, 26, 1-37.  | 7.3 | 188       |
| 446 | TNF- $\alpha$ is critical for ischemia-induced leukostasis, but not retinal neovascularization nor VEGF-induced leakage. <i>Journal of Neuroimmunology</i> , 2007, 182, 73-79.   | 1.1 | 61        |
| 447 | Development of a New Mouse Model of Branch Retinal Vein Occlusion and Retinal Neovascularization. <i>Japanese Journal of Ophthalmology</i> , 2007, 51, 251-257.  | 0.9 | 29        |
| 448 | Retinopathy of prematurity. <i>Angiogenesis</i> , 2007, 10, 133-140.   | 3.7 | 535       |
| 449 | An association between vascular endothelial growth factor gene promoter polymorphisms and diabetic retinopathy. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2007, 246, 39-43.  | 1.0 | 50        |
| 450 | Immunological mechanisms in the pathogenesis of diabetic retinopathy. <i>Seminars in Immunopathology</i> , 2008, 30, 65-84.  | 2.8 | 296       |
| 451 | Inhibition of choroidal neovascularization by blocking vascular endothelial growth factor receptor tyrosine kinase. <i>Japanese Journal of Ophthalmology</i> , 2008, 52, 91-98.  | 0.9 | 33        |
| 452 | Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2008, 246, 837-842. | 1.0 | 162       |
| 453 | History of Angiogenesis. , 2008, , 1-14.   |     | 14        |
| 454 | Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study). <i>Acta Ophthalmologica</i> , 2008, 86, 385-389.  | 0.6 | 113       |
| 455 | Parathyroid hormone stimulates the endothelial expression of vascular endothelial growth factor. <i>European Journal of Clinical Investigation</i> , 2008, 38, 798-803.  | 1.7 | 48        |
| 456 | Polymorphisms in the promoter region of the basic fibroblast growth factor gene and proliferative diabetic retinopathy in Caucasians with type 2 diabetes. <i>Clinical and Experimental Ophthalmology</i> , 2008, 36, 168-172.                                     | 1.3 | 15        |
| 457 | Regulation of retinal blood flow in health and disease. <i>Progress in Retinal and Eye Research</i> , 2008, 27, 284-330.   | 7.3 | 493       |
| 458 | Vascular endothelial growth factor in eye disease. <i>Progress in Retinal and Eye Research</i> , 2008, 27, 331-371.  | 7.3 | 607       |
| 459 | Therapeutic Anti-VEGF Antibodies. <i>Handbook of Experimental Pharmacology</i> , 2008, , 131-150.  | 0.9 | 67        |
| 460 | Vitreous Levels of Stromal Cell-Derived Factor 1 and Vascular Endothelial Growth Factor in Patients with Retinopathy of Prematurity. <i>Ophthalmology</i> , 2008, 115, 1065-1070.e1.   | 2.5 | 137       |
| 461 | Relationship among VEGF, VEGF receptor, AGEs, and macrophages in proliferative diabetic retinopathy. <i>Diabetes Research and Clinical Practice</i> , 2008, 79, 438-445.   | 1.1 | 48        |
| 462 | The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients. <i>Diabetes Research and Clinical Practice</i> , 2008, 81, 56-60.  | 1.1 | 112       |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 463 | Involvement of Angiotensin II-Dependent Vascular Endothelial Growth Factor Gene Expression via NADPH Oxidase in the Retina in a Type 2 Diabetic Rat Model. <i>Current Eye Research</i> , 2008, 33, 885-891. | 0.7 | 34        |
| 464 | Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. <i>British Journal of Ophthalmology</i> , 2008, 92, 213-216.         | 2.1 | 364       |
| 466 | Microglial Activation in Human Diabetic Retinopathy. <i>JAMA Ophthalmology</i> , 2008, 126, 227.  | 2.6 | 346       |
| 467 | Systemic and local effects of angiotensin II blockade in experimental diabetic nephropathy. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2008, 9, 96-102.                           | 1.0 | 30        |
| 468 | Pharmacotherapy for the Treatment of Choroidal Neovascularization Due to Age-Related Macular Degeneration. <i>Annual Review of Pharmacology and Toxicology</i> , 2008, 48, 61-78.                           | 4.2 | 34        |
| 469 | Vascular Endothelial Growth Factor Mediates Corneal Nerve Repair. , 2008, 49, 3870.   |     | 96        |
| 470 | The Pathophysiologic Role of Cyclooxygenases in the Eye. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2008, 24, 141-151.  | 0.6 | 28        |
| 472 | Progress and Prospects in Ocular Gene Therapy. , 2008, , 393-420.   |     | 0         |
| 473 | Receptor for Advanced Glycation End Products (RAGE): A Novel Therapeutic Target for Diabetic Vascular Complication. <i>Current Pharmaceutical Design</i> , 2008, 14, 487-495.                               | 0.9 | 95        |
| 474 | Rosiglitazone and Delayed Onset of Proliferative Diabetic Retinopathy. <i>JAMA Ophthalmology</i> , 2008, 126, 793.  | 2.6 | 85        |
| 475 | Role of Advanced Glycation End Products (AGEs) and Oxidative Stress in Diabetic Retinopathy. <i>Current Pharmaceutical Design</i> , 2008, 14, 962-968.  | 0.9 | 89        |
| 476 | Intracameral Avastin Dramatically Resolves Iris Neovascularization and Reverses Neovascular Glaucoma. <i>European Journal of Ophthalmology</i> , 2008, 18, 255-262.   | 0.7 | 68        |
| 477 | Update on treatments for diabetic macular edema. <i>Current Opinion in Ophthalmology</i> , 2008, 19, 185-189.   | 1.3 | 36        |
| 478 | LONG-TERM SAFETY AND EFFICACY OF INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR THE MANAGEMENT OF CENTRAL RETINAL VEIN OCCLUSION. <i>Retina</i> , 2008, 28, 1325-1337.  | 1.0 | 39        |
| 479 | PROINFLAMMATORY CYTOKINES AND ANGIOGENIC AND ANTI-ANGIOGENIC FACTORS IN VITREOUS OF PATIENTS WITH PROLIFERATIVE DIABETIC RETINOPATHY AND EALESâ€™™ DISEASE. <i>Retina</i> , 2008, 28, 817-824.              | 1.0 | 169       |
| 480 | Effects of Macular Ischemia on the Outcome of Intravitreal Bevacizumab Therapy for Diabetic Macular Edema. <i>Retina</i> , 2008, 28, 957-963.   | 1.0 | 108       |
| 481 | Current and future approaches in the prevention and treatment of diabetic retinopathy. <i>Clinical Ophthalmology</i> , 2008, 2, 425.  | 0.9 | 5         |
| 482 | Treatment of age-related macular degeneration: focus on ranibizumab. <i>Clinical Ophthalmology</i> , 2008, 2, 1.  | 0.9 | 40        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 483 | Two Cases of Subconjunctival Bevacizumab Injection to Prevent Bleb Failure After Trabeculectomy. Journal of Korean Ophthalmological Society, 2008, 49, 1345.                                 | 0.0 | 1         |
| 484 | Through The Eyes of a Child: Understanding Retinopathy through ROP The Friedenwald Lecture. , 2008, 49, 5177.  |     | 184       |
| 485 | Bevacizumab-Augmented Retinal Laser Photocoagulation in Proliferative Diabetic Retinopathy: A Randomized Double-Masked Clinical Trial. European Journal of Ophthalmology, 2008, 18, 263-269. | 0.7 | 116       |
| 486 | AntiangiogÃªnicos no glaucoma. Revista Brasileira De Oftalmologia, 2008, 67, 313-320.  | 0.1 | 0         |
| 487 | Results of Intravitreal Bevacizumab for Macular Edema with Retinal Vein Occlusion and Diabetic Macular Edema. Journal of Korean Ophthalmological Society, 2008, 49, 1275.                    | 0.0 | 6         |
| 488 | Comparison of Effects of Intravitreal Triamcinolone and Bevacizumab in the Treatment of Diabetic Macular Edema. Journal of Korean Ophthalmological Society, 2009, 50, 1190.                  | 0.0 | 7         |
| 489 | Primary treatment of diabetic macular edema. Clinical Interventions in Aging, 2009, 4, 101.  | 1.3 | 5         |
| 491 | FAK and p38-MAP Kinase-Dependent Activation of Apoptosis and Caspase-3 in Retinal Endothelial Cells by I±1(IV)NC1. , 2009, 50, 4567.   |     | 29        |
| 492 | Pegaptanib Sodium for the Treatment of Proliferative Diabetic Retinopathy and Diabetic Macular Edema. Current Diabetes Reviews, 2009, 5, 33-38.  | 0.6 | 9         |
| 493 | Intravitreal Bevacizumab for Treatment of Diabetic Macular Edema. Korean Journal of Ophthalmology: KJO, 2009, 23, 17.  | 0.5 | 24        |
| 494 | Intravitreal Bevacizumab for Diabetic Retinopathy. Current Diabetes Reviews, 2009, 5, 39-46.   | 0.6 | 58        |
| 495 | Attainment of polarity promotes growth factor secretion by retinal pigment epithelial cells: Relevance to age-related macular degeneration. Aging, 2009, 2, 28-42.                           | 1.4 | 80        |
| 496 | Baicalein Reduces Inflammatory Process in a Rodent Model of Diabetic Retinopathy. , 2009, 50, 2319.  |     | 134       |
| 497 | Efficacy and pharmacokinetics of intravitreal non-steroidal anti-inflammatory drugs for intraocular inflammation. British Journal of Ophthalmology, 2009, 93, 1387-1390.                     | 2.1 | 42        |
| 498 | Treatment of retinal diseases with VEGF antagonists. Progress in Brain Research, 2009, 175, 253-267.   | 0.9 | 43        |
| 499 | Vascular endothelial growth factor Trap-Eye for diabetic macular oedema. British Journal of Ophthalmology, 2009, 93, 135-136.  | 2.1 | 7         |
| 500 | Intravitreal injection of pegaptanib sodium for proliferative diabetic retinopathy. British Journal of Ophthalmology, 2009, 93, 1474-1478.   | 2.1 | 56        |
| 501 | Neovascular Glaucoma: A Historical Perspective on Modulating Angiogenesis. Seminars in Ophthalmology, 2009, 24, 106-112.   | 0.8 | 5         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 502 | Pathophysiology of Cyclooxygenase Inhibition in Animal Models. <i>Toxicologic Pathology</i> , 2009, 37, 34-46.  | 0.9 | 60        |
| 503 | Uveitis and Immunological Disorders. <i>Essentials in Ophthalmology</i> , 2009, , .   | 0.0 | 0         |
| 504 | Transient Bevacizumab (Avastin)-Induced Alterations in Rat Eyes. <i>Ophthalmic Research</i> , 2009, 41, 28-35.  | 1.0 | 9         |
| 505 | Role of Angiotensin II Type 1 Receptor on Retinal Vascular Leakage in a Rat Oxygen-Induced Retinopathy Model. <i>Ophthalmic Research</i> , 2009, 41, 210-215.   | 1.0 | 13        |
| 506 | Short-term response of macular oedema to intravitreal bevacizumab. <i>British Journal of Ophthalmology</i> , 2009, 93, 1033-1036.   | 2.1 | 14        |
| 507 | Thrombin induces fibronectin-specific migration of pulmonary microvascular endothelial cells: requirement of calcium/calmodulin-dependent protein kinase II. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2009, 297, L706-L714.                                 | 1.3 | 20        |
| 508 | Limits of the retinal-mapping program in age-related macular degeneration. <i>British Journal of Ophthalmology</i> , 2009, 93, 274-275.   | 2.1 | 2         |
| 509 | Intravitreal Anakinra Inhibits Choroidal Neovascular Membrane Growth in a Rat Model. <i>Ocular Immunology and Inflammation</i> , 2009, 17, 195-200.   | 1.0 | 34        |
| 510 | Cysteine-rich 61, a Member of the CCN Family, as a Factor Involved in the Pathogenesis of Proliferative Diabetic Retinopathy. , 2009, 50, 3447.   |     | 35        |
| 511 | Common Sequence Variation in the VEGFA Gene Predicts Risk of Diabetic Retinopathy. , 2009, 50, 5552.  |     | 64        |
| 512 | Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma. <i>British Journal of Ophthalmology</i> , 2009, 93, 273-274.  | 2.1 | 37        |
| 513 | Somatostatin analogues as therapeutics in retinal disease. , 2009, 122, 324-333.  |     | 22        |
| 514 | A future hope for the treatment of diabetic retinopathy, manipulating hypoxia-inducible factor-1 alpha pathway. <i>International Journal of Diabetes Mellitus</i> , 2009, 1, 55-56.   | 0.6 | 0         |
| 515 | Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2009, 247, 735-743. | 1.0 | 83        |
| 516 | Levels of vascular endothelial growth factor and pigment epithelium-derived factor in eyes before and after intravitreal injection of bevacizumab. <i>Japanese Journal of Ophthalmology</i> , 2009, 53, 243-248.  | 0.9 | 36        |
| 517 | Short-term efficacy of intravitreal bevacizumab for the treatment of macular edema due to diabetic retinopathy and retinal vein occlusion. <i>International Ophthalmology</i> , 2009, 29, 343-348.  | 0.6 | 16        |
| 518 | Protective effect of puerarin on diabetic retinopathy in rats. <i>Molecular Biology Reports</i> , 2009, 36, 1129-1133.  | 1.0 | 67        |
| 519 | Mediators of ocular angiogenesis. <i>Journal of Genetics</i> , 2009, 88, 495-515.   | 0.4 | 153       |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 520 | Intracameral bevacizumab and mitomycin C Trabeculectomy for eyes with neovascular glaucoma: a case series. <i>Journal of Ocular Biology, Diseases, and Informatics</i> , 2009, 2, 40-46.  | 0.2 | 4         |
| 521 | Müller cell-derived VEGF is a significant contributor to retinal neovascularization. <i>Journal of Pathology</i> , 2009, 219, 446-454.  | 2.1 | 196       |
| 522 | Intravitreal bevacizumab (avastin) for proliferative diabetic retinopathy: 6-months follow-up. <i>Eye</i> , 2009, 23, 117-123.  | 1.1 | 109       |
| 523 | Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization. <i>Gene Therapy</i> , 2009, 16, 10-16.  | 2.3 | 100       |
| 524 | Differential effects of nicotine on retinal and vascular cells in vitro. <i>Toxicology</i> , 2009, 259, 69-76.  | 2.0 | 26        |
| 525 | Silver nanoparticles inhibit VEGF induced cell proliferation and migration in bovine retinal endothelial cells. <i>Colloids and Surfaces B: Biointerfaces</i> , 2009, 73, 51-57.  | 2.5 | 217       |
| 526 | The Combination of Intravitreal Bevacizumab and Phacoemulsification Surgery in Patients with Cataract and Coexisting Diabetic Macular Edema. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2009, 25, 83-90.  | 0.6 | 37        |
| 527 | Modulating the hypoxia-inducible factor signaling pathway as a therapeutic modality to regulate retinal angiogenesis. <i>Experimental Eye Research</i> , 2009, 89, 700-717.   | 1.2 | 34        |
| 528 | Microincision Vitrectomy Surgery and Intravitreal Bevacizumab as a Surgical Adjunct to Treat Diabetic Traction Retinal Detachment. <i>Ophthalmology</i> , 2009, 116, 927-938.   | 2.5 | 163       |
| 529 | Primary Intravitreal Bevacizumab for Diffuse Diabetic Macular Edema. <i>Ophthalmology</i> , 2009, 116, 1488-1497.e1.  | 2.5 | 125       |
| 530 | Monitoring Ocular Drug Therapy by Analysis of Aqueous Samples. <i>Ophthalmology</i> , 2009, 116, 2158-2164.   | 2.5 | 60        |
| 531 | Role of combined cataract surgery and intravitreal bevacizumab injection in preventing progression of diabetic retinopathy. <i>Journal of Cataract and Refractive Surgery</i> , 2009, 35, 18-25.  | 0.7 | 61        |
| 532 | Insulin may cause deterioration of proliferative diabetic retinopathy. <i>Medical Hypotheses</i> , 2009, 72, 306-308.   | 0.8 | 6         |
| 533 | Intravitreal Bevacizumab for Diabetic Macular Edema Associated With Severe Capillary Loss: One-Year Results of a Pilot Study. <i>American Journal of Ophthalmology</i> , 2009, 147, 1022-1030.e5.   | 1.7 | 37        |
| 534 | Pathophysiology and management of diabetic retinopathy. <i>Expert Review of Ophthalmology</i> , 2009, 4, 627-647.   | 0.3 | 18        |
| 535 | Effect of Intravitreal Injection of High-Dose Bevacizumab in Monkey Eyes. , 2009, 50, 4905.   |     | 38        |
| 536 | Enalapril Alters Expression of Key Growth Factors in Experimental Diabetic Retinopathy. <i>Current Eye Research</i> , 2009, 34, 976-987.  | 0.7 | 16        |
| 537 | Evaluation of Differential Toxicity of Varying Doses of Bevacizumab on Retinal Ganglion Cells, Retinal Pigment Epithelial Cells, and Vascular Endothelial Growth Factor-Enriched Choroidal Endothelial Cells. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2009, 25, 507-512. | 0.6 | 25        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 538 | Effect of calcium dobesilate on occurrence of diabetic macular oedema (CALDIRET study): randomised, double-blind, placebo-controlled, multicentre trial. <i>Lancet, The</i> , 2009, 373, 1364-1371.              | 6.3 | 65        |
| 539 | SPONTANEOUS RESOLUTION OF MACULAR EDEMA AFTER PANRETINAL PHOTOCOAGULATION IN FLORID PROLIFERATIVE DIABETIC RETINOPATHY. <i>Retina</i> , 2009, 29, 1282-1288.   | 1.0 | 19        |
| 540 | Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. <i>Current Opinion in Ophthalmology</i> , 2009, 20, 158-165.  | 1.3 | 110       |
| 541 | Intracameral Bevacizumab (Avastin) for Neovascular Glaucoma. <i>Journal of Glaucoma</i> , 2009, 18, 140-143.   | 0.8 | 42        |
| 542 | In Vivo Corneal Endothelial Safety of Intracameral Bevacizumab and Effect in Neovascular Glaucoma Combined With Ahmed Valve Implantation. <i>Journal of Glaucoma</i> , 2009, 18, 589-594.                        | 0.8 | 23        |
| 543 | Anti-VEGF Therapy in Proliferative Diabetic Retinopathy. <i>International Ophthalmology Clinics</i> , 2009, 49, 95-107.  | 0.3 | 30        |
| 545 | Stem and Progenitor Cells in the Retina. <i>Frontiers in Diabetes</i> , 2009, , 174-193.   | 0.4 | 0         |
| 546 | Balance between Pigment Epithelium-Derived Factor and Vascular Endothelial Growth Factor in Diabetic Retinopathy. <i>Frontiers in Diabetes</i> , 2009, , 124-141.  | 0.4 | 1         |
| 547 | Diabetic Traction Retinal Detachment. <i>International Ophthalmology Clinics</i> , 2009, 49, 153-165.  | 0.3 | 8         |
| 548 | Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration. <i>Current Opinion in Ophthalmology</i> , 2009, 20, 166-174.                        | 1.3 | 89        |
| 549 | Ranibizumab for Diabetic Retinopathy. <i>Current Diabetes Reviews</i> , 2009, 5, 47-51.  | 0.6 | 26        |
| 550 | Encountering and Advancing Through Antiangiogenesis Therapy for Gliomas. <i>Current Pharmaceutical Design</i> , 2009, 15, 353-364.   | 0.9 | 20        |
| 551 | Diabetic Retinopathy in Pregnancy. <i>Current Diabetes Reviews</i> , 2009, 5, 151-156.   | 0.6 | 13        |
| 552 | CONCENTRATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN AQUEOUS HUMOR OF EYES WITH ADVANCED RETINOPATHY OF PREMATURITY BEFORE AND AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB. <i>Retina</i> , 2009, 29, 579-585. | 1.0 | 45        |
| 553 | Do Not Say Ever Never More: The Ins and Outs of Antiangiogenic Therapies. <i>Current Pharmaceutical Design</i> , 2010, 16, 3932-3957.  | 0.9 | 43        |
| 554 | Resveratrol: A Multifunctional Cytoprotective Molecule. <i>Current Pharmaceutical Biotechnology</i> , 2010, 11, 810-818.   | 0.9 | 49        |
| 555 | THE RESULTS OF INTRAVITREAL BEVACIZUMAB INJECTIONS FOR PERSISTENT NEOVASCULARIZATIONS IN PROLIFERATIVE DIABETIC RETINOPATHY AFTER PHOTOCOAGULATION THERAPY. <i>Retina</i> , 2010, 30, 570-577.                   | 1.0 | 26        |
| 556 | ROLE OF INTRAVITREAL BEVACIZUMAB (AVASTIN) INJECTED AT THE END OF DIABETIC VITRECTOMY IN PREVENTING POSTOPERATIVE RECURRENT VITREOUS HEMORRHAGE. <i>Retina</i> , 2010, 30, 1646-1650.                            | 1.0 | 41        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 557 | Anti-VEGF therapy for glaucoma. <i>Current Opinion in Ophthalmology</i> , 2010, 21, 112-117.  | 1.3  | 77        |
| 558 | CORRELATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR WITH CHEMOKINES IN THE VITREOUS IN DIABETIC RETINOPATHY. <i>Retina</i> , 2010, 30, 339-344.   | 1.0  | 61        |
| 559 | RETINAL TOXICITY OF INTRAVITREAL GENISTEIN IN A RABBIT MODEL. <i>Retina</i> , 2010, 30, 1536-1541.  | 1.0  | 6         |
| 560 | SAFETY EVALUATION OF REPEATED INTRAVITREAL INJECTIONS OF BEVACIZUMAB AND RANIBIZUMAB IN RABBIT EYES. <i>Retina</i> , 2010, 30, 671-681.   | 1.0  | 34        |
| 561 | ACCURATE ESTIMATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR LEVELS IN MICROSAMPLES WITH A LOW-COST BEAD-BASED ASSAY. <i>Retina</i> , 2010, 30, 815-819.   | 1.0  | 3         |
| 562 | Association of Retinal Vascular Endothelial Growth Factor With Avacular Retina in a Rat Model of Retinopathy of Prematurity. <i>JAMA Ophthalmology</i> , 2010, 128, 1014.   | 2.6  | 20        |
| 564 | Polymorphisms of interleukin-8 and -18 genes and diabetic retinopathy. <i>Open Life Sciences</i> , 2010, 5, 421-426.  | 0.6  | 2         |
| 565 | Nanoparticle formulation enhances the delivery and activity of a vascular endothelial growth factor antisense oligonucleotide in human retinal pigment epithelial cells. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 55, 1199-1206. | 1.2  | 50        |
| 566 | Vitreous vascular endothelial growth factor level during gestation. <i>Archives of Gynecology and Obstetrics</i> , 2010, 281, 417-421.  | 0.8  | 2         |
| 567 | Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2010, 248, 785-791.   | 1.0  | 96        |
| 568 | Retinal vein occlusions: The potential impact of a dysregulation of the retinal veins. <i>EPMA Journal</i> , 2010, 1, 253-261.  | 3.3  | 65        |
| 569 | Intravitreal bevacizumab for persistent macular edema with proliferative diabetic retinopathy. <i>International Ophthalmology</i> , 2010, 30, 697-702.  | 0.6  | 12        |
| 570 | The effects of oxygen stresses on the development of features of severe retinopathy of prematurity: knowledge from the 50/10 OIR model. <i>Documenta Ophthalmologica</i> , 2010, 120, 25-39.  | 1.0  | 75        |
| 571 | Silver nano "A trove for retinal therapies. <i>Journal of Controlled Release</i> , 2010, 145, 76-90.  | 4.8  | 98        |
| 572 | Effect of an intravitreal injection of bevacizumab on the expression of VEGF and CD34 in the retina of diabetic rats. <i>Clinical and Experimental Ophthalmology</i> , 2010, 38, 875-884.   | 1.3  | 15        |
| 573 | High glucose attenuates insulin-induced VEGF expression in bovine retinal microvascular endothelial cells. <i>Eye</i> , 2010, 24, 145-151.  | 1.1  | 13        |
| 574 | Blood pressure changes after intravitreal bevacizumab in patients grouped by ocular pathology. <i>Eye</i> , 2010, 24, 1320-1324.  | 1.1  | 6         |
| 575 | Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy. <i>Nature Medicine</i> , 2010, 16, 1107-1111.   | 15.2 | 184       |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 576 | Ãments de physiopathogÃnie de la rÃtinopathie diabÃtique. , 2010, , 7-13.  |     | 0         |
| 577 | Treatment of Diabetic Macular Edema: A Comparative Study. Journal of Korean Ophthalmological Society, 2010, 51, 849.   | 0.0 | 3         |
| 578 | Long-term Effect of Panretinal Photocoagulation Combined With Intravitreal Bevacizumab in High-risk Proliferative Diabetic Retinopathy. Journal of Korean Ophthalmological Society, 2010, 51, 842.         | 0.0 | 1         |
| 580 | Comparison of Intravitreal Triamcinolone Versus Bevacizumab in Bilateral Diabetic Macular Edema by Optical Coherence Tomography (OCT) Patterns. Journal of Korean Ophthalmological Society, 2010, 51, 210. | 0.0 | 3         |
| 581 | Pathophysiological Characteristics of Diabetic Ocular Complications in Spontaneously Diabetic Torii Rat. Journal of Ophthalmology, 2010, 2010, 1-7.  | 0.6 | 16        |
| 582 | Involvement of TAGE-RAGE System in the Pathogenesis of Diabetic Retinopathy. Journal of Ophthalmology, 2010, 2010, 1-12.   | 0.6 | 18        |
| 583 | Involvement of the Toxic AGEs (TAGE)-RAGE System in the Pathogenesis of Diabetic Vascular Complications: A Novel Therapeutic Strategy. Current Drug Targets, 2010, 11, 1468-1482.                          | 1.0 | 81        |
| 584 | Pegaptanib Sodium in the Treatment of Neovascular Age-Related Macular Degeneration. Clinical Medicine Insights Therapeutics, 2010, 2, CMT.S2393.   | 0.4 | 0         |
| 585 | Anti-Angiogenic Properties of Vitreous. , 2010, , 112-119.   |     | 2         |
| 586 | Alterations in the Intraocular Cytokine Milieu after Intravitreal Bevacizumab. , 2010, 51, 2388.   |     | 72        |
| 588 | VEGF-A<sub>165</sub> Is Cytoprotective and Antiangiogenic in the Retina. , 2010, 51, 4273.   |     | 71        |
| 589 | Features of Optical Coherence Tomography Are Predictive of Visual Outcomes after Intravitreal Bevacizumab Injection for Diabetic Macular Edema. Ophthalmologica, 2010, 224, 374-380.                       | 1.0 | 41        |
| 590 | High or Low Oxygen Saturation and Severe Retinopathy of Prematurity: A Meta-analysis. Pediatrics, 2010, 125, e1483-e1492.  | 1.0 | 142       |
| 591 | Comparison of Intravitreal Bevacizumab versus Triamcinolone for the Treatment of Diffuse Diabetic Macular Edema. Ophthalmologica, 2010, 224, 258-264.  | 1.0 | 25        |
| 592 | Ablation of 4E-BP1/2 Prevents Hyperglycemia-Mediated Induction of VEGF Expression in the Rodent Retina and in MÃller Cells in Culture. Diabetes, 2010, 59, 2107-2116.                                     | 0.3 | 41        |
| 593 | Steroids and the Management of Macular Edema. Ophthalmologica, 2010, 224, 31-40.   | 1.0 | 9         |
| 594 | Inhibition of Cytokine Signaling in Human Retinal Endothelial Cells through Downregulation of Sphingomyelinases by Docosahexaenoic Acid. , 2010, 51, 3253.   |     | 59        |
| 595 | Aqueous Humor Endothelin-1 (Et-1), Vascular Endothelial Growth Factor (VEGF) and Cyclooxygenase-2 (COX-2) levels in Mexican Glaucomatous Patients. Current Eye Research, 2010, 35, 287-294.                | 0.7 | 32        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 596 | Müller Cell-Derived VEGF Is Essential for Diabetes-Induced Retinal Inflammation and Vascular Leakage. <i>Diabetes</i> , 2010, 59, 2297-2305.   | 0.3  | 327       |
| 597 | Vitreous VEGF Clearance Is Increased after Vitrectomy. , 2010, 51, 2135.   |      | 104       |
| 598 | Neovascularization in diabetic retinopathy. , 2010, , 514-518.   |      | 1         |
| 599 | Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. <i>British Journal of Ophthalmology</i> , 2010, 94, 1215-1218. | 2.1  | 129       |
| 600 | Effects of Bevacizumab on Apoptosis, Na <sup>+</sup> -K <sup>+</sup> -ATPase and Zonula Occludens 1 Expression on Cultured Corneal Endothelial Cells. <i>Ophthalmic Research</i> , 2010, 44, 43-49.              | 1.0  | 7         |
| 601 | The Role of Cannabis and Cannabinoids in Diabetes. <i>British Journal of Diabetes and Vascular Disease</i> , 2010, 10, 267-273.  | 0.6  | 12        |
| 602 | Effect of systemic medications on onset and progression of diabetic retinopathy. <i>Nature Reviews Endocrinology</i> , 2010, 6, 494-508.   | 4.3  | 42        |
| 603 | Ocular Retinopathies and Clinical Control of Angiogenesis. , 2010, , 27-65.  |      | 1         |
| 604 | Current Approaches to the Management of Diabetic Retinopathy and Diabetic Macular Oedema. <i>Drugs</i> , 2010, 70, 2171-2200.  | 4.9  | 34        |
| 605 | Animal Models of Diabetic Retinopathy. <i>NeuroMethods</i> , 2010, , 113-138.  | 0.2  | 3         |
| 606 | Association between the -634C/G polymorphisms of the vascular endothelial growth factor and retinopathy in type 2 diabetes: A meta-analysis. <i>Diabetes Research and Clinical Practice</i> , 2010, 90, 45-53.   | 1.1  | 25        |
| 607 | Clinical Application of Therapies Targeting VEGF. <i>Cell</i> , 2010, 143, 13-16.  | 13.5 | 48        |
| 608 | Nonsteroidal Anti-inflammatory Drugs in Ophthalmology. <i>Survey of Ophthalmology</i> , 2010, 55, 108-133.   | 1.7  | 300       |
| 609 | Selective and pan-blockade agents in the anti-angiogenic treatment of proliferative diabetic retinopathy: a literature summary. <i>Canadian Journal of Ophthalmology</i> , 2010, 45, 501-508.                    | 0.4  | 8         |
| 610 | Vitreous Proteomics and Diabetic Retinopathy. <i>Seminars in Ophthalmology</i> , 2010, 25, 289-294.  | 0.8  | 27        |
| 611 | A siRNA Targeting Vascular Endothelial Growth Factor-A Inhibiting Experimental Corneal Neovascularization. <i>Current Eye Research</i> , 2010, 35, 375-384.  | 0.7  | 36        |
| 612 | The Influence of Glucose Concentration and Hypoxia on VEGF Secretion by Cultured Retinal Cells. <i>Current Eye Research</i> , 2011, 36, 168-177.   | 0.7  | 26        |
| 613 | Serum VEGF and CFH in Exudative Age-Related Macular Degeneration. <i>Current Eye Research</i> , 2011, 36, 143-148.   | 0.7  | 11        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 614 | Inhibition of Choroidal Neovascularization in a Nonhuman Primate Model by Intravitreal Administration of an AAV2 Vector Expressing a Novel Anti-VEGF Molecule. <i>Molecular Therapy</i> , 2011, 19, 260-265. | 3.7 | 84        |
| 615 | Diabetic retinopathy: Pathogenic mechanisms and current treatments. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2011, 5, 165-172.  | 1.8 | 52        |
| 616 | Management of Neovascular AMD. , 2011, , 79-98.  |     | 0         |
| 617 | Changes in Aqueous Concentrations of Various Cytokines After Intravitreal Triamcinolone Versus Bevacizumab for Diabetic Macular Edema. <i>American Journal of Ophthalmology</i> , 2011, 152, 686-694.        | 1.7 | 247       |
| 618 | The Effect of Adjunctive Intravitreal Bevacizumab for Preventing Postvitrectomy Hemorrhage in Proliferative Diabetic Retinopathy. <i>Ophthalmology</i> , 2011, 118, 2218-2226.                               | 2.5 | 90        |
| 619 | The management of diabetic macular oedema. <i>Saudi Journal of Ophthalmology</i> , 2011, 25, 123-129.  | 0.3 | 1         |
| 620 | Developmental and Pathological Angiogenesis. <i>Annual Review of Cell and Developmental Biology</i> , 2011, 27, 563-584.   | 4.0 | 620       |
| 621 | Treatment of proliferative diabetic retinopathy with anti-VEGF agents. <i>Acta Ophthalmologica</i> , 2011, 89, 405-411.  | 0.6 | 89        |
| 622 | Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy. <i>Acta Ophthalmologica</i> , 2011, 89, e567-e572.                              | 0.6 | 58        |
| 623 | Preparation of Budesonide-Loaded Polycaprolactone Nanobeads by Electrospraying for Controlled Drug Release. <i>Journal of Biomaterials Science, Polymer Edition</i> , 2011, 22, 2431-2444.                   | 1.9 | 34        |
| 624 | Effect of Intravitreal Bevacizumab on Vascular Endothelial Growth Factor Expression in Patients with Proliferative Diabetic Retinopathy. <i>Yonsei Medical Journal</i> , 2011, 52, 151.                      | 0.9 | 15        |
| 625 | Freezing adversely affects measurement of vascular endothelial growth factor levels in human aqueous samples. <i>Clinical Ophthalmology</i> , 2011, 5, 81.   | 0.9 | 8         |
| 626 | Diabetic retinopathy: major unmet medical challenge. <i>Endocrinology Studies</i> , 2011, 1, 7.  | 0.2 | 0         |
| 627 | Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture. <i>Journal of Ophthalmology</i> , 2011, 2011, 1-13.   | 0.6 | 44        |
| 628 | Placental Growth Factor Contributes to Micro-Vascular Abnormalization and Blood-Retinal Barrier Breakdown in Diabetic Retinopathy. <i>PLoS ONE</i> , 2011, 6, e17462.  | 1.1 | 65        |
| 629 | Systemic Safety of Bilateral Intravitreal Anti-VEGF Vascular Endothelial Growth Factor Injections. <i>Retina</i> , 2011, 31, 1-3.  | 1.0 | 48        |
| 630 | Processing of chromogranins/secretogranin in patients with diabetic retinopathy. <i>Regulatory Peptides</i> , 2011, 167, 118-124.  | 1.9 | 16        |
| 631 | Effects of intravitreal bevacizumab (Avastin) on the porcine retina. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2011, 249, 1821-1829.   | 1.0 | 13        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 632 | Diabetes-induced peroxynitrite impairs the balance of pro-nerve growth factor and nerve growth factor, and causes neurovascular injury. <i>Diabetologia</i> , 2011, 54, 657-668.                   | 2.9  | 111       |
| 633 | Co-culture of Retinal and Endothelial Cells Results in the Modulation of Genes Critical to Retinal Neovascularization. <i>Vascular Cell</i> , 2011, 3, 27.   | 0.2  | 32        |
| 634 | Alterations to the Blood-Retinal Barrier in Diabetes: Cytokines and Reactive Oxygen Species. <i>Antioxidants and Redox Signaling</i> , 2011, 15, 1271-1284.  | 2.5  | 114       |
| 635 | Effects of Intravitreally Injected Bevacizumab on Vascular Endothelial Growth Factor in Fellow Eyes. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2011, 27, 379-383.                   | 0.6  | 27        |
| 636 | Endoplasmic reticulum stress induces retinal endothelial permeability of extracellular-superoxide dismutase. <i>Free Radical Research</i> , 2011, 45, 1083-1092.                                   | 1.5  | 28        |
| 637 | Focus on vision: 3 decades of remarkable contributions to biology and medicine. <i>FASEB Journal</i> , 2011, 25, 439-443.  | 0.2  | 3         |
| 638 | Vitreous levels of soluble vascular endothelial growth factor receptor (VEGFR)-1 in eyes with vitreoretinal diseases. <i>British Journal of Ophthalmology</i> , 2011, 95, 1745-1748.               | 2.1  | 11        |
| 639 | Alpha-Lipoic Acid for the Prevention of Diabetic Macular Edema. <i>Ophthalmologica</i> , 2011, 226, 127-137.   | 1.0  | 46        |
| 640 | Tissue Kallikrein Inhibits Retinal Neovascularization via the Cleavage of Vascular Endothelial Growth Factor-165. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 1041-1048. | 1.1  | 34        |
| 641 | Panretinal Photocoagulation for Proliferative Diabetic Retinopathy. <i>New England Journal of Medicine</i> , 2011, 365, 1520-1526.   | 13.9 | 109       |
| 642 | Comparison of Intravitreal Bevacizumab and Ranibizumab Treatment for Diabetic Macular Edema. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2011, 27, 373-377.                           | 0.6  | 29        |
| 643 | Serum inflammatory cytokines IL-1 $\beta$ , IL-6, TNF- $\alpha$ and VEGF have influence on the development of diabetic retinopathy. <i>Folia Medica</i> , 2011, 53, 44-50.                         | 0.2  | 98        |
| 644 | Postoperative conjunctival cyst: A masquerade. <i>Indian Journal of Ophthalmology</i> , 2011, 59, 406.   | 0.5  | 5         |
| 645 | Increased levels of vascular endothelial growth factor in aqueous humor of patients with diabetic retinopathy: Is it the whole truth?. <i>Indian Journal of Ophthalmology</i> , 2011, 59, 405.     | 0.5  | 3         |
| 646 | Intraocular VEGF Level as a Risk Factor for Postoperative Complications after Vitrectomy for Proliferative Diabetic Retinopathy. , 2012, 53, 6403.   |      | 50        |
| 647 | eNOS Overexpression Exacerbates Vascular Closure in the Obliterative Phase of OIR and Increases Angiogenic Drive in the Subsequent Proliferative Stage. , 2012, 53, 6833.                          |      | 18        |
| 648 | Intravitreal Bevacizumab After Intravitreal Triamcinolone for Exudative Age-Related Macular Degeneration. <i>Asia-Pacific Journal of Ophthalmology</i> , 2012, 1, 140-141.                         | 1.3  | 0         |
| 649 | Diabetic Retinopathy: Current and New Treatment Options. <i>Current Diabetes Reviews</i> , 2012, 8, 32-41.   | 0.6  | 30        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 650 | Angiofibrotic Response to Vascular Endothelial Growth Factor Inhibition in Diabetic Retinal Detachment. <i>JAMA Ophthalmology</i> , 2012, 130, 1127.   | 2.6 | 47        |
| 651 | Role of Vascular Endothelial Growth Factor in the Breakdown of the Blood-Aqueous Barrier After Retinal Laser Photocoagulation in Pigmented Rabbits. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2012, 28, 83-88.    | 0.6 | 8         |
| 652 | Management of retinal vascular diseases: a patient-centric approach. <i>Eye</i> , 2012, 26, S1-S16.  | 1.1 | 74        |
| 653 | Peripheral retinal ischaemia, as evaluated by ultra-widefield fluorescein angiography, is associated with diabetic macular oedema. <i>British Journal of Ophthalmology</i> , 2012, 96, 694-698.                                  | 2.1 | 184       |
| 654 | Visual Dysfunction in Diabetes. , 2012, , .  |     | 2         |
| 655 | Vitreous Vascular Endothelial Growth Factor Concentrations in Proliferative Diabetic Retinopathy versus Proliferative Vitreoretinopathy. <i>Ophthalmic Research</i> , 2012, 47, 7-12.  | 1.0 | 26        |
| 656 | Heparanase and Vascular Endothelial Growth Factor Expression Is Increased in Hypoxia-Induced Retinal Neovascularization. , 2012, 53, 6810.   |     | 20        |
| 657 | Triamcinolone and Bevacizumab as Adjunctive Therapies to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy. <i>ISRN Ophthalmology</i> , 2012, 2012, 1-10.   | 1.7 | 7         |
| 658 | The Role of Angiogenesis in the Development of Proliferative Diabetic Retinopathy: Impact of Intravitreal Anti-VEGF Treatment. <i>Experimental Diabetes Research</i> , 2012, 2012, 1-8.  | 3.8 | 74        |
| 659 | Comparison of Intravitreal Bevacizumab Upload Followed by a Dexamethasone Implant versus Dexamethasone Implant Monotherapy for Retinal Vein Occlusion with Macular Edema. <i>Ophthalmologica</i> , 2012, 228, 110-116.           | 1.0 | 34        |
| 660 | Histological and immunohistochemical study on the protective effect of Ginkgo biloba extract against glutamate-induced neurotoxicity in male albino rat retinal cells. <i>Egyptian Journal of Histology</i> , 2012, 35, 176-188. | 0.0 | 2         |
| 661 | Long-term Effects of Ranibizumab on Diabetic Retinopathy Severity and Progression. <i>JAMA Ophthalmology</i> , 2012, 130, 1145.  | 2.6 | 218       |
| 662 | Diabetic retinopathy and inflammation: Novel therapeutic targets. <i>Middle East African Journal of Ophthalmology</i> , 2012, 19, 52.  | 0.5 | 184       |
| 663 | Ranibizumab treatment of retinal vein occlusion. <i>Expert Review of Ophthalmology</i> , 2012, 7, 509-515.   | 0.3 | 0         |
| 664 | EDITORIAL [Hot Topic: Anti-Vascular Endothelial Growth Factor (VEGF) Treatment of Ophthalmic Conditions (Guest Editor: Michael W. Stewart)]. <i>Current Drug Therapy</i> , 2012, 7, 77-79.                                       | 0.2 | 0         |
| 665 | Vascular Endothelial Growth Factor (VEGF) Biochemistry and Development of Inhibitory Drugs. <i>Current Drug Therapy</i> , 2012, 7, 80-89.  | 0.2 | 6         |
| 667 | RETINAL ANGIOMATOUS PROLIFERATION IN AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2012, 32, 416-434.  | 1.0 | 265       |
| 668 | Drug Discoveries. , 2012, , 523-644.   |     | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 669 | New developments in the treatment of diabetic macular edema: latest clinical evidence. <i>Clinical Investigation</i> , 2012, 2, 89-105.   | 0.0 | 0         |
| 670 | Preclinical safety evaluation of subretinal AAV2.sFlt-1 in non-human primates. <i>Gene Therapy</i> , 2012, 19, 999-1009.  | 2.3 | 46        |
| 671 | Plasma, aqueous and vitreous homocysteine levels in proliferative diabetic retinopathy. <i>British Journal of Ophthalmology</i> , 2012, 96, 704-707.  | 2.1 | 22        |
| 672 | Phacoemulsification with Intravitreal Bevacizumab Injection in Patients with Cataract and Coexisting Diabetic Retinopathy: Prospective Randomized Study. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2012, 28, 212-218.                        | 0.6 | 16        |
| 673 | Mechanisms of Age-Related Macular Degeneration. <i>Neuron</i> , 2012, 75, 26-39.  | 3.8 | 756       |
| 674 | Aqueous Humor Levels of Vascular Endothelial Growth Factor Before and After Intravitreal Bevacizumab in Type 3 Versus Type 1 and 2 Neovascularization. A Prospective, Case-Control Study. <i>American Journal of Ophthalmology</i> , 2012, 153, 155-161.e2. | 1.7 | 41        |
| 675 | VEGF-Mediated STAT3 Activation Inhibits Retinal Vascularization by Down-Regulating Local Erythropoietin Expression. <i>American Journal of Pathology</i> , 2012, 180, 1243-1253.  | 1.9 | 52        |
| 676 | Inhibition of pathological retinal angiogenesis by the integrin $\alpha_5\beta_1$ antagonist tetraiodothyroacetic acid (tetrac). <i>Experimental Eye Research</i> , 2012, 94, 41-48.  | 1.2 | 48        |
| 677 | Retinal Not Systemic Oxidative and Inflammatory Stress Correlated with VEGF Expression in Rodent Models of Insulin Resistance and Diabetes. , 2012, 53, 8424.   |     | 46        |
| 678 | Inhibition of Choroidal and Corneal Pathologic Neovascularization by <i>Plgf1-de</i> Gene Transfer. , 2012, 53, 7989.   |     | 16        |
| 679 | Prevention of VEGF-induced growth and tube formation in human retinal endothelial cells by aldose reductase inhibition. <i>Journal of Diabetes and Its Complications</i> , 2012, 26, 369-377.   | 1.2 | 30        |
| 680 | Anti-VEGF therapy for the treatment of glaucoma: a focus on ranibizumab and bevacizumab. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 1641-1647.   | 1.4 | 27        |
| 681 | Role of matrix metalloproteinase-2 and -9 in the development of diabetic retinopathy. <i>Journal of Ocular Biology, Diseases, and Informatics</i> , 2012, 5, 1-8.   | 0.2 | 34        |
| 682 | (Pro)renin receptor is associated with angiogenic activity in proliferative diabetic retinopathy. <i>Diabetologia</i> , 2012, 55, 3104-3113.  | 2.9 | 48        |
| 683 | Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of diabetic retinopathy. <i>Canadian Journal of Ophthalmology</i> , 2012, 47, S1-S30.  | 0.4 | 51        |
| 684 | Development of Anti-VEGF Therapies for Intraocular Use: A Guide for Clinicians. <i>Journal of Ophthalmology</i> , 2012, 2012, 1-13.   | 0.6 | 42        |
| 685 | Antivascular Endothelial Growth Factor Agents for Neovascular Age-Related Macular Degeneration. <i>Journal of Ophthalmology</i> , 2012, 2012, 1-12.   | 0.6 | 39        |
| 686 | Segmentational Analysis of Retinal Thickness after Vitrectomy in Diabetic Macular Edema. , 2012, 53, 6668.  |     | 26        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 687 | Prophylactic Medical Treatment of Diabetic Retinopathy. , 0, , .  |      | 1         |
| 688 | Effect of Triamcinolone on Retinal Vessel-Related Factors in Oxygen-Induced Retinopathy Rats. Journal of Korean Ophthalmological Society, 2012, 53, 1864.   | 0.0  | 1         |
| 689 | Suppression of VEGF and Decrease in Vascular Leakage by Pyridoxal 5'-Phosphate in Diabetic Rats. Journal of Korean Ophthalmological Society, 2012, 53, 700.   | 0.0  | 0         |
| 690 | Relationship between vitreous and serum vascular endothelial growth factor levels, control of diabetes and microalbuminuria in proliferative diabetic retinopathy. Clinical Ophthalmology, 2012, 6, 185.                            | 0.9  | 47        |
| 691 | Elevated Levels of Monocyte Chemoattractant Protein-1 in the Aqueous Humor after Phacoemulsification. , 2012, 53, 7951.   |      | 60        |
| 692 | Diabetic Retinopathy. New England Journal of Medicine, 2012, 366, 1227-1239.  | 13.9 | 1,363     |
| 693 | Green Tea Prevents Hyperglycemia-Induced Retinal Oxidative Stress and Inflammation in Streptozotocin-Induced Diabetic Rats. Ophthalmic Research, 2012, 47, 103-108.   | 1.0  | 75        |
| 694 | Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma. Nature Reviews Drug Discovery, 2012, 11, 541-559.  | 21.5 | 275       |
| 695 | Pharmacologic Induction of Heme Oxygenase-1 Plays a Protective Role in Diabetic Retinopathy in Rats. , 2012, 53, 6541.  |      | 81        |
| 696 | Electroretinographic findings associated with panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab treatment for high-risk proliferative diabetic retinopathy. Documenta Ophthalmologica, 2012, 124, 225-236. | 1.0  | 33        |
| 697 | Therapeutic angiogenesis for myocardial ischemia revisited: basic biological concepts and focus on latest clinical trials. Angiogenesis, 2012, 15, 1-22.  | 3.7  | 116       |
| 698 | Twelve-month experience with Ozurdex for the treatment of macular edema associated with retinal vein occlusion. Eye, 2013, 27, 816-822.   | 1.1  | 61        |
| 699 | Anti-angiogenic effect of KH902 on retinal neovascularization. Graefe's Archive for Clinical and Experimental Ophthalmology, 2013, 251, 2131-2139.  | 1.0  | 25        |
| 700 | Neural Engineering. , 2013, , .   |      | 24        |
| 701 | Vascular Endothelial Growth Factor A in Intraocular Vascular Disease. Ophthalmology, 2013, 120, 106-114.  | 2.5  | 334       |
| 702 | Suppressive effect of aqueous humor from person with Type 2 diabetes with or without retinopathy on reactive oxygen species generation. Diabetes Research and Clinical Practice, 2013, 100, 69-73.                                  | 1.1  | 11        |
| 703 | VEGF $\alpha$ 634G&gt;C polymorphism and diabetic retinopathy risk: A meta-analysis. Gene, 2013, 518, 310-315.  | 1.0  | 36        |
| 704 | Correlation of vascular endothelial growth factor plasma levels and glycemic control in patients with diabetic retinopathy. Acta Ophthalmologica, 2013, 91, e470-e473.  | 0.6  | 27        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 705 | Retinoprotective Effects of <i>Moringa oleifera</i> via Antioxidant, Anti-Inflammatory, and Anti-Angiogenic Mechanisms in Streptozotocin-Induced Diabetic Rats. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2013, 29, 419-426. | 0.6  | 42        |
| 706 | Single injection of triamcinolone versus three repeated injections of bevacizumab for treatment of diabetic macular edema. <i>International Ophthalmology</i> , 2013, 33, 375-380.  | 0.6  | 9         |
| 707 | Pharmacology at Surgery. , 2013, , 2094-2102.   |      | 0         |
| 708 | Emergence of dual VEGF and PDGF antagonists in the treatment of exudative age-related macular degeneration. <i>Expert Review of Ophthalmology</i> , 2013, 8, 475-484.   | 0.3  | 8         |
| 709 | Nonproliferative Diabetic Retinopathy and Diabetic Macular Edema. , 2013, , 940-968.  |      | 23        |
| 710 | Basic Mechanisms of Pathological Retinal and Choroidal Angiogenesis. , 2013, , 562-578.   |      | 2         |
| 711 | A Comprehensive Review of Retinal Gene Therapy. <i>Molecular Therapy</i> , 2013, 21, 509-519.   | 3.7  | 245       |
| 712 | Intravitreal injection of erythropoietin protects against retinal vascular regression at the early stage of diabetic retinopathy in streptozotocin-induced diabetic rats. <i>Experimental Eye Research</i> , 2013, 106, 64-73.              | 1.2  | 36        |
| 713 | G-rich VEGF aptamer with locked and unlocked nucleic acid modifications exhibits a unique G-quadruplex fold. <i>Nucleic Acids Research</i> , 2013, 41, 9524-9536.   | 6.5  | 82        |
| 714 | Short Hairpin RNA-Mediated Knockdown of VEGFA in Müller Cells Reduces Intravitreal Neovascularization in a Rat Model of Retinopathy of Prematurity. <i>American Journal of Pathology</i> , 2013, 183, 964-974.                              | 1.9  | 45        |
| 715 | The vitreous renin-angiotensin system is mediated by soluble (pro)renin receptor in diabetic retinopathy: A new implication of the receptor-associated prorenin system. <i>Taiwan Journal of Ophthalmology</i> , 2013, 3, 51-53.            | 0.3  | 5         |
| 716 | Characterization of Ischemic Index Using Ultra-widefield Fluorescein Angiography in Patients With Focal and Diffuse Recalcitrant Diabetic Macular Edema. <i>American Journal of Ophthalmology</i> , 2013, 155, 1038-1044.e2.                | 1.7  | 104       |
| 717 | Inhibition of high glucose-induced VEGF release in retinal ganglion cells by RNA interference targeting G protein-coupled receptor 91. <i>Experimental Eye Research</i> , 2013, 109, 31-39.   | 1.2  | 36        |
| 718 | A direct and melanopsin-dependent fetal light response regulates mouse eye development. <i>Nature</i> , 2013, 494, 243-246.   | 13.7 | 183       |
| 719 | Recent Advances in the Management of Neovascular Glaucoma. <i>Seminars in Ophthalmology</i> , 2013, 28, 165-172.  | 0.8  | 43        |
| 720 | Intravitreal bevacizumab treatment for refractory diabetic macular edema. <i>International Ophthalmology</i> , 2013, 33, 659-663.   | 0.6  | 10        |
| 722 | Using the Past to Inform the Future: Anti-VEGF Therapy as a Road Map to Develop Novel Therapies for Diabetic Retinopathy. <i>Diabetes</i> , 2013, 62, 1808-1815.  | 0.3  | 48        |
| 723 | Aflibercept ophthalmic solution: drug development and clinical uses. <i>Clinical Investigation</i> , 2013, 3, 1045-1056.  | 0.0  | 2         |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 724 | Targeting neovascularization in ischemic retinopathy: recent advances. Expert Review of Ophthalmology, 2013, 8, 267-286.  | 0.3 | 39        |
| 725 | Randomized Clinical Trial Evaluating Intravitreal Ranibizumab or Saline for Vitreous Hemorrhage From Proliferative Diabetic Retinopathy. JAMA Ophthalmology, 2013, 131, 283.  | 1.4 | 90        |
| 726 | Structural Changes in Individual Retinal Layers in Diabetic Macular Edema. Journal of Diabetes Research, 2013, 2013, 1-11.  | 1.0 | 107       |
| 727 | Inhibition of Corneal Neovascularization with the Combination of Bevacizumab and Plasmid Pigment Epithelium-Derived Factor-Synthetic Amphiphile INTERaction-18 (p-PEDF-SAINT-18) Vector in a Rat Corneal Experimental Angiogenesis Model. International Journal of Molecular Sciences, 2013, 14, 8291-8305. | 1.8 | 8         |
| 728 | Vitreous Mediators in Retinal Hypoxic Diseases. Mediators of Inflammation, 2013, 2013, 1-16.  | 1.4 | 35        |
| 729 | Contemporary Management of Diabetic Retinopathy in Canada: From Guidelines to Algorithm Guidance. Ophthalmologica, 2013, 231, 2-15.   | 1.0 | 13        |
| 730 | Identification of VEGF-Independent Cytokines in Proliferative Diabetic Retinopathy Vitreous. , 2013, 54, 6472.  |     | 61        |
| 731 | Anti-vascular endothelial growth factor therapy for diabetic macular edema. Therapeutic Advances in Endocrinology and Metabolism, 2013, 4, 151-169.   | 1.4 | 145       |
| 732 | Influence of Preoperative Intravitreal Bevacizumab on Visual Function in Eyes with Proliferative Diabetic Retinopathy. Ophthalmic Research, 2013, 49, 30-36.  | 1.0 | 11        |
| 733 | Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration. British Journal of Ophthalmology, 2013, 97, 1443-1446.  | 2.1 | 90        |
| 734 | Ang-2 upregulation correlates with increased levels of MMP-9, VEGF, EPO and TGF $\beta$ 21 in diabetic eyes undergoing vitrectomy. Acta Ophthalmologica, 2013, 91, 531-539.   | 0.6 | 79        |
| 735 | PsÅrdoksfoliasyon sendromlu gÅrçlerin heidelberg retinal tomografi ile deÄYerlendirilmesi. Medical Journal of Bakirkoy, 2013, , 126-130.  | 0.0 | 0         |
| 736 | Zinc and Diabetic Retinopathy. Journal of Diabetes Research, 2013, 2013, 1-8.   | 1.0 | 34        |
| 737 | The relationship between vascular endothelial growth factor Å2578C/A polymorphism and age-related macular degeneration. Ophthalmic Genetics, 2013, 34, 112-114.   | 0.5 | 1         |
| 738 | Proliferative Diabetic Retinopathy. , 2013, , 969-1000.   |     | 5         |
| 739 | An AntiÅangiogenic Reverse Thermal Gel as a DrugÅDelivery System for AgeÅRelated Wet Macular Degeneration. Macromolecular Bioscience, 2013, 13, 464-469.  | 2.1 | 27        |
| 740 | Genetics of Diabetic Retinopathy. Seminars in Ophthalmology, 2013, 28, 337-346.   | 0.8 | 13        |
| 741 | Vascular Endothelial Growth Factor Gene Polymorphisms and Vitreous Proteome Changes in Diabetic Retinopathy. Seminars in Ophthalmology, 2013, 28, 347-354.  | 0.8 | 3         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 742 | Intravitreal Bevacizumab (Avastin) and Panretinal Photocoagulation in the Treatment of High-Risk Proliferative Diabetic Retinopathy. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2013, 29, 550-555.  | 0.6 | 46        |
| 743 | PRERETINAL PARTIAL PRESSURE OF OXYGEN GRADIENTS BEFORE AND AFTER EXPERIMENTAL PARS PLANA VITRECTOMY. <i>Retina</i> , 2013, 33, 170-178.   | 1.0 | 8         |
| 744 | INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR PERSISTENT NEW VESSELS IN DIABETIC RETINOPATHY (IBEPE) Tj ET Oq0 0 0 rgBT /Overloc   | 1.0 | 12        |
| 745 | EFFECTS OF SOLUBLE CD14 AND CYTOKINE LEVELS ON DIABETIC MACULAR EDEMA AND VISUAL ACUITY. <i>Retina</i> , 2013, 33, 1020-1025.   | 1.0 | 13        |
| 746 | CHANGES IN VISUAL ACUITY IN PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIBIZUMAB IN DAILY CLINICAL PRACTICE. <i>Retina</i> , 2013, 33, 474-481.                               | 1.0 | 182       |
| 747 | Macular Migration toward the Optic Disc after Inner Limiting Membrane Peeling for Diabetic Macular Edema. , 2013, 54, 629.  |     | 50        |
| 748 | Vitrectomy Combined with Intravitreal Triamcinolone Acetonide Injection and Macular Laser Photocoagulation for Nontractional Diabetic Macular Edema. <i>Korean Journal of Ophthalmology: KJO</i> , 2013, 27, 186. | 0.5 | 8         |
| 749 | Review of Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration. <i>Clinical Medicine Insights Therapeutics</i> , 2013, 5, CMT.S8921.   | 0.4 | 1         |
| 750 | Biomarkers in Diabetic Retinopathy and the Therapeutic Implications. <i>Mediators of Inflammation</i> , 2013, 2013, 1-11.   | 1.4 | 38        |
| 751 | Aqueous Concentrations of Vascular Endothelial Growth Factor in Eyes with High Myopia with and without Choroidal Neovascularization. <i>Journal of Ophthalmology</i> , 2013, 2013, 1-5.                           | 0.6 | 26        |
| 752 | Tratamento cirÃ©rgico da retinopatia diabÃ©tica. <i>Revista Brasileira De Oftalmologia</i> , 2013, 72, 204-209.   | 0.1 | 0         |
| 753 | Fluocinolone acetonide and its potential in the treatment of chronic diabetic macular edema. <i>Clinical Ophthalmology</i> , 2013, 7, 503.  | 0.9 | 8         |
| 754 | EGF-Like-Domain-7 Is Required for VEGF-Induced Akt/ERK Activation and Vascular Tube Formation in an Ex Vivo Angiogenesis Assay. <i>PLoS ONE</i> , 2014, 9, e91849.  | 1.1 | 24        |
| 755 | Nuclear Factor Kappa-B Signaling Is Integral to Ocular Neovascularization in Ischemia-Independent Microenvironment. <i>PLoS ONE</i> , 2014, 9, e101602.   | 1.1 | 11        |
| 756 | Vitreous and Plasma VEGF Levels as Predictive Factors in the Progression of Proliferative Diabetic Retinopathy after Vitrectomy. <i>PLoS ONE</i> , 2014, 9, e110531.  | 1.1 | 58        |
| 757 | Effect of intravitreal bevacizumab on diabetic macular edema with hard exudates. <i>Clinical Ophthalmology</i> , 2014, 8, 1479.   | 0.9 | 15        |
| 758 | An open-label, one-year, noncomparative study to evaluate the safety and tolerability of intravitreal pegaptanib sodium in patients with diabetic macular edema. <i>Clinical Ophthalmology</i> , 2014, 8, 1565.   | 0.9 | 10        |
| 759 | Effectiveness of intravitreal injection of Bevacizumab (Avastin) in the treatment of diabetic macular edema.. <i>Pakistan Journal of Medical Sciences</i> , 2014, 30, 1383-7.                                     | 0.3 | 0         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 760 | Quantification of the Changes in the Openness of the Major Temporal Arcade in Retinal Fundus Images of Preterm Infants With Plus Disease. <i>Investigative Ophthalmology and Visual Science</i> , 2014, 55, 6728-6735. | 3.3 | 9         |
| 761 | Analysis of Aqueous Humor Cytokines in Diabetic Retinopathy. <i>Journal of Korean Ophthalmological Society</i> , 2014, 55, 1821.   | 0.0 | 3         |
| 762 | Intravitreal anti-vascular endothelial growth factor treatment for retinal diseases. <i>Journal of the Korean Medical Association</i> , 2014, 57, 614.   | 0.1 | 0         |
| 763 | Therapeutic efficacy of a novel non-peptide $\alpha_5\beta_1$ integrin antagonist for pathological retinal angiogenesis in mice. <i>Experimental Eye Research</i> , 2014, 129, 119-126.                                | 1.2 | 17        |
| 764 | Role of Metallothioneins 1 and 2 in Ocular Neovascularization. <i>Investigative Ophthalmology and Visual Science</i> , 2014, 55, 3851-6860.  | 3.3 | 9         |
| 765 | Treating maculopathy at the expense of proliferative disease: an emerging problem in $\alpha$ -macular treatment centres <sup>TM</sup> . <i>Eye</i> , 2014, 28, 1390-1391.   | 1.1 | 2         |
| 766 | Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture. <i>British Journal of Ophthalmology</i> , 2014, 98, i11-i16.       | 2.1 | 102       |
| 767 | Endothelial Progenitor Cells in Diabetic Retinopathy. <i>Frontiers in Endocrinology</i> , 2014, 5, 44.   | 1.5 | 67        |
| 768 | Diabetic retinopathy: loss of neuroretinal adaptation to the diabetic metabolic environment. <i>Annals of the New York Academy of Sciences</i> , 2014, 1311, 174-190.  | 1.8 | 186       |
| 769 | Development of gene therapy for treatment of age-related macular degeneration. <i>Acta Ophthalmologica</i> , 2014, 92, 1-38.   | 0.6 | 22        |
| 770 | Potential Therapeutic Effects of Baicalein, Baicalin, and Wogonin in Ocular Disorders. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2014, 30, 605-614.   | 0.6 | 60        |
| 771 | The Kallikrein-Kinin System in Diabetic Retinopathy. , 2014, 69, 111-143.  |     | 29        |
| 772 | Pharmacotherapy for Treatment and Prevention of Proliferative Diabetic Retinopathy. <i>Current Ophthalmology Reports</i> , 2014, 2, 175-183.   | 0.5 | 0         |
| 773 | Gene profiling of human VEGF signaling pathways in human endothelial and retinal pigment epithelial cells after anti VEGF treatment. <i>BMC Research Notes</i> , 2014, 7, 617.   | 0.6 | 8         |
| 774 | Current Management of Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy. <i>International Ophthalmology Clinics</i> , 2014, 54, 141-153.   | 0.3 | 46        |
| 775 | Intracameral Ranibizumab and Subsequent Mitomycin C Augmented Trabeculectomy in Neovascular Glaucoma. <i>Journal of Glaucoma</i> , 2014, 23, 437-440.  | 0.8 | 19        |
| 776 | Understanding regulatory pathways of neovascularization in diabetes. <i>Expert Review of Endocrinology and Metabolism</i> , 2014, 9, 487-501.  | 1.2 | 1         |
| 777 | Human Ciliary Epithelium as a Source of Synthesis and Secretion of Vascular Endothelial Growth Factor in Neovascular Glaucoma. <i>JAMA Ophthalmology</i> , 2014, 132, 1350.  | 1.4 | 34        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 778 | Retinal Vascular Disease. , 2014, , 87-118.   |     | 0         |
| 779 | Proliferative Diabetic Retinopathy. , 2014, , 123-162.  |     | 0         |
| 780 | Increased intravitreal angiopoietin-2 levels associated with rhegmatogenous retinal detachment. Graefe's Archive for Clinical and Experimental Ophthalmology, 2014, 252, 881-888.   | 1.0 | 9         |
| 781 | Allosteric regulation of pathologic angiogenesis: potential application for angiogenesis-related blindness. Archives of Pharmacal Research, 2014, 37, 285-298.  | 2.7 | 7         |
| 782 | Increased intravitreous interleukin-18 correlated to vascular endothelial growth factor in patients with active proliferative diabetic retinopathy. Graefe's Archive for Clinical and Experimental Ophthalmology, 2014, 252, 1229-1234. | 1.0 | 23        |
| 783 | Aptamer-based therapeutics of the past, present and future: from the perspective of eye-related diseases. Drug Discovery Today, 2014, 19, 1309-1321.  | 3.2 | 33        |
| 784 | Current and investigational pharmacotherapeutic approaches for modulating retinal angiogenesis. Expert Review of Clinical Pharmacology, 2014, 7, 375-391.   | 1.3 | 21        |
| 785 | New Insights Into Molecular Mechanisms of Diabetic Kidney Disease. American Journal of Kidney Diseases, 2014, 63, S63-S83.  | 2.1 | 152       |
| 786 | Surgical Treatment for Macular Edema. Seminars in Ophthalmology, 2014, 29, 242-256.   | 0.8 | 13        |
| 787 | Glycobiology of ocular angiogenesis. Glycobiology, 2014, 24, 1275-1282.   | 1.3 | 12        |
| 788 | Level of Vascular Endothelial Growth Factor 165b in Human Aqueous Humor. Current Eye Research, 2014, 39, 830-836.   | 0.7 | 8         |
| 789 | Clinical Strategies in the Management of Diabetic Retinopathy. , 2014, , .  |     | 8         |
| 790 | Retinal Microangiopathy in a Mouse Model of Inducible Mural Cell Loss. American Journal of Pathology, 2014, 184, 2618-2626.   | 1.9 | 26        |
| 791 | Monitoring the VEGF level in aqueous humor of patients with ophthalmologically relevant diseases via ultrahigh sensitive paper-based ELISA. Biomaterials, 2014, 35, 3729-3735.  | 5.7 | 74        |
| 792 | The Harvard angiogenesis story. Survey of Ophthalmology, 2014, 59, 361-364.   | 1.7 | 5         |
| 794 | EFFECT OF COMBINED CATARACT SURGERY AND RANIBIZUMAB INJECTION IN POSTOPERATIVE MACULAR EDEMA IN NONPROLIFERATIVE DIABETIC RETINOPATHY. Retina, 2014, 34, 149-156.   | 1.0 | 59        |
| 795 | Aflibercept for the treatment of neovascular glaucoma. Clinical and Experimental Ophthalmology, 2015, 43, 803-807.  | 1.3 | 28        |
| 796 | The Champalimaud Vision Award: honouring basic and translational research. Acta Ophthalmologica, 2015, 93, 493-495.   | 0.6 | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 797 | The clinical utility of aflibercept for diabetic macular edema. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2015, 8, 473.  | 1.1 | 7         |
| 798 | New Therapeutic Approaches in Diabetic Retinopathy. <i>Review of Diabetic Studies</i> , 2015, 12, 196-210.  | 0.5 | 28        |
| 799 | Intracameral Interleukin 1 $\beta$ , 6, 8, 10, 12p, Tumor Necrosis Factor $\alpha$ and Vascular Endothelial Growth Factor and Axial Length in Patients with Cataract. <i>PLoS ONE</i> , 2015, 10, e0117777. | 1.1 | 18        |
| 800 | Role of implants in the treatment of diabetic macular edema: focus on the dexamethasone intravitreal implant. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2015, 8, 555.          | 1.1 | 15        |
| 801 | Diabetic Retinopathy: Vascular and Inflammatory Disease. <i>Journal of Diabetes Research</i> , 2015, 2015, 1-16.  | 1.0 | 287       |
| 802 | The Vitreomacular Interface in Diabetic Retinopathy. <i>Journal of Ophthalmology</i> , 2015, 2015, 1-10.  | 0.6 | 11        |
| 803 | Association Between Diabetic Macular Edema and Cardiovascular Events in Type 2 Diabetes Patients. <i>Medicine (United States)</i> , 2015, 94, e1220.  | 0.4 | 9         |
| 804 | Clinical Outcome after Switching Therapy from Ranibizumab and/or Bevacizumab to Aflibercept in Central Retinal Vein Occlusion. <i>Ophthalmic Research</i> , 2015, 54, 150-156.                              | 1.0 | 23        |
| 805 | A platform of integrative studies from in vitro to in vivo experiments: Towards drug development for ischemic retinopathy. <i>Biomedicine and Pharmacotherapy</i> , 2015, 69, 367-373.                      | 2.5 | 5         |
| 806 | Long-term Effects of Therapy with Ranibizumab on Diabetic Retinopathy Severity and Baseline Risk Factors for Worsening Retinopathy. <i>Ophthalmology</i> , 2015, 122, 367-374.                              | 2.5 | 164       |
| 807 | Gene- and Cell-Based Treatment Strategies for the Eye. <i>Essentials in Ophthalmology</i> , 2015, , .   | 0.0 | 2         |
| 808 | Retinal pericytes and cytomegalovirus infectivity: implications for HCMV-induced retinopathy and congenital ocular disease. <i>Journal of Neuroinflammation</i> , 2015, 12, 2.                              | 3.1 | 26        |
| 809 | Combination of Bevacizumab and NGF Reduces the Risk of Diabetic Retinopathy. <i>Cell Biochemistry and Biophysics</i> , 2015, 73, 79-85.   | 0.9 | 3         |
| 810 | The role of ranibizumab in the management of diabetic retinopathy. <i>Expert Review of Ophthalmology</i> , 2015, 10, 329-340.   | 0.3 | 1         |
| 811 | A Study of VEGF Gene Polymorphism in Egyptian Patients with Diabetic Retinopathy. <i>Ophthalmic Genetics</i> , 2015, 36, 315-320.   | 0.5 | 7         |
| 812 | Macular morphologic findings on optical coherence tomography after microincision vitrectomy for proliferative diabetic retinopathy. <i>Japanese Journal of Ophthalmology</i> , 2015, 59, 236-243.           | 0.9 | 15        |
| 813 | Stem cell based therapies for age-related macular degeneration: The promises and the challenges. <i>Progress in Retinal and Eye Research</i> , 2015, 48, 1-39.  | 7.3 | 167       |
| 814 | Effect of adiponectin on expression of vascular endothelial growth factor and pigment epithelium-derived factor: An in vitro study. <i>Indian Journal of Pharmacology</i> , 2015, 47, 117.                  | 0.4 | 12        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 816 | Biology and therapy of inherited retinal degenerative disease: insights from mouse models. <i>DMM Disease Models and Mechanisms</i> , 2015, 8, 109-129.   | 1.2 | 207       |
| 817 | Conbercept (KH-902) for the treatment of neovascular age-related macular degeneration. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 541-548.  | 1.3 | 34        |
| 818 | Vascular Endothelial Growth Factor Receptor 2 Antibody, BC001, Attenuates Laser-Induced Choroidal Neovascularization in Rhesus Monkeys ( <i>Macaca mulatta</i> ). <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2015, 31, 611-616. | 0.6 | 6         |
| 819 | Cardiac and vascular toxicities of angiogenesis inhibitors: The other side of the coin. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 195-205.   | 2.0 | 7         |
| 821 | Complications of Diabetes Mellitus. , 2016, , 1484-1581.  |     | 13        |
| 822 | VEGF: From Discovery to Therapy: The Champalimaud Award Lecture. <i>Translational Vision Science and Technology</i> , 2016, 5, 9.   | 1.1 | 45        |
| 823 | Effects of Intravitreal Injection of Bevacizumab or Ranibizumab on Systemic Circulation. <i>Journal of Korean Ophthalmological Society</i> , 2016, 57, 429.   | 0.0 | 3         |
| 824 | VEGF and Intraocular Neovascularization: From Discovery to Therapy. <i>Translational Vision Science and Technology</i> , 2016, 5, 10.   | 1.1 | 74        |
| 825 | Inner Retinal Oxygen Delivery, Metabolism, and Extraction Fraction in <i>Ins2<sup>Akita</sup></i> Diabetic Mice. , 2016, 57, 5903.  |     | 11        |
| 826 | Application of Arterial Spin Labelling in the Assessment of Ocular Tissues. <i>BioMed Research International</i> , 2016, 2016, 1-13.  | 0.9 | 6         |
| 827 | Protective Effects of Melatonin on Retinal Inflammation and Oxidative Stress in Experimental Diabetic Retinopathy. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-13.   | 1.9 | 66        |
| 828 | A Computational Model of Peripheral Photocoagulation for the Prevention of Progressive Diabetic Capillary Occlusion. <i>Journal of Diabetes Research</i> , 2016, 2016, 1-13.  | 1.0 | 4         |
| 829 | Vascular Normalization by ROCK Inhibitor: Therapeutic Potential of Ripasudil (K-115) Eye Drop in Retinal Angiogenesis and Hypoxia. , 2016, 57, 2264.  |     | 55        |
| 830 | Early Results of Dexamethasone Implant, Ranibizumab, and Triamcinolone in Macular Edema Due to Branch Retinal Vein Occlusion. <i>European Journal of Ophthalmology</i> , 2016, 26, 54-59.   | 0.7 | 13        |
| 831 | Comparison of Choroidal Thickness Changes following Intravitreal Dexamethasone, Ranibizumab, and Triamcinolone in Eyes with Retinal Vein Occlusion. <i>European Journal of Ophthalmology</i> , 2016, 26, 627-632.                             | 0.7 | 15        |
| 832 | Diabetic retinopathy clinical practice guidelines: Customized for Iranian population. <i>Journal of Ophthalmic and Vision Research</i> , 2016, 11, 394.   | 0.7 | 10        |
| 833 | Restoration of foveal photoreceptors after intravitreal ranibizumab injections for diabetic macular edema. <i>Scientific Reports</i> , 2016, 6, 39161.  | 1.6 | 53        |
| 834 | Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia. <i>The Cochrane Library</i> , 2016, 2016, CD011160.  | 1.5 | 25        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 835 | Aflibercept Traps Galectin-1, an Angiogenic Factor Associated with Diabetic Retinopathy. Scientific Reports, 2016, 5, 17946.   | 1.6 | 53        |
| 836 | Opportunities for the Development of Newer Drugs for Ocular Use. , 2016, , 13-35.  |     | 0         |
| 837 | The effect of intravitreal vascular endothelial growth factor on inner retinal oxygen delivery and metabolism in rats. Experimental Eye Research, 2016, 143, 141-147.  | 1.2 | 8         |
| 838 | Comprehensive Review of Ocular and Systemic Safety Events with Intravitreal Aflibercept Injection in Randomized Controlled Trials. Ophthalmology, 2016, 123, 1511-1520.  | 2.5 | 54        |
| 839 | Fluocinolone acetonide for the treatment of diabetic macular edema. Expert Review of Clinical Pharmacology, 2016, 9, 367-374.  | 1.3 | 4         |
| 840 | Neutralization of IL-23 depresses experimental ocular neovascularization. Experimental Eye Research, 2016, 146, 242-251.   | 1.2 | 14        |
| 841 | Effect of intravitreal dexamethasone implant on retinal and choroidal thickness in refractory diabetic macular oedema after multiple anti-VEGF injections. Eye, 2016, 30, 718-725.   | 1.1 | 24        |
| 843 | Anti-VEGF therapy in ophthalmology: a qualitative analysis of transformative drug development. Drug Discovery Today, 2016, 21, 1019-1026.  | 3.2 | 4         |
| 844 | Outcomes of vitrectomy, membranectomy and internal limiting membrane peeling in patients with refractory diabetic macular edema and non-tractional epiretinal membrane. Journal of Current Ophthalmology, 2016, 28, 199-205. | 0.3 | 19        |
| 845 | Bone Microarchitecture in Type 1 Diabetes: It Is Complicated. Current Osteoporosis Reports, 2016, 14, 351-358.   | 1.5 | 24        |
| 846 | Th17 cell frequency and IL-17A concentrations in peripheral blood mononuclear cells and vitreous fluid from patients with diabetic retinopathy. Journal of International Medical Research, 2016, 44, 1403-1413.              | 0.4 | 23        |
| 847 | Anti-VEGF Vascular Endothelial Growth Factor Agents in the Treatment of Retinal Disease. Ophthalmology, 2016, 123, S78-S88.  | 2.5 | 100       |
| 848 | Anti-angiogenic Therapy for Retinal Disease. Handbook of Experimental Pharmacology, 2016, 242, 271-307.  | 0.9 | 38        |
| 849 | Vascular Endothelial Growth Factor Inhibitors for Diabetic Retinopathy. Current Diabetes Reports, 2016, 16, 122.   | 1.7 | 24        |
| 850 | 199A Novel Selective Inhibitor for Plasma Membrane Calcium Atpase 4 Improves VEGF-Mediated Angiogenesis. Heart, 2016, 102, A134.1-A134.  | 1.2 | 0         |
| 851 | Receptor-associated prorenin system contributes to development of inflammation and angiogenesis in proliferative diabetic retinopathy. Inflammation and Regeneration, 2016, 36, 22.  | 1.5 | 2         |
| 852 | An Update in the Management of Proliferative Diabetic Retinopathy. International Ophthalmology Clinics, 2016, 56, 209-225.   | 0.3 | 3         |
| 853 | Nanoparticle-mediated miR200-b delivery for the treatment of diabetic retinopathy. Journal of Controlled Release, 2016, 236, 31-37.  | 4.8 | 39        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 854 | Ten years of anti-vascular endothelial growth factor therapy. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 385-403.  | 21.5 | 724       |
| 855 | Fit for the Eye: Aptamers in Ocular Disorders. <i>Nucleic Acid Therapeutics</i> , 2016, 26, 127-146.   | 2.0  | 103       |
| 856 | Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab. <i>Eye</i> , 2016, 30, 463-472.  | 1.1  | 62        |
| 857 | Vascular Endothelial Growth Factor and Diabetic Retinal Disease. <i>Seminars in Ophthalmology</i> , 2016, 31, 40-48.   | 0.8  | 44        |
| 858 | Conversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema. <i>American Journal of Ophthalmology</i> , 2016, 164, 118-127.e2.   | 1.7  | 79        |
| 859 | Pharmacokinetics and biodistribution of recently-developed siRNA nanomedicines. <i>Advanced Drug Delivery Reviews</i> , 2016, 104, 93-109.   | 6.6  | 77        |
| 860 | Diabetic Eye Disease. , 2016, , 907-919.e5.  |      | 0         |
| 861 | Aptamers as Therapeutics. <i>Annual Review of Pharmacology and Toxicology</i> , 2017, 57, 61-79.   | 4.2  | 383       |
| 862 | Retinal oxygen: from animals to humans. <i>Progress in Retinal and Eye Research</i> , 2017, 58, 115-151.   | 7.3  | 170       |
| 863 | Retinal vascular calibre changes after intravitreal bevacizumab or dexamethasone implant treatment for diabetic macular oedema. <i>British Journal of Ophthalmology</i> , 2017, 101, 1329-1333.  | 2.1  | 11        |
| 864 | Recent Advances of Activatable Molecular Probes Based on Semiconducting Polymer Nanoparticles in Sensing and Imaging. <i>Advanced Science</i> , 2017, 4, 1600481.  | 5.6  | 217       |
| 865 | Efficacy of aflibercept (EYLEA Â® ) on inhibition of human VEGF in vitro. <i>Annals of Anatomy</i> , 2017, 211, 135-139.   | 1.0  | 4         |
| 866 | Morphological and functional changes in recalcitrant diabetic macular oedema after intravitreal dexamethasone implant. <i>British Journal of Ophthalmology</i> , 2017, 101, 791-795.   | 2.1  | 21        |
| 867 | Vandetanib and ADAM inhibitors synergistically attenuate the pathological migration of EBV-infected retinal pigment epithelial cells by regulating the VEGF-mediated MAPK pathway. <i>Experimental and Therapeutic Medicine</i> , 2017, 13, 1415-1425. | 0.8  | 9         |
| 868 | Targeting Vascular Endothelial Growth Factor. , 2017, , 99-139.  |      | 0         |
| 869 | Ranibizumab in the Treatment of Diabetic Macular Edema: A Review of the Current Status, Unmet Needs, and Emerging Challenges. <i>Advances in Therapy</i> , 2017, 34, 1270-1282.  | 1.3  | 37        |
| 870 | The Diabetic Retina: Anatomy and Pathophysiology. , 2017, , 29-72.   |      | 0         |
| 871 | Subchoroidal Release of VEGF and bFGF Produces Choroidal Neovascularization in Rabbit. <i>Current Eye Research</i> , 2017, 42, 237-243.  | 0.7  | 13        |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 872 | INTRAVITREAL BEVACIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY. <i>Retina</i> , 2017, 37, 334-343.  | 1.0 | 43        |
| 873 | Serum retinol levels and neonatal outcomes in preterm infants. <i>Journal of the Formosan Medical Association</i> , 2017, 116, 626-633.  | 0.8 | 13        |
| 875 | Changes in choroidal thickness in patients with diabetic retinopathy. <i>International Ophthalmology</i> , 2018, 38, 279-286.  | 0.6 | 15        |
| 876 | Beneficial effects of the Src inhibitor, dasatinib, on breakdown of the blood-retinal barrier. <i>Archives of Pharmacal Research</i> , 2017, 40, 197-203.  | 2.7 | 13        |
| 877 | Excerpt from the Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of diabetic retinopathy. <i>Canadian Journal of Ophthalmology</i> , 2017, 52, S45-S74.   | 0.4 | 18        |
| 878 | Early Response to Ranibizumab Is Associated with 12-Month Outcome in Diabetic Macular Edema after Prior Macular Laser Therapy. <i>Ophthalmologica</i> , 2017, 238, 139-146.  | 1.0 | 2         |
| 879 | “Open-top” microfluidic device for in vitro three-dimensional capillary beds. <i>Lab on A Chip</i> , 2017, 17, 3405-3414.  | 3.1 | 65        |
| 880 | Soluble Vascular Adhesion Protein-1 Mediates Spermine Oxidation as Semicarbazide-Sensitive Amine Oxidase: Possible Role in Proliferative Diabetic Retinopathy. <i>Current Eye Research</i> , 2017, 42, 1674-1683.  | 0.7 | 22        |
| 881 | Perioperative Inflammation as Triggering Origin of Metastasis Development. , 2017, , .   |     | 2         |
| 882 | Aqueous vascular endothelial growth factor and clinical outcomes correlation after single intravitreal injection of bevacizumab in patients with neovascular age-related macular degeneration. <i>International Journal of Retina and Vitreous</i> , 2017, 3, 6. | 0.9 | 15        |
| 883 | PERSISTENT OVERPRODUCTION OF INTRAOCULAR VASCULAR ENDOTHELIAL GROWTH FACTOR AS A CAUSE OF LATE VITREOUS HEMORRHAGE AFTER VITRECTOMY FOR PROLIFERATIVE DIABETIC RETINOPATHY. <i>Retina</i> , 2017, 37, 2317-2325.   | 1.0 | 13        |
| 884 | First Therapeutic Aptamer: VEGF-Targeting Macugen. , 2017, , 319-333.  |     | 0         |
| 885 | Vertebrate embryos as tools for anti-angiogenic drug screening and function. <i>Reproductive Toxicology</i> , 2017, 70, 49-59.   | 1.3 | 11        |
| 886 | Retinal reperfusion in diabetic retinopathy following treatment with anti-VEGF intravitreal injections. <i>Clinical Ophthalmology</i> , 2017, Volume 11, 193-200.  | 0.9 | 63        |
| 887 | Vascular Adhesion Protein-1 Blockade Suppresses Ocular Inflammation After Retinal Laser Photocoagulation in Mice. , 2017, 58, 3254.  |     | 11        |
| 888 | Apatinib, an Inhibitor of Vascular Endothelial Growth Factor Receptor 2, Suppresses Pathologic Ocular Neovascularization in Mice. , 2017, 58, 3592.  |     | 27        |
| 889 | Assessment of biomarkers using multiplex assays in aqueous humor of patients with diabetic retinopathy. <i>BMC Ophthalmology</i> , 2017, 17, 176.  | 0.6 | 57        |
| 890 | Effects of Histone Deacetylase Inhibitor (Valproic Acid) on the Expression of Hypoxia-inducible Factor-1 Alpha in Human Retinal Müller Cells. <i>Korean Journal of Ophthalmology: KJO</i> , 2017, 31, 80.  | 0.5 | 7         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 891 | Effect of Anti-vascular Endothelial Growth Factor Antibody on the Survival of Cultured Retinal Ganglion Cells. Korean Journal of Ophthalmology: KJO, 2017, 31, 360.   | 0.5 | 12        |
| 892 | Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema. Clinical Ophthalmology, 2017, Volume 11, 567-571.   | 0.9 | 32        |
| 894 | Coronary Artery Development: Origin, Malformations, and Translational Vascular Reparative Therapy. Journal of Cardiovascular Pharmacology and Therapeutics, 2018, 23, 292-300.  | 1.0 | 7         |
| 895 | Proteolytic cleavage of vascular adhesion protein-1 induced by vascular endothelial growth factor in retinal capillary endothelial cells. Japanese Journal of Ophthalmology, 2018, 62, 256-264.                                       | 0.9 | 10        |
| 896 | Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study). Ophthalmology, 2018, 125, 691-700.  | 2.5 | 84        |
| 897 | Recognizing intraventricular silicone. Emergency Radiology, 2018, 25, 215-218.  | 1.0 | 11        |
| 898 | Ranibizumab-induced retinal reperfusion and regression of neovascularization in diabetic retinopathy: An angiographic illustration. American Journal of Ophthalmology Case Reports, 2018, 9, 41-44.                                   | 0.4 | 23        |
| 899 | Outcomes of Diabetic Macular Edema Eyes with Limited Early Response in the VISTA and VIVID Studies. Ophthalmology Retina, 2018, 2, 558-566.   | 1.2 | 20        |
| 900 | CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA. Retina, 2018, 38, 1801-1808.  | 1.0 | 35        |
| 901 | Endothelial dysfunction in pulmonary arterial hypertension: an evolving landscape (2017 Grover) Tj ETQq1 1 0.784314 rgBT /Overlock 115  | 0.8 | 115       |
| 902 | A novel and less invasive technique to assess cytokine profile of vitreous in patients of diabetic macular oedema. Eye, 2018, 32, 820-829.  | 1.1 | 23        |
| 903 | Changes in aqueous concentrations of various cytokines after intravitreal bevacizumab and subtenon triamcinolone injection for diabetic macular edema. Graefes Archive for Clinical and Experimental Ophthalmology, 2018, 256, 39-47. | 1.0 | 21        |
| 904 | Both Autocrine Signaling and Paracrine Signaling of HB-EGF Enhance Ocular Neovascularization. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 174-185.  | 1.1 | 18        |
| 905 | Vascular endothelial growth factors and placenta growth factor in retinal vasculopathies: Current research and future perspectives. Cytokine and Growth Factor Reviews, 2018, 39, 102-115.  | 3.2 | 47        |
| 906 | Emerging role of angiogenesis in adaptive and maladaptive right ventricular remodeling in pulmonary hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 314, L443-L460.                      | 1.3 | 51        |
| 907 | Evolving multidimensional pharmacological approaches to CNV therapy in AMD. Current Eye Research, 2018, 43, 147-154.  | 0.7 | 8         |
| 908 | Retinal changes in rabbit after intravitreal injection of sunitinib encapsulated into solid lipid nanoparticles and polymeric nanocapsules. Arquivos Brasileiros De Oftalmologia, 2018, 81, 408-413.                                  | 0.2 | 16        |
| 909 | Functional Characterization of Abicipar-Pegol, an Anti-VEGF DARPIn Therapeutic That Potently Inhibits Angiogenesis and Vascular Permeability. , 2018, 59, 5836.   |     | 61        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 910 | Lymphatic Vascular Structures: A New Aspect in Proliferative Diabetic Retinopathy. <i>International Journal of Molecular Sciences</i> , 2018, 19, 4034.   | 1.8 | 14        |
| 911 | Lycium Barbarum Polysaccharides Improve Retinopathy in Diabetic Sprague-Dawley Rats. <i>Evidence-based Complementary and Alternative Medicine</i> , 2018, 2018, 1-12.   | 0.5 | 9         |
| 912 | Optical coherence tomography findings predictive of response to treatment in diabetic macular edema. <i>Journal of International Medical Research</i> , 2018, 46, 4455-4464.  | 0.4 | 11        |
| 913 | Posterior Subtenon Infusion of triamcinolone acetonide as adjunctive treatment to panretinal photocoagulation using pattern scan laser for diabetic retinopathy. <i>Japanese Journal of Ophthalmology</i> , 2018, 62, 686-692.  | 0.9 | 4         |
| 914 | Pharmacotherapeutic management of macular edema in diabetic subjects undergoing cataract surgery. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1551-1563.   | 0.9 | 11        |
| 915 | Imaging of Hypoxia in Retinal Vascular Disease. , 0, , .  |     | 4         |
| 916 | Clinical applications of retinal gene therapies. <i>Precision Clinical Medicine</i> , 2018, 1, 5-20.  | 1.3 | 11        |
| 917 | Difference in the Vitreal Protein Profiles of Patients with Proliferative Diabetic Retinopathy with and without Intravitreal Conbercept Injection. <i>Journal of Ophthalmology</i> , 2018, 2018, 1-11.  | 0.6 | 11        |
| 918 | Evaluation of TGF-Beta 2 and VEGF Gene Expression Levels in Epiretinal Membranes and Internal Limiting Membranes in the Course of Retinal Detachments, Proliferative Diabetic Retinopathy, Macular Holes, and Idiopathic Epiretinal Membranes. <i>Journal of Ophthalmology</i> , 2018, 2018, 1-6. | 0.6 | 7         |
| 919 | The role of the retinal pigment epithelium and Müller cells secretome in neovascular retinal pathologies. <i>Biochimie</i> , 2018, 155, 104-108.  | 1.3 | 21        |
| 920 | Current Transport Systems and Clinical Applications for Small Interfering RNA (siRNA) Drugs. <i>Molecular Diagnosis and Therapy</i> , 2018, 22, 551-569.  | 1.6 | 23        |
| 921 | Therapeutic Effects of a Novel Phenylphthalimide Analog for Corneal Neovascularization and Retinal Vascular Leakage. , 2018, 59, 3630.  |     | 8         |
| 922 | Diabetic Retinopathy: Pathophysiology and Treatments. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1816.  | 1.8 | 656       |
| 923 | Extended Duration Vascular Endothelial Growth Factor Inhibition in the Eye: Failures, Successes, and Future Possibilities. <i>Pharmaceutics</i> , 2018, 10, 21.   | 2.0 | 37        |
| 924 | Pro- and antiangiogenic therapies: current status and clinical implications. <i>FASEB Journal</i> , 2019, 33, 34-48.  | 0.2 | 56        |
| 925 | IL-27 regulates HIF-1-mediated VEGFA response in macrophages of diabetic retinopathy patients and healthy individuals. <i>Cytokine</i> , 2019, 113, 238-247.  | 1.4 | 12        |
| 926 | Advances in the treatment of diabetic retinopathy. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 107417.   | 1.2 | 43        |
| 927 | Boswellic acids ameliorate doxorubicin-induced nephrotoxicity in mice: a focus on antioxidant and antiapoptotic effects. <i>Egyptian Journal of Basic and Applied Sciences</i> , 2019, 6, 10-24.  | 0.2 | 7         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 928 | Systemic Factors Related to Intraocular Levels of Interleukin-6 and Vascular Endothelial Growth Factor in Diabetic Retinopathy. <i>Journal of Ophthalmology</i> , 2019, 2019, 1-6.  | 0.6 | 2         |
| 929 | Pathophysiology of Diabetic Retinopathy: Contribution and Limitations of Laboratory Research. <i>Ophthalmic Research</i> , 2019, 62, 196-202.   | 1.0 | 25        |
| 930 | Effectiveness of prophylactic intravitreal bevacizumab injection to proliferative diabetic retinopathy patients with elevated preoperative intraocular VEGF in preventing complications after vitrectomy. <i>Clinical Ophthalmology</i> , 2019, Volume 13, 1063-1070. | 0.9 | 5         |
| 931 | Insights into the G-rich VEGF-binding aptamer V7t1: when two G-quadruplexes are better than one!. <i>Nucleic Acids Research</i> , 2019, 47, 8318-8331.  | 6.5 | 32        |
| 932 | Unsaturated Aldehyde Acrolein Promotes Retinal Glial Cell Migration. , 2019, 60, 4425.  |     | 12        |
| 933 | Subclavian vein stent: Two decades of unassisted patency. <i>Hemodialysis International</i> , 2019, 23, 504-505.  | 0.4 | 0         |
| 934 | Nicotine increased VEGF and MMP2 levels in the rat eye and kidney. <i>Environmental Science and Pollution Research</i> , 2019, 26, 33517-33523.   | 2.7 | 5         |
| 935 | OCT angiography-based monitoring of neovascular regression on fibrovascular membrane after preoperative intravitreal conbercept injection. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2019, 257, 1611-1619.                                | 1.0 | 20        |
| 936 | Association between interleukin-10 gene rs1800896 polymorphism and diabetic retinopathy in a Chinese Han population. <i>Bioscience Reports</i> , 2019, 39, .  | 1.1 | 5         |
| 937 | Decision Making in Proliferative Diabetic Retinopathy Treatment. <i>Current Ophthalmology Reports</i> , 2019, 7, 45-50.   | 0.5 | 3         |
| 938 | Nutraceuticals for the Treatment of Diabetic Retinopathy. <i>Nutrients</i> , 2019, 11, 771.   | 1.7 | 77        |
| 939 | C1q/TNF-related protein-9 attenuates retinal inflammation and protects blood-retinal barrier in db/db mice. <i>European Journal of Pharmacology</i> , 2019, 853, 289-298.   | 1.7 | 31        |
| 940 | Discovering Mechanisms in the Changing and Diverse Pathology of Retinopathy of Prematurity: The Weisenfeld Award Lecture. , 2019, 60, 1286.   |     | 9         |
| 941 | Short-term effects of intravitreal bevacizumab in contrast sensitivity of patients with diabetic macular edema and optimizing glycemic control. <i>Diabetes Research and Clinical Practice</i> , 2019, 149, 170-178.  | 1.1 | 7         |
| 942 | Translational Preclinical Pharmacologic Disease Models for Ophthalmic Drug Development. <i>Pharmaceutical Research</i> , 2019, 36, 58.  | 1.7 | 36        |
| 943 | Association of Serum Zinc and Vitamin A Levels with Severity of Retinopathy in Type 2 Diabetic Patients: a Cross-Sectional Study. <i>Biological Trace Element Research</i> , 2019, 192, 123-128.  | 1.9 | 17        |
| 944 | Current RNA-based Therapeutics in Clinical Trials. <i>Current Gene Therapy</i> , 2019, 19, 172-196.   | 0.9 | 82        |
| 945 | Intravitreal bevacizumab improves the clearance of vitreous haemorrhage and visual outcomes in patients with proliferative diabetic retinopathy. <i>BMJ Open Ophthalmology</i> , 2019, 4, e000390.  | 0.8 | 15        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 946 | Nanoscale delivery systems in treatment of posterior ocular neovascularization: strategies and potential applications. <i>Therapeutic Delivery</i> , 2019, 10, 737-747.  | 1.2 | 9         |
| 947 | Intravitreal ranibizumab injection at the end of vitrectomy for diabetic vitreous hemorrhage (Observational Study). <i>Medicine (United States)</i> , 2019, 98, e15735.  | 0.4 | 5         |
| 948 | Intravitreal Bevacizumab in Diabetic Retinopathy. Recommendations from the Pan-American Collaborative Retina Study Group (PACORES): The 2016 Knobloch Lectur. <i>Asia-Pacific Journal of Ophthalmology</i> , 2019, 7, 36-39. | 1.3 | 11        |
| 949 | Association of 18bp insertion/deletion polymorphism, at $\sim$ 2549 position of VEGF gene, with diabetic vascular complications in type 2 diabetes mellitus. <i>Advances in Medical Sciences</i> , 2019, 64, 137-143.        | 0.9 | 7         |
| 950 | Efficacy comparison of intravitreal injections of conbercept and ranibizumab for severe proliferative diabetic retinopathy. <i>Canadian Journal of Ophthalmology</i> , 2019, 54, 291-296.                                    | 0.4 | 10        |
| 951 | Proliferative Diabetic Retinopathy. , 2019, , 185-246.   |     | 0         |
| 952 | (Pro)renin receptor: Involvement in diabetic retinopathy and development of molecular targeted therapy. <i>Journal of Diabetes Investigation</i> , 2019, 10, 6-17.   | 1.1 | 22        |
| 953 | The Short-Term Efficacy of Biweekly Subconjunctival Bevacizumab in Diabetic Macular Edema. <i>Current Eye Research</i> , 2020, 45, 585-590.  | 0.7 | 1         |
| 954 | The 100 Most Cited Articles on Vitrectomy. <i>Ophthalmology Retina</i> , 2020, 4, 361-368.   | 1.2 | 8         |
| 955 | The Benefits of Flavonoids in Diabetic Retinopathy. <i>Nutrients</i> , 2020, 12, 3169.   | 1.7 | 32        |
| 956 | The prognostic value of peripheral retinal nonperfusion in diabetic retinopathy using ultra-widefield fluorescein angiography. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2020, 258, 2681-2690.   | 1.0 | 16        |
| 957 | Pathological Role of Unsaturated Aldehyde Acrolein in Diabetic Retinopathy. <i>Frontiers in Immunology</i> , 2020, 11, 589531.   | 2.2 | 8         |
| 958 | New developments in angiography for the diagnosis and management of diabetic retinopathy. <i>Diabetes Research and Clinical Practice</i> , 2020, 167, 108361.  | 1.1 | 11        |
| 959 | Relationship between Serum Vascular Endothelial Growth Factor Levels and Stages of Diabetic Retinopathy and Other Biomarkers. <i>Journal of Ophthalmology</i> , 2020, 2020, 1-7.   | 0.6 | 9         |
| 960 | Characterization of Retinal Microvascular Complications and the Effects of Endoplasmic Reticulum Stress in Mouse Models of Diabetic Atherosclerosis. , 2020, 61, 49.   |     | 6         |
| 961 | Retinal Physiology and Circulation: Effect of Diabetes. , 2020, 10, 933-974.   |     | 11        |
| 962 | 100 most-cited articles on diabetic retinopathy. <i>British Journal of Ophthalmology</i> , 2021, 105, 1329-1336.   | 2.1 | 13        |
| 963 | Endothelial Dysfunction in Diabetic Retinopathy. <i>Frontiers in Endocrinology</i> , 2020, 11, 591.  | 1.5 | 83        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 964 | Iris thickness measurements in patients with diabetic retinopathy. <i>European Journal of Ophthalmology</i> , 2020, , 112067212097262.  | 0.7 | 1         |
| 965 | Small-Molecule Modulation of PPARs for the Treatment of Prevalent Vascular Retinal Diseases. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9251.   | 1.8 | 6         |
| 966 | Fabrication, Optimization, and In Vitro and In Vivo Characterization of Intra-vitreous Implant of Budesonide Generally Made of PHBV. <i>AAPS PharmSciTech</i> , 2020, 21, 314.  | 1.5 | 4         |
| 967 | Eicosanoid Profiles in the Vitreous Humor of Patients with Proliferative Diabetic Retinopathy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7451.   | 1.8 | 12        |
| 968 | Hypoxia-inducible factor-1 $\beta$ : A promising therapeutic target for vasculopathy in diabetic retinopathy. <i>Pharmacological Research</i> , 2020, 159, 104924.  | 3.1 | 39        |
| 969 | Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group. <i>Eye</i> , 2020, 34, 1-51.  | 1.1 | 104       |
| 970 | Proliferative diabetic retinopathy without preoperative pan-retinal photocoagulation is associated with higher levels of intravitreal IL-6 and postoperative inflammation. <i>International Journal of Retina and Vitreous</i> , 2020, 6, 24.                                   | 0.9 | 10        |
| 971 | Resistance Mechanisms to Anti-angiogenic Therapies in Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 221.   | 1.3 | 213       |
| 972 | Glucocorticoid-transactivated TSC22D3 attenuates hypoxia- and diabetes-induced Müller glial galectin-1 expression via HIF-1 $\beta$ destabilization. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 4589-4599.   | 1.6 | 14        |
| 973 | Semaphorins in Angiogenesis and Autoimmune Diseases: Therapeutic Targets?. <i>Frontiers in Immunology</i> , 2020, 11, 346.  | 2.2 | 38        |
| 974 | High glucose concentration produces a short-term increase in pERK1/2 and p85 proteins, having a direct angiogenic effect by an action similar to VEGF. <i>Acta Diabetologica</i> , 2020, 57, 947-958.   | 1.2 | 2         |
| 975 | Regulation of Spermine Oxidase through Hypoxia-Inducible Factor-1 $\beta$ Signaling in Retinal Glial Cells under Hypoxic Conditions. , 2020, 61, 52.  |     | 14        |
| 976 | The effect of adjunctive intravitreal conbercept at the end of diabetic vitrectomy for the prevention of post-vitrectomy hemorrhage in patients with severe proliferative diabetic retinopathy: a prospective, randomized pilot study. <i>BMC Ophthalmology</i> , 2020, 20, 43. | 0.6 | 11        |
| 977 | A Mechanistic and Translational Pharmacokinetic-Pharmacodynamic Model of Abicipar Pegol and Vascular Endothelial Growth Factor Inhibition. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 373, 184-192.   | 1.3 | 7         |
| 978 | Role of small interfering RNA (siRNA) in targeting ocular neovascularization: A review. <i>Experimental Eye Research</i> , 2021, 202, 108329.   | 1.2 | 13        |
| 979 | Diabetic retinopathy its genetics and single nucleotide polymorphism associated with multi-ethnic cohort " A review. <i>Materials Today: Proceedings</i> , 2021, 37, 1640-1647.   | 0.9 | 4         |
| 980 | Anti-VEGF DNA-based aptamers in cancer therapeutics and diagnostics. <i>Medicinal Research Reviews</i> , 2021, 41, 464-506.   | 5.0 | 39        |
| 981 | Factors Affecting a Short-Term Response to Anti-VEGF Therapy in Diabetic Macular Edema. <i>Life</i> , 2021, 11, 83.   | 1.1 | 11        |

| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 982  | Pharmacotherapy of Age-Related Macular Degeneration. , 2021, , 1-26.   |     | 0         |
| 983  | PRODUCTION AND APPLICATION OF ANGIOSTATINS FOR THE TREATMENT OF OCULAR NEOVASCULAR DISEASES. <i>Biotechnologia Acta</i> , 2021, 14, 5-24.  | 0.3 | 1         |
| 984  | Evaluation of vitrectomy combined preoperative intravitreal ranibizumab and postoperative intravitreal triamcinolone acetonide for proliferative diabetic retinopathy. <i>International Ophthalmology</i> , 2021, 41, 1635-1642.                               | 0.6 | 8         |
| 986  | Prevention of doxorubicin-induced renal function abnormalities by turmeric in Wistar rats. <i>GSC Biological and Pharmaceutical Sciences</i> , 2021, 14, 143-156.  | 0.1 | 0         |
| 987  | From the Hypotheses to Clinical Evidence in Retinal Therapy. <i>Journal of Ophthalmic and Vision Research</i> , 2021, 16, 287-290.   | 0.7 | 0         |
| 988  | Intravitreal bevacizumab (IVB) versus IVB in combination with pars plana vitrectomy for vitreous hemorrhage secondary to proliferative diabetic retinopathy: a randomized clinical trial. <i>International Journal of Retina and Vitreous</i> , 2021, 7, 35.   | 0.9 | 4         |
| 989  | Astaxanthin mediated regulation of VEGF through HIF1 $\alpha$ and XBP1 signaling pathway: An insight from ARPE-19 cell and streptozotocin mediated diabetic rat model. <i>Experimental Eye Research</i> , 2021, 206, 108555.                                   | 1.2 | 15        |
| 990  | Ultra-wide field swept-source optical coherence tomography angiography in patients with diabetes without clinically detectable retinopathy. <i>BMC Ophthalmology</i> , 2021, 21, 192.  | 0.6 | 18        |
| 991  | Autophagy: A Novel Pharmacological Target in Diabetic Retinopathy. <i>Frontiers in Pharmacology</i> , 2021, 12, 695267.  | 1.6 | 16        |
| 992  | Comparison of the effects of intravitreal ranibizumab and aflibercept on retinal vessel diameters in patients with diabetic macular edema. <i>Photodiagnosis and Photodynamic Therapy</i> , 2021, 34, 102282.  | 1.3 | 2         |
| 993  | Efficacy and Safety of Intravitreal Injection Ranibizumab versus Triamcinolone Acetonide in Diabetic Macular Oedema - A Prospective Randomized Study, Gorakhpur, Uttar Pradesh. <i>Journal of Evidence Based Medicine and Healthcare</i> , 2021, 8, 2444-2450. | 0.0 | 0         |
| 994  | The Vitreous Ecosystem in Diabetic Retinopathy: Insight into the Patho-Mechanisms of Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7142.   | 1.8 | 9         |
| 995  | Macrophage-Like Cell Density Is Increased in Proliferative Diabetic Retinopathy Characterized by Optical Coherence Tomography Angiography. , 2021, 62, 2.  |     | 41        |
| 996  | VEGFR1 signaling in retinal angiogenesis and microinflammation. <i>Progress in Retinal and Eye Research</i> , 2021, 84, 100954.  | 7.3 | 123       |
| 997  | Unveiling the role of polyphenols in diabetic retinopathy. <i>Journal of Functional Foods</i> , 2021, 85, 104608.  | 1.6 | 8         |
| 998  | Effect of anti-vascular endothelial growth factor on the surgical outcome of neovascular glaucoma. <i>Medicine (United States)</i> , 2021, 100, e27326.  | 0.4 | 4         |
| 999  | Retinal Protein O-GlcNAcylation and the Ocular Renin Angiotensin System: Signaling Cross-Roads in Diabetic Retinopathy. <i>Current Diabetes Reviews</i> , 2021, 17, .  | 0.6 | 2         |
| 1000 | Retinal Vascular Disease. , 2021, , 89-123.  |     | 0         |

| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 1001 | Fatty acid-binding protein 4 is an independent factor in the pathogenesis of retinal vein occlusion. PLoS ONE, 2021, 16, e0245763.  | 1.1 | 3         |
| 1003 | Imaging Oxygen Pressure in the Rodent Retina by Phosphorescence Lifetime. , 2006, 578, 119-124.   |     | 9         |
| 1004 | Molecular Neurobiology of Retinal Degeneration. , 2007, , 47-92.  |     | 2         |
| 1005 | Ocular Neovascularization. , 2008, , 517-531.   |     | 3         |
| 1006 | Pathophysiology of Diabetic Retinopathy. , 2010, , 1-30.  |     | 10        |
| 1007 | Rodent Models of Oxygen-Induced Retinopathy. , 2008, , 57-80.   |     | 1         |
| 1008 | The Biology of Vascular Endothelial Growth Factor, a Specific Regulator of Angiogenesis. , 1997, , 317-332.   |     | 2         |
| 1009 | The Biology of Vascular Endothelial Growth Factor. , 1996, , 73-83.   |     | 2         |
| 1010 | Complement Involvement in Neovascular Ocular Diseases. Advances in Experimental Medicine and Biology, 2012, 946, 161-183.   | 0.8 | 38        |
| 1011 | Poly-ADP-Ribosylation of Vascular Endothelial Growth Factor and Its Implications on Angiogenesis. Advances in Experimental Medicine and Biology, 2012, 749, 269-278.                                    | 0.8 | 7         |
| 1012 | Sensitivity of Different Vascular Beds in the Eye to Neovascularization and Blood-Retinal Barrier Breakdown in VEGF Transgenic Mice. Advances in Experimental Medicine and Biology, 2000, 476, 129-138. | 0.8 | 20        |
| 1013 | Receptor Tyrosine Kinases in Angiogenesis. , 2002, , 409-452.   |     | 2         |
| 1014 | Role of Vascular Endothelial Growth Factor in Regulation of Angiogenesis. , 1999, , 119-141.  |     | 15        |
| 1016 | Endogenous Angiogenic Inhibitors in Diabetic Retinopathy. , 2006, , 23-44.  |     | 1         |
| 1017 | The Role of Inflammation in the Pathophysiology of Diabetic Retinopathy. , 2008, , 303-331.   |     | 4         |
| 1018 | Retinal Neovascularization and the Role of VEGF. , 2008, , 353-373.   |     | 3         |
| 1019 | Vascular permeability factor/vascular endothelial growth factor:A multifunctional angiogenic cytokine. Exs, 1997, 79, 233-269.  | 1.4 | 353       |
| 1020 | Vascular endothelial growth factor: Basic biology and clinical implications. Exs, 1997, 79, 209-232.  | 1.4 | 92        |



| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 1021 | Tumor Angiogenesis: from Bench to Bedside. , 2008, , 3-28.   |     | 13        |
| 1022 | Vascular Endothelial Growth Factor: Molecular and Biological Aspects. Current Topics in Microbiology and Immunology, 1999, 237, 1-30.  | 0.7 | 449       |
| 1023 | Vascular Permeability Factor/Vascular Endothelial Growth Factor and the Significance of Microvascular Hyperpermeability in Angiogenesis. Current Topics in Microbiology and Immunology, 1999, 237, 97-132. | 0.7 | 591       |
| 1024 | Anti-Angiogenic Properties of Vitreousâ†. , 2017, , .  |     | 1         |
| 1025 | Etiologic Mechanisms in Diabetic Retinopathy. , 2006, , 1241-1270.   |     | 23        |
| 1026 | Vitreoretinal Interface. , 2006, , 1921-1989.  |     | 10        |
| 1027 | Intraocular Neovascularization. , 2006, , 2403-2411.   |     | 1         |
| 1028 | Proliferative Diabetic Retinopathy: Principles and Techniques of Surgical Treatment. , 2006, , 2413-2449.  |     | 17        |
| 1029 | Retinal and Choroidal Circulations. , 2008, , 1657-1675.   |     | 1         |
| 1030 | Neovascular Glaucoma. , 2008, , 2689-2712.   |     | 4         |
| 1031 | Complications of Diabetes Mellitus. , 2011, , 1462-1551.   |     | 8         |
| 1032 | Molecular complexities underlying the vascular complications of diabetes mellitus â€“ A comprehensive review. Journal of Diabetes and Its Complications, 2020, 34, 107613.                                 | 1.2 | 84        |
| 1033 | Molecular biology of choroidal neovascularization. Ophthalmology Clinics of North America, 2006, 19, 323-34.   | 1.8 | 39        |
| 1034 | Role of vascular endothelial growth factor in ocular angiogenesis. Ophthalmology Clinics of North America, 2006, 19, 335-44.   | 1.8 | 76        |
| 1035 | The Conformation-dependent Interaction of Î±2-Macroglobulin with Vascular Endothelial Growth Factor. Journal of Biological Chemistry, 2000, 275, 26806-26811.  | 1.6 | 42        |
| 1036 | The pathogenesis of diabetic retinopathy: old concepts and new questions. , 0, .   |     | 5         |
| 1037 | EFFECT OF A TOPICALLY APPLIED NEUTRALIZING ANTIBODY AGAINST VASCULAR ENDOTHELIAL GROWTH FACTOR ON CORNEAL ALLOGRAFT REJECTION OF RAT1. Transplantation, 1998, 66, 1519-1524.                               | 0.5 | 34        |
| 1038 | Molecular mechanisms of growth factor action in diabetic retinopathy. Current Opinion in Endocrinology, Diabetes and Obesity, 1999, 6, 146-156.  | 0.6 | 7         |

| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 1039 | Foveal Retinal Neovascularization in Proliferative Diabetic Retinopathy: Assessment by Optical Coherence Tomography Angiography. <i>Retina</i> , 2017, 37, e135-e137.   | 1.0 | 8         |
| 1040 | Arterial Gene Therapy for Therapeutic Angiogenesis in Patients With Peripheral Artery Disease. <i>Circulation</i> , 1995, 91, 2687-2692.  | 1.6 | 179       |
| 1041 | Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1 $\alpha$ and VEGF. <i>Journal of Clinical Investigation</i> , 2002, 109, 805-815.   | 3.9 | 176       |
| 1042 | Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo.. <i>Journal of Clinical Investigation</i> , 1996, 98, 1667-1675.   | 3.9 | 367       |
| 1043 | Reversal of experimental diabetic neuropathy by VEGF gene transfer. <i>Journal of Clinical Investigation</i> , 2001, 107, 1083-1092.  | 3.9 | 271       |
| 1044 | Advanced glycation end products increase retinal vascular endothelial growth factor expression.. <i>Journal of Clinical Investigation</i> , 1998, 101, 1219-1224.   | 3.9 | 363       |
| 1045 | Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1 $\alpha$ and VEGF. <i>Journal of Clinical Investigation</i> , 2002, 109, 805-815.   | 3.9 | 115       |
| 1046 | Increased ocular levels of IGF-1 in transgenic mice lead to diabetes-like eye disease. <i>Journal of Clinical Investigation</i> , 2004, 113, 1149-1157.   | 3.9 | 142       |
| 1047 | Retinal expression, regulation, and functional bioactivity of prostacyclin-stimulating factor. <i>Journal of Clinical Investigation</i> , 2000, 106, 541-550.   | 3.9 | 53        |
| 1048 | Progression of Diabetic Capillary Occlusion: A Model. <i>PLoS Computational Biology</i> , 2016, 12, e1004932.   | 1.5 | 24        |
| 1049 | Blockade of VEGFR1 and 2 Suppresses Pathological Angiogenesis and Vascular Leakage in the Eye. <i>PLoS ONE</i> , 2011, 6, e21411.   | 1.1 | 70        |
| 1050 | Comparison of Combined and Sequential Surgery for Proliferative Diabetic Retinopathy: A Single Surgeon Study. <i>PLoS ONE</i> , 2014, 9, e108933.   | 1.1 | 8         |
| 1051 | Protective effects on the retina after ranibizumab treatment in an ischemia model. <i>PLoS ONE</i> , 2017, 12, e0182407.  | 1.1 | 26        |
| 1054 | Vascular endothelial growth factor (VEGF)-related polymorphisms rs10738760 and rs6921438 are not risk factors for proliferative diabetic retinopathy (PDR) in patients with type 2 diabetes mellitus (T2DM). <i>Bosnian Journal of Basic Medical Sciences</i> , 2019, 19, 94-100. | 0.6 | 9         |
| 1055 | Association of vascular endothelial growth factor -634G/C and receptor for advanced glycation end products G82S gene polymorphisms with diabetic retinopathy. <i>International Journal of Ophthalmology</i> , 2016, 9, 1106-11.   | 0.5 | 6         |
| 1056 | Ligands of peroxisome proliferator-activated receptor-gamma increase the generation of vascular endothelial growth factor in vascular smooth muscle cells and in macrophages.. <i>Acta Biochimica Polonica</i> , 2000, 47, 1147-1157.   | 0.3 | 59        |
| 1057 | CXCL5 drives obesity to diabetes, and further. <i>Aging</i> , 2009, 1, 674-677.   | 1.4 | 30        |
| 1058 | Ranibizumab in neovascular age-related macular degeneration. <i>Clinical Interventions in Aging</i> , 2006, 1, 451-466.   | 1.3 | 15        |

| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 1059 | Pathological Perturbations in Diabetic Retinopathy: Hyperglycemia, AGEs, Oxidative Stress and Inflammatory Pathways. <i>Current Protein and Peptide Science</i> , 2018, 20, 92-110.   | 0.7 | 55        |
| 1060 | Prevention and Treatment of Diabetic Retinopathy: Evidence from Clinical Trials and Perspectives. <i>Current Diabetes Reviews</i> , 2011, 7, 190-200.   | 0.6 | 37        |
| 1061 | Accumulation of AGEs and VEGF in Eyes of SDT Rats. <i>The Open Diabetes Journal</i> , 2011, 4, 41-44.   | 0.4 | 2         |
| 1062 | Dual Targeting of Retinal Vasculature in the Mouse Model of Oxygen Induced Retinopathy. <i>The Open Diabetes Journal</i> , 2011, 4, 60-74.  | 0.4 | 1         |
| 1063 | Reversal of Retinal Vascular Changes Associated with Ocular Neovascularization by Small Molecules: Progress toward Identifying Molecular Targets for Therapeutic Intervention. <i>The Open Diabetes Journal</i> , 2011, 4, 75-95.                     | 0.4 | 3         |
| 1064 | Effects of Topical Nipradilol on Early Diabetic Retinopathy in SDT Rats. <i>The Open Diabetes Journal</i> , 2011, 4, 114-118.   | 0.4 | 2         |
| 1065 | Spectral Domain Optical Coherence Tomography Based Alterations in Macular Thickness and Inner Segment Ellipsoidare Associated with Severity of Diabetic Retinopathy. <i>International Journal of Ophthalmology and Clinical Research</i> , 2015, 2, . | 0.1 | 3         |
| 1066 | Role of chronic inflammation in diabetic retinopathy. <i>Inflammation and Regeneration</i> , 2013, 33, 230-237.   | 1.5 | 2         |
| 1068 | Effect of Resveratrol on Bcl-2 and VEGF Expression in Oxygen-Induced Retinopathy of Prematurity. <i>Journal of Pediatric Ophthalmology and Strabismus</i> , 2012, 49, 230-235.  | 0.3 | 18        |
| 1069 | Iris Neovascularization After Vitrectomy Combined With Phacoemulsification and Intraocular Lens Implantation for Proliferative Diabetic Retinopathy. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2001, 32, 19-24.                           | 0.4 | 39        |
| 1070 | The Relation Between Bevacizumab Injection and the Formation of Subretinal Fibrosis in Diabetic Patients With Panretinal Photocoagulation. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2010, 41, 190-195.                                   | 0.4 | 17        |
| 1071 | Venous Loop Reveals an Occult Retinoblastoma Tumor. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2017, 48, 768-770.  | 0.4 | 4         |
| 1072 | Short term apoptotic activity of intravitreal bevacizumab on rabbit retina. <i>International Journal of Ophthalmology</i> , 2013, 6, 785-9.   | 0.5 | 2         |
| 1073 | Comparison of the effect of intravitreal bevacizumab and intravitreal fasudil on retinal VEGF, TNF $\alpha$ , and caspase 3 levels in an experimental diabetes model. <i>International Journal of Ophthalmology</i> , 2014, 7, 57-61.                 | 0.5 | 4         |
| 1074 | Platelet-Derived Growth Factor and Angiogenesis.. <i>Trends in Glycoscience and Glycotechnology</i> , 1996, 8, 231-251.   | 0.0 | 19        |
| 1075 | Update on wide- and ultra-widefield retinal imaging. <i>Indian Journal of Ophthalmology</i> , 2015, 63, 575.  | 0.5 | 42        |
| 1076 | The future implications and indications of anti-vascular endothelial growth factor therapy in ophthalmic practice. <i>Indian Journal of Ophthalmology</i> , 2007, 55, 445.  | 0.5 | 19        |
| 1077 | Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population. <i>Indian Journal of Ophthalmology</i> , 2007, 55, 451.   | 0.5 | 37        |

| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 1078 | Increased levels of vascular endothelial growth factor in the aqueous humor of patients with diabetic retinopathy. Indian Journal of Ophthalmology, 2010, 58, 375.  | 0.5 | 53        |
| 1079 | Quantitative physiological measurements to evaluate the response of antivascular endothelial growth factor treatment in patients with neovascular diseases. Indian Journal of Ophthalmology, 2017, 65, 559. | 0.5 | 4         |
| 1080 | Case report on two diabetic donor eyes with no retinopathy: Clinicopathological and molecular studies. Indian Journal of Ophthalmology, 2019, 67, 1762.   | 0.5 | 1         |
| 1081 | Functions of Müller cell-derived vascular endothelial growth factor in diabetic retinopathy. World Journal of Diabetes, 2015, 6, 726.   | 1.3 | 47        |
| 1082 | Gastric angiogenesis and Helicobacter pylori infection. Revista Espanola De Enfermedades Digestivas, 2006, 98, 527-41.  | 0.1 | 15        |
| 1083 | Disease-modifying effects of ranibizumab for central retinal vein occlusion. Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, 260, 799-805.  | 1.0 | 1         |
| 1084 | Association of VEGFA promoter polymorphisms rs699947 and rs35569394 with diabetic retinopathy among North-Central Indian subjects: a case-control study. Ophthalmic Genetics, 2022, 43, 80-87.              | 0.5 | 2         |
| 1085 | Proliferative Diabetic Retinopathy: Current Treatment Strategies for Progression. , 2002, , 89-104.   |     | 0         |
| 1086 | New Insights into the Molecular Mechanisms of Vascular Permeability in Diabetes. , 2002, , 23-33.   |     | 0         |
| 1087 | Apoptosis and Neurodegeneration in Diabetes: Lessons from the Retina. , 2002, , 35-45.  |     | 0         |
| 1088 | Angiogenesis Therapies. , 2002, , 547-571.  |     | 7         |
| 1089 | Involvement of Leukocytes in Diabetic Retinopathy and Choroidopathy. , 2003, , 559-569.   |     | 2         |
| 1090 | Management of Diabetic Retinopathy. An Overview. Hormones, 2004, 3, 92-99.  | 0.9 | 1         |
| 1091 | Adeno-Associated Virus-Mediated Expression of Vascular Endothelial Growth Factor Peptides Inhibits Retinal Neovascularization in a Mouse Model of Oxygen-Induced Retinopathy. Human Gene Therapy, 2005, ,   | 1.4 | 0         |
| 1094 | Ocular Angiogenesis. , 2008, , 473-493.   |     | 0         |
| 1096 | Anti-VEGF Therapy as an Emerging Treatment for Diabetic Retinopathy. , 2008, , 401-422.   |     | 0         |
| 1097 | Diagnosis, Management, and Treatment of Nonproliferative Diabetic Retinopathy. , 2008, , 1775-1791.   |     | 1         |
| 1100 | Electrophysiological and Morphological Changes After Intravitreal Bevacizumab Injection with Macular Edema or Choroidal Neovascularization. Journal of Korean Ophthalmological Society, 2009, 50, 1824.     | 0.0 | 1         |

| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 1101 | Vitreotomy en Pacientes Diabéticos con Glaucoma Neovascular. Highlights of Vitreoretina, 2010, 2, 4-7.  | 0.0 | 0         |
| 1103 | Proteomics in the Vitreous of Diabetic Retinopathy Patients. , 2012, , 173-188.   |     | 0         |
| 1104 | Molecular Regulation of Endothelial Cell Tight Junctions and the Blood-Retinal Barrier. , 2012, , 123-141.  |     | 0         |
| 1105 | Pathologie, Klinik und Behandlung von diabetischen retinalen GefÄÄÿerkrankungen. , 2012, , 99-162.  |     | 0         |
| 1108 | Retinal Bioengineering. , 2013, , 565-634.  |     | 0         |
| 1109 | The effect of L-arginine and L-NAME on myocardial capillary density in normal rats. Advanced Biomedical Research, 2013, 2, 67.  | 0.2 | 0         |
| 1110 | Use of intravitreal bevacizumab or triamcinolone acetonide as a preoperative adjunct to vitrectomy for vitreous haemorrhage in diabetics. Revista Brasileira De Oftalmologia, 2013, 72, 12-16.  | 0.1 | 3         |
| 1111 | Diabetes Mellitus and Neovascularization. Japanese Journal of Thrombosis and Hemostasis, 1996, 7, 123-129.  | 0.1 | 0         |
| 1113 | Angiogenesis in diabetic retinopathy: a history of accomplishment, discovery and promise. , 1998, , 181-196.  |     | 0         |
| 1114 | Receptor Tyrosine Kinase Signaling in Vasculogenesis and Angiogenesis. Developments in Cardiovascular Medicine, 1999, , 179-191.  | 0.1 | 0         |
| 1115 | Neovascular Age-Related Macular Degeneration: Secretion Gene Therapy. Essentials in Ophthalmology, 2015, , 65-76.   | 0.0 | 0         |
| 1116 | Observation of the Vitreous in Diabetic Macular Edema Using Swept-Source OCT. Advances in Ophthalmology & Visual System, 2015, 2, .   | 0.2 | 0         |
| 1117 | COMPARATIVE EFFICACY OF LASER PHOTOCOAGULATION MONOTHERAPY, INTRAVITREAL BEVACIZUMAB MONOTHERAPY AND COMBINED LASER PHOTOCOAGULATION AND INTRAVITREAL BEVACIZUMAB THERAPY IN THE MANAGEMENT OF MACULAR OEDEMA â€œ 350 Åµm IN NONISCHAEMIC, NON-PROLIFERATIVE DIABETIC RETINOPATHY IN TYPE 2 DIABETES MELLITUS. Journal of Evolution of Medical and Dental Sciences, 2017, 6, 721-726. | 0.1 | 0         |
| 1118 | Peri-operative Shift in Angiogenesis-Related Factors in Breast Cancer Patients. , 2017, , 55-81.  |     | 0         |
| 1119 | PANRETINAL PHOTOCOAGULATION VS. PANRETINAL PHOTOCOAGULATION PLUS INTRAVITREAL RANIBIZUMAB IN HIGH-RISK PROLIFERATIVE DIABETIC RETINOPATHY. Journal of Evidence Based Medicine and Healthcare, 2017, 4, 5776-5779.   | 0.0 | 0         |
| 1120 | SAFETY AND EFFICACY OF PREOP INTRAVITREAL TRIAMCINOLONE PLUS BEVACIZUMAB COMBINATION AND BEVACIZUMAB ALONE IN VITREOUS SURGERY FOR NON-RESOLVING VITREOUS HAEMORRHAGE IN PROLIFERATIVE DIABETIC RETINOPATHY (PDR). Journal of Evidence Based Medicine and Healthcare, 2018, 4, 218-221.   | 0.0 | 0         |
| 1121 | Serum Levels of Interferon-Gamma in Patients with Diabetic Retinopathy. Iranian South Medical Journal, 2019, 22, 106-118.   | 0.2 | 0         |
| 1123 | Neovascular Glaucoma. , 2020, , 1-39.   |     | 0         |

| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 1126 | Gene Therapy for Neovascular Retinopathies. , 2006, , 355-371.   |     | 0         |
| 1128 | Inflammation as a Stimulus for Vascular Leakage and Proliferation. , 2007, , 97-107.   |     | 0         |
| 1129 | Is Diabetic Retinopathy an Inflammatory Disease? Inflammation as a Stimulus for Vascular Leakage and Proliferati on. Essentials in Ophthalmology, 2009, , 29-43.   | 0.0 | 0         |
| 1131 | Vascular endothelial growth factor and ocular neovascularization. American Journal of Pathology, 1997, 151, 13-23.   | 1.9 | 89        |
| 1132 | Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. American Journal of Pathology, 1997, 151, 281-91.  | 1.9 | 311       |
| 1133 | Mouse model of angiogenesis. American Journal of Pathology, 1998, 152, 1667-79.  | 1.9 | 564       |
| 1134 | Molecular framework for angiogenesis: a complex web of interactions between extravasated plasma proteins and endothelial cell proteins induced by angiogenic cytokines. American Journal of Pathology, 1996, 149, 1-7.   | 1.9 | 198       |
| 1135 | Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Molecular Medicine, 1995, 1, 182-93.   | 1.9 | 97        |
| 1136 | Neutralizing antibody to VEGF reduces intravitreal neovascularization and may not interfere with ongoing intraretinal vascularization in a rat model of retinopathy of prematurity. Molecular Vision, 2008, 14, 345-57.  | 1.1 | 58        |
| 1137 | Significance of wine and resveratrol in cardiovascular disease: French paradox revisited. Experimental and Clinical Cardiology, 2006, 11, 217-25.  | 1.3 | 80        |
| 1138 | Local and genetic determinants of vascular endothelial growth factor expression in advanced proliferative diabetic retinopathy. Molecular Vision, 2008, 14, 1382-7.  | 1.1 | 54        |
| 1141 | Studies on the pathogenesis of avascular retina and neovascularization into the vitreous in peripheral severe retinopathy of prematurity (an american ophthalmological society thesis). Transactions of the American Ophthalmological Society, 2010, 108, 96-119.  | 1.4 | 33        |
| 1142 | Polymorphisms in the vascular endothelial growth factor gene and the risk of diabetic retinopathy in Chinese patients with type 2 diabetes. Molecular Vision, 2011, 17, 3088-96.   | 1.1 | 35        |
| 1143 | Comparison of aqueous humor cytokine and chemokine levels in diabetic patients with and without retinopathy. Molecular Vision, 2012, 18, 830-7.  | 1.1 | 74        |
| 1144 | Vascular endothelial growth factors and their inhibitors in ocular neovascular disorders. Journal of Ophthalmic and Vision Research, 2009, 4, 105-14.  | 0.7 | 12        |
| 1145 | Study of 27 aqueous humor cytokines in patients with type 2 diabetes with or without retinopathy. Molecular Vision, 2013, 19, 1734-46.   | 1.1 | 78        |
| 1146 | Intravitreal bevacizumab as anti-vascular endothelial growth factor in the management of complications of proliferative diabetic retinopathy. Medical Hypothesis, Discovery, and Innovation in Ophthalmology, 2013, 2, 20-4.   | 0.4 | 10        |
| 1147 | Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis). Transactions of the American Ophthalmological Society, 2014, 112, 160-98. | 1.4 | 20        |

| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 1148 | Characterization of cells from patient-derived fibrovascular membranes in proliferative diabetic retinopathy. <i>Molecular Vision</i> , 2015, 21, 673-87.   | 1.1 | 10        |
| 1149 | Ranibizumab for the Prevention of Radiation Complications in Patients Treated With Proton Beam Irradiation for Choroidal Melanoma. <i>Transactions of the American Ophthalmological Society</i> , 2016, 114, T2.  | 1.4 | 33        |
| 1150 | Antiangiogenic effect of dasatinib in murine models of oxygen-induced retinopathy and laser-induced choroidal neovascularization. <i>Molecular Vision</i> , 2017, 23, 823-831.  | 1.1 | 7         |
| 1151 | Single-dose Intravitreal Bevacizumab after Complete Panretinal Photocoagulation in Proliferative Diabetic Retinopathy: an Effective Adjunctive Treatment. <i>Medical Hypothesis, Discovery, and Innovation in Ophthalmology</i> , 2017, 6, 76-81.             | 0.4 | 4         |
| 1152 | The effects of bevacizumab treatment in a rat model of retinal ischemia and perfusion injury. <i>Molecular Vision</i> , 2018, 24, 239-250.  | 1.1 | 12        |
| 1153 | Oleanolic Acids Inhibit Vascular Endothelial Growth Factor Receptor 2 Signaling in Endothelial Cells: Implication for Anti-Angiogenic Therapy. <i>Molecules and Cells</i> , 2018, 41, 771-780.  | 1.0 | 7         |
| 1154 | High cell density induces vascular endothelial growth factor expression via protein tyrosine phosphorylation. <i>Gene Expression</i> , 1998, 7, 53-60.  | 0.5 | 18        |
| 1155 | An In Vitro Model of Diabetic Retinal Vascular Endothelial Dysfunction and Neuroretinal Degeneration. <i>Journal of Diabetes Research</i> , 2021, 2021, 1-12.   | 1.0 | 3         |
| 1156 | Visual outcomes in diabetic macular edema patients after avastin injection. <i>Biometrics &amp; Biostatistics International Journal</i> , 2020, 9, 189-192.   | 0.2 | 0         |
| 1157 | Sulpiride-induced hyperprolactinaemia increases retinal vasoinhibin and protects against diabetic retinopathy in rats. <i>Journal of Neuroendocrinology</i> , 2022, 34, e13091.   | 1.2 | 5         |
| 1158 | Decreased Levels of miR-126 and miR-132 in Plasma and Vitreous Humor of Non-Proliferative Diabetic Retinopathy Among Subjects with Type-2 Diabetes Mellitus. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2022, Volume 15, 345-358. | 1.1 | 5         |
| 1159 | It is time for a moonshot to find "Cures" for diabetic retinal disease. <i>Progress in Retinal and Eye Research</i> , 2022, 90, 101051.   | 7.3 | 15        |
| 1160 | Vitreous Biomarkers: What they Are and how they May be Used to Advance the Management of Diabetic Retinopathy. <i>Biomarkers in Disease</i> , 2022, , 1-28.   | 0.0 | 1         |
| 1161 | Update on Management of Non-proliferative Diabetic Retinopathy without Diabetic Macular Edema; Is There a Paradigm Shift?. <i>Journal of Ophthalmic and Vision Research</i> , 2022, 17, 108-117.  | 0.7 | 4         |
| 1162 | The effect of stiffened diabetic red blood cells on wall shear stress in a reconstructed 3D microaneurysm. <i>Computer Methods in Biomechanics and Biomedical Engineering</i> , 2022, 25, 1691-1709.  | 0.9 | 13        |
| 1163 | Regulation of inflammation by VEGF/BDNF signaling in mouse retinal Müller glial cells exposed to high glucose. <i>Cell and Tissue Research</i> , 2022, 388, 521-533.  | 1.5 | 5         |
| 1164 | Optical coherence tomography angiography findings before and after onset of foveal retinal neovascularization in diabetic retinopathy. <i>American Journal of Ophthalmology Case Reports</i> , 2022, 26, 101435.  | 0.4 | 1         |
| 1165 | Obstructive Sleep Apnoea, Other Sleep Parameters and Diabetic Retinopathy. <i>Current Diabetes Reports</i> , 2021, 21, 58.  | 1.7 | 3         |

| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 1166 | Analysis of cytokines in the aqueous humor during intravitreal Ranibizumab treatment of diabetic macular edema. <i>Scientific Reports</i> , 2021, 11, 23981.   | 1.6 | 4         |
| 1167 | Efficacy and Safety of Antivascular Endothelial Growth Factor (Anti-VEGF) in Treating Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Meta-analysis. <i>Journal of Immunology Research</i> , 2022, 2022, 1-11. | 0.9 | 3         |
| 1170 | Nonproliferative and Proliferative Diabetic Retinopathy. , 2022, , 2955-2993.  |     | 1         |
| 1171 | Neovascular Glaucoma. , 2022, , 1769-1806.   |     | 0         |
| 1172 | Pharmacotherapy of Age-Related Macular Degeneration. , 2022, , 3619-3644.  |     | 1         |
| 1173 | Study of the Association between VEGF Polymorphisms and the Risk of Coronary Artery Disease in Koreans. <i>Journal of Personalized Medicine</i> , 2022, 12, 761.   | 1.1 | 1         |
| 1174 | Proliferative diabetic retinopathy. , 2012, , 528-535.   |     | 0         |
| 1175 | Platelets and (Lymph)angiogenesis. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2023, 13, a041174.   | 2.9 | 7         |
| 1176 | Changes in aqueous and vitreous inflammatory cytokine levels in proliferative diabetic retinopathy: a systematic review and meta-analysis. <i>Eye</i> , 0, , .   | 1.1 | 16        |
| 1177 | The Angiogenic Balance and Its Implications in Cancer and Cardiovascular Diseases: An Overview. <i>Medicina (Lithuania)</i> , 2022, 58, 903.   | 0.8 | 2         |
| 1178 | Deep Capillary Nonperfusion on OCT Angiography Predicts Complications in Eyes with Referable Nonproliferative Diabetic Retinopathy. <i>Ophthalmology Retina</i> , 2023, 7, 14-23.  | 1.2 | 11        |
| 1180 | Nanomedicine and drug delivery to the retina: current status and implications for gene therapy. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2022, 395, 1477-1507.  | 1.4 | 22        |
| 1181 | Retinal and Choroidal Neovascularization Antivascular Endothelial Growth Factor Treatments: The Role of Gene Therapy. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 0, , .  | 0.6 | 0         |
| 1182 | Vitreous Biomarkers: What They Are and How They May Be Used to Advance the Management of Diabetic Retinopathy. <i>Biomarkers in Disease</i> , 2023, , 963-990.   | 0.0 | 0         |
| 1185 | Anti-Vascular Endothelial Growth Factor for Neovascular Glaucoma. <i>Essentials in Ophthalmology</i> , 2022, , 121-130.  | 0.0 | 0         |
| 1186 | Sustained therapeutic effect of an anti-inflammatory peptide encapsulated in nanoparticles on ocular vascular leakage in diabetic retinopathy. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .                               | 1.8 | 2         |
| 1187 | Pathophysiology of Diabetic Macular Edema. , 2022, , 7-25.   |     | 1         |
| 1188 | Prophylactic intravitreal injection of aflibercept for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy: A randomized controlled trial. <i>Frontiers in Public Health</i> , 0, 10, .                             | 1.3 | 1         |



| #    | ARTICLE   | IF   | CITATIONS |
|------|---|------|-----------|
| 1189 | Human glial Müller and umbilical vein endothelial cell coculture as an in vitro model to investigate retinal oxidative damage. A morphological and molecular assessment. <i>Microscopy Research and Technique</i> , 0, .      | 1.2  | 0         |
| 1190 | Risk Factors for Surgery or Blindness in Neovascular Glaucoma Eyes Treated with Anti-VEGF Injections by a Retina Specialist. <i>Retina</i> , 2023, Publish Ahead of Print, .  | 1.0  | 0         |
| 1191 | Short-term peripapillary structural and vascular changes following anti-VEGF vs. Dexamethasone intravitreal therapy in patients with DME. <i>European Journal of Ophthalmology</i> , 2023, 33, 2236-2242.                     | 0.7  | 1         |
| 1192 | Macular Perfusion Deficits on OCT Angiography Correlate with Nonperfusion on Ultrawide-field Fluorescein Angiography in Diabetic Retinopathy. <i>Ophthalmology Retina</i> , 2023, 7, 692-702.                                 | 1.2  | 6         |
| 1193 | Pre-operative intravitreal bevacizumab for tractional retinal detachment secondary to proliferative diabetic retinopathy: the Alvaro Rodriguez lecture 2023. <i>International Journal of Retina and Vitreous</i> , 2023, 9, . | 0.9  | 0         |
| 1196 | Biology and therapeutic targeting of vascular endothelial growth factor A. <i>Nature Reviews Molecular Cell Biology</i> , 2023, 24, 816-834.  | 16.1 | 28        |
| 1201 | Nanotechnological strategies for the treatment of diabetic retinopathy. , 2023, , 285-304.  |      | 0         |